

BIBLIOGRAPHY

A. Original articles

	IF 2017	CI 2017
1987		
1. Weller M , Wiedemann P, Heimann K. Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro. Graefe's Arch Clin Exp Ophthalmol 1987;225:235-238	2.249	16
1988		
2. Ginns EI, Rehavi M, Martin BM, Weller M , O'Malley KL, LaMarca ME, McAllister CG, Paul SM. Expression of human tyrosine hydroxylase cDNA in invertebrate cells using a baculovirus vector. J Biol Chem 1988;263:7406-7410	2.939	31
3. Weller M , Heimann K, Wiedemann P. Demonstration of mononuclear phagocytes in a human epiretinal membrane using a monoclonal anti-human macrophage antibody. Graefe's Arch Clin Exp Ophthalmol 1988;226:252-254	2.249	28
4. Weller M , Heimann K, Wiedemann P. Immunochemical studies of epiretinal membranes using APAAP complexes: evidence for macrophage involvement in traumatic proliferative vitreoretinopathy. Int Ophthalmol 1988;11:181-186		34
5. Weller M , Wiedemann P, Heimann K, Zilles K. Fibronectin quantification in plasma and vitreous by a noncompetitive ELISA technique. Doc Ophthalmol 1988;69:341-351	2.362	4
6. Weller M , Wiedemann P, Heimann K, Zilles K. The significance of fibronectin in vitreoretinal pathology: a critical evaluation. Graefe's Arch Clin Exp Ophthalmol 1988;226:294-298	2.249	31
7. Wiedemann P, Weller M , Heimann K. Traktionsamotio bei Morbus Coats. Klin Monatsbl Augenheilkd 1988;193:200-201	0.882	1
8. Weller M , Fischbach R, Heimann K, Wiedemann P. Zur Bedeutung der Fibronectine bei proliferativen Netzhauterkrankungen. Fortschr Ophthalmol 1988;85:263-266		
9. Weller M , Heimann K, Wiedemann P. L'importance des macrophages et de la fibronectine pour la prolifération vitréo-rétinienne. J Fr Ophtalmol 1988;11:243-247	0.636	8
10. Weller M , Wiedemann P, Fischbach R, Hartmann C, Heimann K. Evaluation of daunomycin toxicity on lens epithelium in vitro. Int Ophthalmol 1988;12:127-130		21
1989		
11. Weller M , Wiedemann P, Moter H, Heimann K. Transferrin and transferrin receptor expression in proliferative intraocular disease. APAAP labeling and ELISA for vitreal transferrin. Graefe's Arch Clin Exp Ophthalmol 1989;227:281-286	2.249	19
12. Weller M , Heimann K, Wiedemann P. Immunohistochemische Befunde bei proliferativen Netzhauterkrankungen. Zur Bedeutung von Fibronektin, Makrophagen und Transferrin. Fortschr Ophthalmol 1989;86:121-123		2
13. Hartmann C, Wiedemann P, Weller M , Pharmakakis N, Heimann K. In Vitro Veränderungen des Linsenepithels und Hornhautendothels durch das Zytostatikum Daunomycin. Fortschr Ophthalmol 1989;86:167-171		13

14. Moter H, Wiedemann P, **Weller M**, Heimann K. Isoelektrische Fokussierung von Glaskörperproteinen. *Fortschr Ophthalmol* 1989;86:399-402 2
15. **Weller M**, Bresgen M, Heimann K, Wiedemann P. Zur Immunhistologie der proliferativen Vitreoretinopathie nach Riesenriss-Amotio. *Klin Monatsbl Augenheilkd* 1989;195:323-325 0.882 2
- 1990**
16. Hartmann C, Wiedemann P, Gothe K, **Weller M**, Heimann K. Prévention de la cataracte secondaire par application endocapsulaire de l'antimitotique daunomycine. *Ophthalmologie* 1990;4:102-106 23
17. **Weller M**, Wiedemann P, Bresgen M, Heimann K. Giant preretinal fibrin membrane formation behind a silicone oil bubble in a hypotensive eye. *Retina* 1990;10:86-91 4.013 3
18. **Weller M**, Wiedemann P, Bresgen M, Heimann K. Vitronektin: Mediator der Zelladhäsion bei der proliferativen Vitreoretinopathie. *Fortschr Ophthalmol* 1990;87:221-225 6
19. Bresgen M, **Weller M**, Heimann K, Wiedemann P. Nachweis von Blutgerinnungsfaktor XIII im Glaskörper und periretinalen Membranen bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:279-282
20. Clausen R, **Weller M**, Hilgers RD, Heimann K, Wiedemann P. Quantitative Bestimmung von sechs Glaskörperproteinen im normalen Glaskörper und bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:283-286 4
21. Moter H, **Weller M**, Heimann K, Wiedemann P. Laktoferrin und Transferrin. Eisenbindende Proteine in physiologischem und pathologischem Glaskörper. *Fortschr Ophthalmol* 1990;87:336-339 1
22. Esser P, **Weller M**, Heimann K, Wiedemann P. Vitronektin- und Fibronektinrezeptoren bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:344-347 3
23. **Weller M**, Bresgen M, Heimann K, Wiedemann P. Blood coagulation factor XIII contributes to the development of periretinal membranes. *Acta Ophthalmol* 1990;68:246-252 3.324 9
24. **Weller M**, Clausen R, Heimann K, Wiedemann P. Iron-binding proteins in the human vitreous. Lactoferrin and transferrin in health and in proliferative intraocular disease. *Ophthalmic Res* 1990;22:194-200 1.826 12
25. **Weller M**, Clausen R, Bresgen M, Heimann K, Wiedemann P. Immunoglobulin G, complement factor C3 and lymphocytes in proliferative intraocular disorders. *Int Ophthalmol* 1990;14:277-283 7
26. **Weller M**, Poremba M, Dichgans J. Opercular syndrome without opercular lesions: Foix-Chavany-Marie syndrome in progressive supranuclear motor system degeneration. *Eur Arch Psychiatr Clin Neurosci* 1990;239:370-372 3.617 18
27. **Weller M**, Sommer N, Stevens A, Wiethölter H. Increased intrathecal synthesis of fibronectin in bacterial and carcinomatous meningitis. *Acta Neurol Scand* 1990;82:138-142 3.126 20
28. **Weller M**, Sommer N, Stevens A, Wiethölter H. Zur klinischen Bedeutung der Fibronektinbestimmung im Liquor. *Aktuel Neurol* 1990;17:187-189

1991

29.	Weller M , Wiedemann P, Bresgen M, Heimann K. Vitronectin and proliferative intraocular disorders. I. A colocalization study of the serum spreading factor, vitronectin, and fibronectin in periretinal membranes. <i>Int Ophthalmol</i> 1991;15:93-101		20
30.	Weller M , Wiedemann P, Bresgen M, Heimann K. Vitronectin and proliferative intraocular disorders. II. Expression of cell surface receptors for fibronectin and vitronectin in periretinal membranes. <i>Int Ophthalmol</i> 1991;15:103-108		20
31.	Clausen R, Weller M , Wiedemann P, Heimann K, Hilgers RD, Zilles K. An immunochemical quantitative analysis of the protein pattern in physiological and pathologic vitreous. <i>Graefe's Arch Clin Exp Ophthalmol</i> 1991;229:186-190	2.249	23
32.	Weller M , Esser P, Heimann K, Wiedemann P. Retinal microglia: a new cell in idiopathic proliferative vitreoretinopathy. <i>Exp Eye Res</i> 1991;53:275-281	3.152	27
33.	Esser P, Weller M , Heimann K, Wiedemann P. Thrombospondin und seine Bedeutung bei proliferativen Netzhauterkrankungen. <i>Fortschr Ophthalmol</i> 1991;88:337-340		8
34.	Bresgen M, Martiny B, Weller M , Heimann K, Wiedemann P. Analyse des Proteinmusters in physiologischen und pathologischen Glaskörpern durch Elektrophorese und immunologische Identifizierung. <i>Fortschr Ophthalmol</i> 1991;88:665-670		11
35.	Grisanti S, Wiedemann P, Weller M , Heimann K, Zilles K. The significance of complement in proliferative vitreoretinopathy. <i>Invest Ophthalmol Vis Sci</i> 1991;32:2711-2717	3.388	19
36.	Weller M , Leo-Kottler B, Berg PA, Wiethölter H. Effective suppression of crescendo amaurosis fugax associated with antiphospholipid antibodies by low dose aspirin. <i>Neuroophthalmology</i> 1991;11:195-197		
37.	Wilhelm H, Weller M , Wiethölter H, Schiefer U. Ross-Syndrom: Adie-Syndrom mit Störungen der Schweiss- und Temperaturregulation. <i>Klein Monatsbl Augenheilkd</i> 1991;199:442-443	0.882	2
38.	Weller M , Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H. Comparative analysis of cytokine patterns in immunologic, inflammatory, and oncological neurological disorders. <i>J Neurol Sci</i> 1991;104:215-221	2.448	79
39.	Weller M , Stevens A, Sommer N, Wiethölter H, Dichgans J. CSF interleukins, immunoglobulins, and fibronectin in neuroborreliosis. <i>Arch Neurol</i> 1991;48:837-841	11.460	38
40.	Sommer N, Weller M , Petersen D, Wiethölter H, Dichgans J. Neurosarcoidosis without systemic sarcoidosis. <i>Eur Arch Psychiatr Clin Neurosci</i> 1991;240:334-338	3.617	23
41.	Weller M , Leo-Kottler B, Berg PA, Wiethölter H. Antiphospholipidsyndrom: Neurologische Komplikationen und therapeutische Möglichkeiten. <i>Dtsch Med Wschr</i> 1991;116:1794-1796, <i>DMW Japan</i> 1991;13:1653-1655	0.523	4
42.	Kornhuber J, Weller M . Post-partum psychosis and mastitis: a new indication for clozapine? <i>Am J Psychiatry</i> 1991;148:1751-1752	13.396	8
1992			
43.	Esser P, Weller M , Bresgen M, Heimann K, Wiedemann P. The effects of basic fibroblast growth factor on bovine retinal pigment epithelium in vitro. <i>German J Ophthalmol</i> 1992;1:58-61		12
44.	Weller M , Esser P, Bresgen M, Heimann K, Wiedemann P. Thrombospondin: a new attachment protein in preretinal traction membranes. <i>Eur J Ophthalmol</i> 1992;2:10-14	1.897	10

45.	Molitor R, Esser P, Weller M , Wiedemann P, Heimann K. Kontraktile Elemente bei proliferativen Netzhauterkrankungen. <i>Ophthalmologie</i> 1992;89:34-38	0.842	4
46.	Grisanti S, Esser P, Weller M , Wiedemann P, Heimann K. Die proliferative Vitreoretinopathie. Aktivierung des Komplementsystems. <i>Ophthalmologie</i> 1992;89:50-54	0.842	2
47.	Weller M , Esser P, Heimann K, Wiedemann P. Die idiopathische proliferative Vitreoretinopathie. Die Aktivierung von Mikrogliazellen als entscheidender Faktor. <i>Ophthalmologie</i> 1992;89:387-390	0.842	6
48.	Wiethölter H, Schabet M, Stevens A, Melms A, Sommer N, Weller M . Influence of gangliosides on experimental allergic neuritis. <i>J Neuroimmunol</i> 1992;38:221-228	2.655	10
49.	Weller M , Stevens A, Sommer N, Wiethölter H. Tumor necrosis factor- α in malignant melanomatous meningitis. <i>J Neurol Neurosurg Psychiatry</i> 1992;55:74	7.144	1
50.	Weller M , Liedtke W, Petersen D, Opitz H, Poremba M. Very late onset adrenoleukodystrophy. Possible precipitation of demyelination by cerebral contusion. <i>Neurology</i> 1992;42:367-370	8.055	25
51.	Weller M , Stevens A, Sommer N, Wiethölter H. Intrathekale Immunantwort bei Meningeosis neoplastica. IgG, IgM, oligoklonale Banden und Zytokine. <i>Nervenarzt</i> 1992;63:213-217	0.738	1
52.	Liedtke W, Weller M , Wiethölter H, Dichgans J. Immunological abnormalities in the tears of multiple sclerosis patients. <i>Acta Neurol Scand</i> 1992;85:228-230	3.126	5
53.	Weller M , Stevens A, Sommer N, Schabet M, Wiethölter H. Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. <i>Cancer</i> 1992;69:1475-1480	6.537	17
55.	Eblen F, Weller M , Dichgans J. Automatic-voluntary dissociation: an unusual facial paresis in a patient with probable multiple sclerosis. <i>Eur Arch Psychiatr Clin Neurosci</i> 1992;242:93-95	3.617	6
56.	Weller M , Stevens A, Sommer N, Dichgans J, Kappler B, Wiethölter H. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? <i>J Neurol</i> 1992;239:455-459	3.783	30
57.	Weller M , Stevens A, Sommer N, Wiethölter H. Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy? <i>Eur Arch Psychiatr Clin Neurosci</i> 1992;242:122-126	3.617	13
58.	Weller M , Stevens A, Sommer N, Schabet M, Wiethölter H. Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. <i>Acta Neurol Scand</i> 1992;86:129-133	3.126	23
59.	Stevens A, Weller M , Wiethölter H. CSF and serum ganglioside antibody patterns in MS. <i>Acta Neurol Scand</i> 1992;86:485-489	3.126	29
60.	Becker T, Hoffmann E, Struck M, Weller M , Sperling W, Lanczik M. Marchiafava-Bignami-Syndrom: CT- und MR-Befunde in einem atypischen Fall. <i>Klin Neuroradiol</i> 1992;2:24-27		
61.	Weller M , Kornhuber J, Beckmann H. Elektrokonvulsionstherapie zur Behandlung der akuten lebensbedrohlichen Katatonie bei toxischer epidermaler Nekrolyse (Lyell-Syndrom). <i>Nervenarzt</i> 1992;63:308-310	0.738	9
62.	Weller M , Müller U, Kornhuber J. Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence? <i>J Clin Psychiatry</i> 1992;53:257-258	4.247	1

63.	Weller M , Kornhuber J. Differentielle Neurolepsie bei schizophrenen Psychosen im Wochenbett: Vorteile des atypischen Neuroleptikums Clozapin. <i>Nervenarzt</i> 1992;63:440-441	0.738	5
64.	Weller M , Kornhuber J. Lyell syndrome and lethal catatonia: a case for ECT. <i>Am J Psychiatry</i> 1992;149:1114	13.396	3
65.	Weller M , Kornhuber J. Clozapine rechallenge after an episode of "neuroleptic malignant syndrome". <i>Br J Psychiatry</i> 1992;161:855-856 (Comment in: 1993;162:566 and 1993;163:121-122)	5.867	31
66.	Weller M , Kornhuber J. ECT in a geriatric patient with multiple bony fractures and generalized plasmacytoma. <i>Pharmacopsychiatry</i> 1992;25:278-280	2.064	8
67.	Becker T, Kornhuber J, Hofmann E, Weller M , Rupprecht C, Beckmann H. MRI white matter hyperintensity in neuroleptic malignant syndrome - a clue to pathogenesis? <i>J Neural Transmission [Gen Sect]</i> 1992;90:151-159	2.779	14
68.	Stevens A, Weller M . Ganglioside antibody patterns in schizophrenia and major depression. <i>Biol Psychiatry</i> 1992;32:728-730	11.984	12
69.	Weller M , Marini AM, Paul SM. Niacinamide blocks 3-acetylpyridine toxicity of cerebellar granule cells in vitro. <i>Brain Res</i> 1992;594:160-164	3.125	28
1993			
70.	Stevens A, Weller M , Wiethölter H. A characteristic ganglioside antibody pattern in the CSF of amyotrophic lateral sclerosis patients. <i>J Neurol Neurosurg Psychiatry</i> 1993;56:361-364	7.144	26
71.	Weller M , Stevens A, Sommer N, Wiethölter H. Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma. <i>J Neuro-Oncol</i> 1993;16:55-59	3.060	2
72.	Müller U, Warmuth-Metz M, Weller M , Hönes S, Becker T. Intrakranielle Epidermoide und Dermoiden in der Psychiatrie. Drei Fallbeispiele und Literaturübersicht. <i>Neuropsychiatrie</i> 1993;7:138-146		
73.	Kornhuber J, Weller M . Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. <i>J Neural Transmission [Gen Sect]</i> 1993;92:57-65	2.779	33
74.	Weller M , Kornhuber J. Clozapin: Risikoneuroleptikum für die Auslösung eines malignen neuroleptischen Syndroms (MNS) oder neuroleptische Alternative bei positiver MNS-Anamnese? <i>Fortschr Neurol Psychiatr</i> 1993;61:217-222	0.395	12
75.	Weller M , Kornhuber J. Serum iron levels in neuroleptic malignant syndrome. <i>Biol Psychiatry</i> 1993;34:123-124	11.984	6
76.	Weller M , Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. <i>Brain Res</i> 1993;613:143-148	3.125	72
77.	Montpied P, Weller M , Paul SM. N-methyl-D-aspartate receptor agonists decrease protooncogene <i>bcl-2</i> mRNA expression in cultured rat cerebellar granule neurons. <i>Biochem Biophys Res Commun</i> 1993;195:623-629	2.559	31
78.	Weller M , Paul SM. 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. <i>Eur J Pharmacol [Environmental Toxicol Pharmacol Sect]</i> 1993;248:223-228	3.040	36

79. **Weller M**, Marini AM, Finiels-Marlier F, Martin B, Paul SM. MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. *Eur J Pharmacol [Environmental Toxicol Pharmacol Sect]* 1993;248:303-312 3.040 19

1994

80. Esser P, Bresgen M, **Weller M**, Heimann K, Wiedemann P. The significance of vitronectin in proliferative diabetic retinopathy. *Graefe's Arch Clin Exp Ophthalmol* 1994;232:477-481 2.249 12

81. **Weller M**, Montpied P, Paul SM. NMDA receptor-mediated excitoprotection of cultured cerebellar granule neurons fails to alter glutamate-induced expression of *c-fos* and *c-jun* mRNAs. *Mol Brain Res* 1994;22:227-235 3.125 20

82. **Weller M**, Marini AM, Martin B, Paul SM. The reduced unsubstituted pteroyl moiety is required for folate toxicity of cultured cerebellar granule neurons. *J Pharmacol Exp Ther* 1994;269:393-401 3.706 7

83. Yan GM, Ni B, **Weller M**, Wood KA, Paul SM. Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons. *Brain Res* 1994;656:43-51 3.125 180

84. **Weller M**, Constam D, Malipiero U, Fontana A. Transforming growth factor- β 2 induces apoptosis of murine T cell clones without down-regulating *bcl-2* mRNA expression. *Eur J Immunol* 1994;24:1293-1300 4.248 129

85. **Weller M**, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. *J Clin Invest* 1994;94:954-964 13.251 353

1995

86. Kornhuber J, **Weller M**. Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. *Convulsive Therapy* 1995;11:104-109 9

87. Sommer N, Löschnann PA, Northoff GH, **Weller M**, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmüller A, Dichgans J, Fontana A, Martin R. Cytokine-directed suppression of autoimmune encephalomyelitis by the antidepressant rolipram. *Nat Med* 1995;1:244-248 32.621 286

88. **Weller M**, Malipiero U, Groscurth P, Fontana A. T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor- β 2: modulation by the phosphatase inhibitors, okadaic acid and calyculin A. *Exp Cell Res* 1995;221:395-403 3.309 33

89. **Weller M**, Malipiero UV, Aguzzi A, Reed JC, Fontana A. Protooncogene *bcl-2* gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. *J Clin Invest* 1995;95:2633-2643 13.251 257

90. **Weller M**, Malipiero U, Rensing-Ehl A, Barr P, Fontana A. Fas/APO-1 gene transfer for human malignant glioma. *Cancer Res* 1995;55:2936-2944 9.130 136

91. Yan GM, Irwin RP, Lin SZ, **Weller M**, Wood KA, Paul SM. Diphenylhydantoin induces apoptotic cell death of cerebellar granule neurons. *J Pharmacol Exp Ther* 1995;274:983-990 3.706 36

92. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, **Weller M**, Aebischer P, Krammer PH, 4.248 189

Fontana A. Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing *in vivo*. Eur J Immunol 1995;25:2253-2258

93. Esser P, Heimann K, Abts H, Fontana A, **Weller M**. CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells. Biochem Biophys Res Commun 1995;213:1026-1034 2.559 32
94. Wüllner U, Löschmann PA, **Weller M**, Klockgether T. Apoptotic cell death in the cerebellum of mutant *weaver* and *lurcher* mice. Neurosci Lett 1995;200:109-112 2.159 77

1996

95. Esser P, Bartz-Schmidt KU, Walter P, Kaszli F, Heimann K, **Weller M**. Apoptotic cell death in proliferative vitreoretinopathy. Ger J Ophthalmol 1996;5:73-78 10
96. **Weller M**, Petersen D, Dichgans J, Klockgether T. Cerebral angiography complications link cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy to familial hemiplegic migraine. Neurology 1996;46:844 8.055 9
97. Bingisser R, Stey C, **Weller M**, Groscurth P, Russi E, Frei K. Apoptosis in human alveolar macrophages is induced by endotoxin and is modulated by cytokines. Am J Resp Cell Mol Biol 1996;15:64-70 3.785 88
98. Trepel M, **Weller M**, Petersen D, Dichgans J. Voluntary facial palsy with a pontine lesion. J Neurol Neurosurg Psychiatry 1996;61:531-533 7.144 8
99. De Luca A, **Weller M**, Fontana A. TGF- β -induced apoptosis of cerebellar granule neurons is prevented by depolarization. J Neurosci 1996;16:4174-4185 5.971 67
100. Schulz JB, **Weller M**, Klockgether T. Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. J Neurosci 1996;16:4696-4706 5.971 309
101. De Luca A, **Weller M**, Frei K, Fontana A. Maturation-dependent modulation of apoptosis in cultured cerebellar granule neurons by cytokines and neurotrophins. Eur J Neurosci 1996;8:1994-2005 2.832 15

1997

102. **Weller M**, Heimann K, Bartz-Schmidt KU, Fontana A, Esser P. CD95 expression in traumatic proliferative vitreoretinopathy: a target for the induction of apoptosis. Ger J Ophthalmol 1997;5:332-337 2
103. Esser P, Heimann K, Bartz-Schmidt KU, Fontana A, **Weller M**. Apoptosis in proliferative vitreoretinal disorders. Possible involvement of TGF- β -induced RPE cell apoptosis. Exp Eye Res 1997;65:365-378 3.152 45
104. **Weller M**, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 1997;48:1704-1709 8.055 75
105. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, **Weller M**. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 1997;44:55-63 4.225 88
106. Esser P, Heimann K, Bartz-Schmidt KU, Walter P, Krott R, **Weller M**. Plasminogen in proliferative vitreoretinal disorders. Br J Ophthalmol 1997;81:590-594 3.384 18

107.	Klockgether T, Weller M , Haarmeier T, Kaskas B, Maier G, Dichgans J. Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. <i>Neurology</i> 1997;48:275-276	8.055	29
108.	Sommer N, Sigg B, Melms A, Weller M , Schepelmann K, Herzau V, Dichgans J. Ocular myasthenia gravis: response to long term immunosuppressive treatment. <i>J Neurol Neurosurg Psychiatry</i> 1997;62:156-162	7.144	94
109.	Wagenknecht B, Gulbins E, Lang F, Dichgans J, Weller M . Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. <i>FEBS Lett</i> 1997;409:17-23	2.999	39
110.	Wüllner U, Weller M , Groscurth P, Löschnann PA, Schulz JB, Müller I, Klockgether T. Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: the effects of 3-acetylpyridine neurotoxicity. <i>Neuroscience</i> 1997;81:721-734	3.382	22
111.	Weller M , Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC. Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. <i>Neurol Res</i> 1997;19:459-470	1.449	67
112.	Wagenknecht B, Trepel M, Von Deimling A, Grimmel C, Rollbrocker B, Hayashi Y, Lang F, Dichgans J, Gulbins J, Weller M . p53 accumulation promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein in human malignant glioma cells. <i>Cell Physiol Biochem</i> 1997;7:304-311	5.500	4
113.	Weller M , Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E. CD95-dependent T cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. <i>Cell Physiol Biochem</i> 1997;7:282-288	5.500	31
114.	Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M . Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. <i>J Immunol</i> 1997;159:2108-2115	4.539	63
115.	Esser P, Grisanti S, Kociok N, Abts H, Hueber A, Unfried K, Heimann K, Weller M . Expression and up-regulation of MAP1B in cultured retinal pigment epithelial cells. <i>Invest Ophthalmol Vis Sci</i> 1997;38:2852-2856	3.388	13
116.	Schulz JB, Bremen D, Reed JC, Lommatzsch J, Takayama S, Wüllner U, Löschnann PA, Klockgether T, Weller M . Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. <i>J Neurochem</i> 1997;69:2075-2086	4.609	102
117.	Weller M , Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β -lapachone. <i>Int J Cancer</i> 1997;73:707-714	7.360	71
118.	Trepel M, Scheduling S, Groscurth P, Horny HP, Malipiero U, Brugger W, Dichgans J, Weller M . A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. <i>Leukemia</i> 1997;11:1842-1849	10.023	22
1998			
119.	Ständer M, Dichgans J, Weller M . Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. <i>J Neuro-Oncol</i> 1998;37:191-198	3.060	14

120.	Hueber A, Winter S, Weller M . Chemotherapy primes malignant glioma cells for CD95L-induced apoptosis. <i>Eur J Pharmacol</i> 1998;352:111-115	3.040	11
121.	Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M . Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. <i>Br J Cancer</i> 1998;77:404-411	5.922	59
122.	Weller M , Dichgans J, Klockgether T. Acetazolamide-responsive migraine in CADASIL. <i>Neurology</i> 1998;50:1505	8.055	24
123.	Esser P, Tervooren D, Heimann K, Kociok N, Bartz-Schmidt KU, Walter P, Weller M . Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. <i>Invest Ophthalmol Vis Sci</i> 1998;39:164-170	3.388	25
124.	Zipp F, Faber E, Sommer N, Müller C, Dichgans J, Krammer PH, Martin R, Weller M . CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. <i>J Neuroimmunol</i> 1998;81:168-172	2.655	23
125.	Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J, Weller M . Potentiation of treosulfan toxicity by the glutathione-depleting agent, buthionine sulfoximine, in human malignant glioma cells: the role of bcl-2. <i>Biochem Pharmacol</i> 1998;55:349-359	2.559	29
126.	Brenner B, Ferlinz K, Weller M , Grassmé H, Koeppenhofer U, Dichgans J, Sandhoff K, Lang F, Gulbins E. Fas/CD95/APO-1 activates the acidic sphingomyelinase via caspases. <i>Cell Death Differ</i> 1998;5:29-37	8.000	102
127.	Rieger L, Weller M , Bornemann A, Schabet M, Dichgans J, Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. <i>J Neurol Sci</i> 1998;155:68-75	2.448	57
128.	Weller M , Klockgether T. Minocycline-induced benign intracranial hypertension. <i>J Neurol</i> 1998;245:55	3.783	2
129.	Zipp F, Weller M , Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. <i>Ann Neurol</i> 1998;43:116-120	10.250	65
130.	Winter S, Roth W, Dichgans J, Weller M . Synergistic activity of CD95 ligand and teniposide (VM26) does not involve enhanced formation of cleavable DNA complexes or changes in CD95/CD95 ligand expression. <i>Eur J Pharmacol</i> 1998;341:323-328	3.040	8
131.	Gulbins E, Hermisson M, Brenner B, Grassmé HU, Linderkamp O, Dichgans J, Weller M , Lang F. Cellular stimulation via CD95 involves activation of phosphoinositide-3-kinase. <i>Pflügers Arch - Eur J Physiol</i> 1998;435:546-554	2.765	16
132.	Weller M , Bornemann A, Ständer M, Schabet M, Dichgans J, Meyermann R. Humoral immune response to p53 in malignant glioma. <i>J Neurol</i> 1998;245:169-172	3.783	13
133.	Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M . Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. <i>J Neuro-Oncol</i> 1998;39:19-32	3.060	40
134.	Abele M, Leonhardt M, Dichgans J, Weller M . CCNU overdose during PCV chemotherapy for anaplastic astrocytoma. <i>J Neurol</i> 1998;245:236-238	3.783	2
135.	Weller M , Schuster M, Pietsch T, Schabet M. CD95 ligand-induced apoptosis of human	6.491	11

medulloblastoma cells. *Cancer Lett* 1998;128:121-126

136. Wüllner U, **Weller M**, Schulz JB, Krajewski S, Reed JC, Klockgether T. Bcl-2, Bax, and Bcl-x expression in neuronal apoptosis: a study of mutant *weaver* and *lurcher* mice. *Acta Neuropathol* 1998;96:233-238 15.876 25
137. Zipp F, Otzelberger K, Dichgans J, Martin R, **Weller M**. Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. *J Neuroimmunol* 1998;86:151-154 2.655 49
138. Heneka M,T, Löschmann PA, Gleichmann M, **Weller M**, Schulz JB, Wüllner U, Klockgether T. Induction of nitric oxide synthase (iNOS) and NO-mediated apoptosis in neuronal PC12 cells after stimulation with TNF α /LPS. *J Neurochem* 1998;71:88-94 4.609 182
139. Gleichmann M, Beinroth S, Reed JC, Krajewski S, Schulz JB, Wüllner U, Klockgether T, **Weller M**. Potassium deprivation-induced apoptosis of cerebellar granule neurons: cytochrome C release in the absence of altered expression of bcl-2 family proteins. *Cell Physiol Biochem* 1998;8:194-201 5.500 23
140. Schulz JB, Beinroth S, **Weller M**, Wüllner U, Klockgether T. Endonucleolytic DNA fragmentation is not required for apoptosis of cerebellar granule neurons. *Neurosci Lett* 1998;245:9-12 2.159 13
141. Roth W, Wagenknecht B, Dichgans J, **Weller M**. Interferon- α enhances CD95L-induced apoptosis of human malignant glioma cells. *J Neuroimmunol* 1998;87:121-129 2.655 38
142. Naumann U, **Weller M**. Retroviral bax gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. *Int J Cancer* 1998;77:645-648 7.360 16
143. Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann PA, Gulbins E, Dichgans J, **Weller M**. Decorin gene-transfer mediated suppression of TGF- β synthesis abrogates experimental malignant glioma growth in vivo. *Gene Therapy* 1998;5:1187-1194 3.203 88
144. Rieger J, Naumann U, Glaser T, Ashkenazi A, **Weller M**. APO2 ligand: a novel lethal weapon against malignant glioma? *FEBS Lett* 1998;427:124-128 2.999 171
145. Winter S, **Weller M**. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L expression. *J Pharmacol Exp Ther* 1998;286:1374-1382 3.706 12
146. Schulz JB, **Weller M**, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, von Coelln R, Wüllner U, Löschmann PA, Beal MF, Dichgans J, Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. *Cell Death Differ* 1998;5:847-857 8.000 74
147. Naumann U, Durka S, **Weller M**. Dexamethasone-mediated protection from drug toxicity linked to p21^{WAF/CIP1} protein accumulation. *Oncogene* 1998;17:1567-1575 6.854 65
148. Hueber A, Esser P, Heimann K, Kociok N, Schraermeyer U, Winter S, **Weller M**. The topoisomerase I inhibitors, camptothecin and β -lapachone, induce apoptosis of human retinal pigment epithelial cells. *Exp Eye Res* 1998;67:525-530 3.152 27
149. Rieger J, Ständer M, Löschmann PA, Heneka M, Dichgans J, Klockgether T, **Weller M**. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF- β , dexamethasone, and p53 gene transfer. *Oncogene* 1998;17:2323-2332 6.854 26

150.	Hueber A, Durka S, Weller M . CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. <i>FEBS Lett</i> 1998;432:155-157	2.999	10
151.	Weller M , Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, Von Deimling A, Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. <i>Int J Cancer</i> 1998;79:640-644	7.360	141
152.	Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M . BCL-2 promotes migration and invasiveness of human glioma cells. <i>FEBS Lett</i> 1998;440:419-424	2.999	79
153.	Roller A, Weller M . Antioxidants specifically inhibit cisplatin toxicity of human malignant glioma cells. <i>Anticancer Res</i> 1998;18:4493-4497	1.865	14
154.	Wagenknecht B, Schulz JB, Gulbins E, Weller M . Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. <i>Cell Death Differ</i> 1998;5:894-900	8.000	48
155.	Streffer J, Schuster M, Zipp F, Weller M . Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy? <i>J Neuro-Oncol</i> 1998;40:233-235	3.060	9
1999			
156.	Rieger J, Ohgaki H, Kleihues P, Weller M . Human astrocytic brain tumors express APO2L/TRAIL. <i>Acta Neuropathol</i> 1999;97:1-4	15.876	49
157.	Simons M, Beinroth S, Gleichmann M, Liston P, Korneluk RG, MacKenzie AE, Bähr M, Klockgether T, Robertson GS, Weller M , Schulz JB. Adenovirus-mediated gene transfer of IAPs delays apoptotic cell death in cerebellar granule neurons. <i>J Neurochem</i> 1999;72:292-301	4.609	92
158.	Abele M, Weller M , Mescheriakov S, Bürk K, Dichgans J, Klockgether T. Immunoglobulin treatment in a case of cerebellar ataxia with autoantibodies to glutamic acid decarboxylase. <i>Neurology</i> 1999;52:857-859	8.055	55
159.	Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HPT, Schabet M, Weller M . Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug toxicity. <i>Br J Cancer</i> 1999;80:756-765	5.922	105
160.	Pohl U, Wagenknecht B, Naumann U, Weller M . p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. <i>Cell Physiol Biochem</i> 1999;9:29-37	5.500	21
161.	Leonhardt M, Abele M, Klockgether T, Dichgans J, Weller M . Pathological yawning (chasm) associated with periodic leg movements in sleep (PLMS): cure by levodopa. <i>J Neurol</i> 1999;246:621-622	3.783	3
162.	Rieger J, Durka S, Streffer J, Dichgans J, Weller M . Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. <i>Eur J Pharmacol</i> 1999;365:301-308	3.040	51
163.	Münz C, Naumann U, Grimmel C, Rammensee HG, Weller M . TGF- β -independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells? <i>Eur J Immunol</i> 1999;29:1032-1040	4.248	27
164.	Schmidt F, Schuster M, Streffer J, Schabet M, Weller M . Topotecan-based combination chemotherapy for human malignant glioma. <i>Anticancer Res</i> 1999;19:1217-1222	1.865	9

165.	Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M . Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. <i>J Pharmacol Exp Ther</i> 1999;289:1306-1312	3.706	116
166.	Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M . PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> 1999;18:3936-3943	6.854	90
167.	Wüllner U, Kornhuber J, Weller M , Schulz JB, Löschmann PA, Riederer P, Klockgether T. Cell death and apoptosis regulating proteins in Parkinson's disease: a cautionary note. <i>Acta Neuropathol</i> 1999;97:408-412	15.876	85
168.	Wagenknecht B, Glaser T, Naumann U, Kügler S, Isenmann S, Bähr M, Korneluk R, Liston P, Weller M . Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. <i>Cell Death Differ</i> 1999;6:370-376	8.000	97
169.	Deininger M, Weller M , Streffer J, Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas <i>in vivo</i> . <i>Acta Neuropathol</i> 1999;98:240-244	15.876	84
170.	Bartussek C, Naumann U, Weller M . Accumulation of p53 modulates the growth, clonogenicity and radiochemosensitivity of malignant glioma cells independently of their endogenous p53 status. <i>Exp Cell Res</i> 1999;253:432-439	3.309	19
171.	Borbé R, Rieger J, Weller M . The failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. <i>Cancer Chemother Pharmacol</i> 1999;44:217-227	2.824	13
172.	Eitel K, Wagenknecht B, Weller M . Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. <i>Cancer Lett</i> 1999;142:11-16	6.491	18
173.	Engel S, Isenmann S, Ständer M, Rieger J, Bähr M, Weller M . Inhibition of experimental rat glioma growth by decorin gene transfer does not involve enhanced microglial recruitment. <i>J Neuroimmunol</i> 1999;99:13-18	2.655	19
174.	Soldner F, Weller M , Haid S, Beinroth S, Miller SW, Wüllner U, Davis RE, Dichgans J, Klockgether T, Schulz JB. MPP ⁺ inhibits proliferation of PC12 cells by a p21WAF1/Cip1-dependent pathway and induces cell death in cells lacking p21WAF1/Cip1. <i>Exp Cell Res</i> 1999;250:75-85	3.309	41
175.	Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M . Death ligand/receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells. <i>Oncogene</i> 1999;18:5044-5053	6.854	39
176.	Evert BO, Wüllner U, Schulz JB, Weller M , Groscurth P, Trottier Y, Brice A, Klockgether T. High-level expression of expanded full-length ataxin-3 causes cell death and formation of intranuclear inclusions in neuronal cells <i>in vitro</i> . <i>Hum Mol Genet</i> 1999;8:1169-1176	4.902	62
177.	Wagenknecht B, Hermisson M, Eitel K, Weller M . Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. <i>Cell Physiol Biochem</i> 1999;9:117-125	5.500	53
178.	Deininger M, Weller M , Streffer J, Meyermann R. Antiapoptotic BCL-2 family protein expression increases in oligodendroglioma progression. <i>Cancer</i> 1999;86:1832-1839	6.537	23
179.	Wüllner U, Seyfried J, Groscurth P, Beinroth S, Winter S, Gleichmann M, Heneka M, Löschmann PA, Schulz JB, Weller M , Klockgether T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. <i>Brain Res</i>	3.125	135

	1999;826:53-62		
180.	Roller A, Bähr O, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M . Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. <i>Biochem Biophys Res Commun</i> 1999;259:600-605	2.559	45
181.	Weller M , List U, Schabet M, Melms A, Dichgans J. Elevated CSF lactoferrin in superficial siderosis of the central nervous system. <i>J Neurol</i> 1999;246:943-945	3.783	5
182.	Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M , Meyermann R. Bcl-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. <i>J Neurol Neurosurg Psychiatry</i> 1999;67:763-768	7.144	76
183.	Streffer J, Schuster M, Pohl U, Belka C, Dichgans J, Bamberg M, Weller M . Irradiation-induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions. <i>Anticancer Res</i> 1999;19:5265-5270	1.865	7
184.	Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A, Weller M . Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. <i>Int J Oncol</i> 1999;15:829-834	3.333	13
185.	Naumann U, Weit S, Rieger L, Meyermann R, Weller M . p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. <i>Biochem Biophys Res Commun</i> 1999;261:890-896	2.559	37
186.	Klöcker N, Kermer P, Gleichmann M, Weller M , Bähr M. Both the neuronal and inducible isoform contribute to upregulation of retinal NOS activity by BDNF. <i>J Neurosci</i> 1999;19:8517-8527	5.971	46
187.	Lepple-Wienhues A, Belka C, Laun T, Jekle A, Walter B, Wieland U, Welz M, Heil L, Kun J, Busch G, Weller M , Bamberg M, Gulbins E, Lang F. Stimulation of CD95 (FAS) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. <i>Proc Natl Acad Sci USA</i> 1999;96:13975-13800	9.504	135
188.	Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M . Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. <i>Biochem Biophys Res Commun</i> 1999;265:479-483	2.559	172
2000			
189.	Zipp F, Beyer M, Gelderblom H, Wernet D, Zschenderlein R, Weller M . No induction of apoptosis by IFN- β in human antigen-specific T cells. <i>Neurology</i> 2000;54:485-487	8.055	20
190.	Rieger L, Rieger J, Winter S, Esser P, Dichgans J, Meyermann R, Weller M . Evidence for a constitutive, verapamil-sensitive, non-Pgp multidrug resistance phenotype that is unaltered by radiochemotherapy in vivo. <i>Acta Neuropathol</i> 2000;99:555-562	15.876	19
191.	Herrlinger U, Klingel K, Meyermann R, Kandolf R, Kaiserling E, Kortmann RD, Melms A, Skalej M, Dichgans J, Weller M . Central nervous system Hodgkin's lymphoma without systemic manifestation: case report and review of the literature. <i>Acta Neuropathol</i> 2000;99:709-714	15.876	19
192.	Nakamura M, Rieger J, Weller M , Kim J, Kleihues P, Ohgaki H. APO2L/TRAIL expression in human brain tumors. <i>Acta Neuropathol</i> 2000;99:1-6	15.876	31

193.	Wüllner U, Weller M , Kornhuber J, Bornemann A, Schulz JB, Riederer P, Klockgether T. Altered expression of calcium- and apoptosis-regulating proteins in multiple system atrophy Purkinje cells. <i>Movement Disorders</i> 2000;15:269-275	8.324	14
194.	Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M . Expression and functional activity of heat shock proteins in human glioblastoma multiforme. <i>Neurology</i> 2000;54:1357-1365	8.055	67
195.	Roth W, Grimmel C, Rieger L, Strik H, Takayama S, Krajewski S, Meyermann R, Reed JC, Weller M . Bag-1 and bcl-2 gene transfer in malignant glioma: modulation of cell cycle regulation and apoptosis. <i>Brain Pathol</i> 2000;10:223-234	6.187	29
196.	Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M . PCV salvage chemotherapy for recurrent primary CNS lymphoma. <i>Neurology</i> 2000;54:1707-1708	8.055	68
197.	Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M . A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. <i>J Neurol</i> 2000;247:297-302	3.783	39
198.	Herrlinger U, Weller M , Dichgans J, Melms A. Association of primary CNS lymphoma with long-term azathioprine therapy for myasthenia gravis? <i>Ann Neurol</i> 2000;47:682-683	10.250	23
199.	Gleichmann M, Weller M , Schulz JB. Insulin-like growth factor (IGF)-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation. <i>Neurosci Lett</i> 2000;282:69-72	2.159	36
200.	Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M . Transforming growth factors β_1 (TGF- β_1) and TGF- β_2 promote glioma cell migration <i>via</i> up-regulation of $\alpha_v\beta_3$ integrin expression. <i>Biochem Biophys Res Commun</i> 2000;268:607-611	2.559	101
201.	Hermisson M, Wagenknecht B, Wolburg H, Glaser T, Dichgans J, Weller M . Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. <i>Oncogene</i> 2000;19:2338-2345	6.854	38
202.	Küker W, Friese S, Vogel M, Schmidt F, Weller M . Incomplete resolution of basilar artery occlusion after intraarterial thrombolysis: abciximab and heparin prevent early rethrombosis. <i>Cerebrovasc Dis</i> 2000;10:484-486	2.931	7
203.	Hermisson M, Weller M . Hyperthermia enhances the chemosensitivity of human malignant glioma cells. <i>Anticancer Res</i> 2000;20:1819-1824	1.865	12
204.	Wendling U, Walczak H, Dörr J, Jacobi C, Weller M , Krammer PH, Zipp F. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. <i>Cell Death Differ</i> 2000;7:637-644	8.000	49
205.	Winter S, Weller M . Poly(ADP-ribose)polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. <i>Eur J Pharmacol</i> 2000;398:177-183	3.040	4
206.	Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M . Treosulfan chemotherapy for recurrent malignant glioma. <i>J Neuro-Oncol</i> 2000;49:231-234	3.060	7
207.	Schmidt F, Groscurth P, Dichgans J, Weller M . Human malignant glioma cells are refractory to retinoic acid-mediated differentiation and sensitization to apoptosis. <i>Cell Physiol Biochem</i> 2000;10:159-168	5.500	13

208.	Zipp F, Wendling U, Beyer M, Grieger U, Walczies S, Wagenknecht B, Haas J, Weller M . Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. <i>J Neuroimmunol</i> 2000;110:214-222	2.655	21
209.	Kirschnek S, Paris F, Weller M , Ferlinz K, Riehle A, Fuks Z, Kolesnick R, Gulbins E. CD95-mediated apoptosis in vivo involves acid sphingomyelinase. <i>J Biol Chem</i> 2000;275:27316-27323	2.939	106
210.	Roth W, Wild-Bode C, Platten M, Grimm C, Melkonyan HS, Dichgans J, Weller M . Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. <i>Oncogene</i> 2000;19:4210-4220	6.854	119
211.	Grassmé H, Kirschnek S, Riethmüller J, Riehle A, von Kürthy G, Lang F, Weller M , Gulbins E. Host defense to <i>Pseudomonas aeruginosa</i> requires mammalian cell apoptosis via CD95/CD95 ligand. <i>Science</i> 2000;290:527-530	41.058	200
212.	Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M . Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. <i>J Neurochem</i> 2000;75:2288-2297	4.609	76
213.	Winter S, Strik H, Rieger J, Beck J, Meyermann R, Weller M . Glutathione S-transferase and drug sensitivity in malignant glioma. <i>J Neurol Sci</i> 2000;179:115-121	2.448	10
214.	Vietor M, Winter S, Groscurth P, Naumann U, Weller M . On the significance of telomerase activity in human malignant glioma cells. <i>Eur J Pharmacol</i> 2000;407:27-37	3.040	3
215.	Strik H, Weller M , Frank B, Hermisson M, Deininger MH, Dichgans J, Meyermann R. Heat shock protein expression in human gliomas. <i>Anticancer Res</i> 2000;20:4457-4462	1.865	32
216.	Eberhardt O, v. Coelln R, Kügler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, Isenmann S, Gravel C, Srinivasan A, Bähr M, Weller M , Dichgans J, Schulz JB. Protection by synergistic effects of adenovirus-mediated XIAP and GDNF gene transfer in the MPTP model of Parkinson's disease. <i>J Neurosci</i> 2000;20:9126-9134	5.971	153
2001			
217.	Weller M , Streffer J, Wick W, Kortmann RD, Heiss E, Küker W, Meyermann R, Dichgans J, Bamberg M. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma: a phase II study. <i>Cancer</i> 2001;91:423-427	6.537	21
218.	Weber RG, Rieger J, Naumann U, Lichter P, Weller M . Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. <i>Int J Cancer</i> 2001;91:213-218	7.360	24
219.	Küker W, Schmidt F, Friese S, Block F, Weller M . Unilateral thalamic oedema in internal cerebral venous thrombosis. <i>Cerebrovasc Dis</i> 2001;12:341-345	2.931	13
220.	Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M . Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. <i>Acta Neuropathol</i> 2001;101:217-224	15.876	24
221.	Isenmann S, Engel S, Kügler S, Gravel C, Weller M , Bähr M. Intravitreal adenoviral gene transfer evokes an immune response in the retina that is directed against the heterologous lacZ transgene product but does not limit transgene expression. <i>Brain Res</i> 2001;892:229-240	3.125	21

222.	Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kanz L, Bamberg M, Dichgans J, Weller M . Primary CNS lymphoma 1991-1997: Outcome and late adverse effects after combined modality treatment. <i>Cancer</i> 2001;91:130-135	6.537	33
223.	Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M . Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. <i>Eur J Pharmacol</i> 2001;412:21-25	3.040	23
224.	Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M . APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. <i>Cell Death Differ</i> 2001;8:403-410	8.000	70
225.	Brötz D, Weller M , Küker W, Dichgans J, Götz A. Mechanische physiotherapeutische Diagnostik und Therapie bei Patienten mit lumbalen Bandscheibenvorfällen. <i>Aktuel Neurol</i> 2001;28:74-81		3
226.	Glaser T, Castro M, Lowenstein P, Weller M . Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells. <i>Gene Therapy</i> 2001;8:469-476	3.203	14
227.	Von Coelln R, Kügler S, Bähr M, Weller M , Dichgans J, Schulz JB. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. <i>J Neurochem</i> 2001;77:263-273	4.609	61
228.	Gerhardt E, Kügler S, Leist M, Beier C, Berliocchi L, Volbracht C, Weller M , Bähr M, Nicotera P, Schulz JB. Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. <i>Mol Cell Neurosci</i> 2001;17:717-731	3.312	72
229.	Streffer J, Bitzer M, Schabet M, Dichgans J, Weller M . Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. <i>Neurology</i> 2001;56:1219-1221	8.055	44
230.	Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M . The soluble decoy receptor-3 is expressed by malignant glioma and suppresses CD95 ligand-induced apoptosis and chemotaxis. <i>Cancer Res</i> 2001;61:2759-2765	9.130	152
231.	Glaser T, Weller M . Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. <i>Biochem Biophys Res Commun</i> 2001;281:322-327	2.559	25
232.	Wild-Bode C, Weller M , Rimmer A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. <i>Cancer Res</i> 2001;61:2744-2750	9.130	325
233.	Wagenknecht B, Roth W, Gulbins E, Wolburg H, Weller M . C2-ceramide signalling in glioma cells: synergistic enhancement of CD95-mediated, caspase dependent apoptosis. <i>Cell Death Differ</i> 2001;8:595-602	8.000	24
234.	Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M . N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits TGF- β release and reduces migration and invasiveness of human malignant glioma cells. <i>Int J Cancer</i> 2001;93:53-61	7.360	55
235.	Bähr O, Wick W, Weller M . Modulation of MDR/MRP by wild-type and mutant p53 (letter). <i>J Clin Invest</i> 2001;107:643-645	13.251	30
236.	Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M . Ezrin-dependent	5.971	73

promotion of glioma cell clonogenicity, motility and invasion mediated by BCL-2 and TGF- β_2 . *J Neurosci* 2001;21:3360-3368

- | | | | |
|-------------|--|--------|-----|
| 237. | Bühring U, Herrlinger U, Krings T, Thiex R, Weller M , Küker W. MRI features of primary central nervous system lymphomas (PCNSL) at presentation. <i>Neurology</i> 2001;57:393-396 | 8.055 | 136 |
| 238. | Glaser T, Wagenknecht B, Weller M . Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. <i>Oncogene</i> 2001;20:4757-4767 | 6.854 | 45 |
| 239. | Wild-Bode C, Weller M , Wick W. Molecular determinants of glioma cell migration and invasion. <i>J Neurosurg</i> 2001;94:978-984 | 4.319 | 87 |
| 240. | Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, Weller M , Platten M. Processing of immunosuppressive pro-TGF- $\beta_{1,2}$ by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. <i>J Immunol</i> 2001;166:7238-7243 | 4.539 | 80 |
| 241. | Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M . CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. <i>Oncogene</i> 2001;20:4128-4137 | 6.854 | 76 |
| 242. | Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M . Chimeric tumor suppressor 1 (CTS1), a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. <i>Cancer Res</i> 2001;61:5833-5842 | 9.130 | 33 |
| 243. | Xia XG, Harding T, Weller M , Bienemann A, Uney JB, Schulz JB. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. <i>Proc Natl Acad Sci USA</i> 2001;98:10433-10438 | 9.504 | 183 |
| 244. | Naumann U, Weit S, Wischhusen J, Weller M . Diva/boo is a negative regulator of cell death in human glioma cells. <i>FEBS Lett</i> 2001;505:23-26 | 2.999 | 14 |
| 245. | Wick W, Platten M, Weller M . Glioma cell invasion: regulation of metalloproteinase activity by TGF- β . <i>J Neuro-Oncol</i> 2001;53:177-185 | 3.060 | 148 |
| 246. | Platten M, Wick W, Wischhusen J, Weller M . N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon- γ (IFN- γ). <i>Br J Pharmacol</i> 2001;134:1279-1284 | 6.810 | 16 |
| 247. | Grassmé H, Kirschnek S, Riethmueller J, Riehle A, von Kürthy G, Lang F, Weller M , Gulbins E. Role of apoptosis in <i>Pseudomonas aeruginosa</i> pneumonia. <i>Science</i> 2001;294:1783a (Reply) | 41.058 | |
| 248. | Rimner A, Wischhusen J, Naumann U, Gleichmann M, Steinbach JP, Weller M . Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells. <i>Anticancer Res</i> 2001;21:3505-3508 | 1.865 | 3 |
| 2002 | | | |
| 249. | Steinbach JP, Supra P, Huang HJS, Cavenee WK, Weller M . CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. <i>Brain Pathol</i> 2002;12:12-20 | 6.187 | 30 |
| 250. | Herrlinger U, Weller M , Küker W. Primary CNS lymphoma of the spinal cord: clinical manifestation may precede MRI detectability. <i>Neuroradiology</i> 2002;44:239-244 | 2.346 | 16 |

251.	Hermisson M, Klein R, Schmidt F, Weller M , Küker W. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. <i>Acta Neurol Scand</i> 2002;105:450-453	3.126	19
252.	Gleichmann M, Buchheim G, El-Bizri H, Yokota Y, Klockgether T, Kügler S, Bähr M, Weller M , Schulz JB. Identification of inhibitor-of-differentiation 2 as a modulator of neuronal apoptosis. <i>J Neurochem</i> 2002;80:755-762	4.609	26
253.	Von Pfeil A, Hakenjos L, Herskind C, Dittmann KH, Weller M , Rodemann HP. Irradiated homozygous TGFβ1-knockout fibroblasts show enhanced clonogenic survival as compared to TGFβ1-wild-type fibroblasts. <i>Int J Radiat Biol</i> 2002;78:331-339	1.970	25
254.	Herrlinger U, Schabet M, Brugger W, Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benöhr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M , for the Neuro-Oncology Working Group (NOA) of the German Cancer Society. German cancer society neuro-oncology group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. <i>Ann Neurol</i> 2002;51:247-252	10.250	116
255.	Hueber A, Welsandt G, Jordan JF, Mietz H, Weller M , Krieglstein GK, Esser PJ. Characterization of CD95 ligand (CD95L)-induced apoptosis in human Tenon fibroblasts. <i>Exp Eye Res</i> 2002;75:1-8	3.152	8
256.	Streffler JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M . Bcl-2 family protein expression modulates radiosensitivity in human glioma cells. <i>J Neuro-Oncol</i> 2002;56:43-49	3.060	43
257.	Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M . Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. <i>Cancer Res</i> 2002;62:1915-1919	9.130	87
258.	Herrlinger U, Küker W, Dichgans J, Weller M . First-line therapy with temozolomide induces regression of primary CNS lymphoma. <i>Neurology</i> 2002;58:1573-1574	8.055	26
259.	Wiendl H, Mitsdörffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M . A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. <i>J Immunol</i> 2002;168:4772-4780	4.539	237
260.	Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M . Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. <i>Cancer Res</i> 2002;62:2592-2599	9.130	112
261.	Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M , Kleihues P, Ohgaki H. Methylation of the p73 gene in gliomas. <i>Acta Neuropathol</i> 2002;104:357-362	15.876	39
262.	Reichert M, Steinbach J, Supra P, Weller M . Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. A new look at the efficacy of nitrosoureas. <i>Cancer</i> 2002;95:1113-1119	6.537	42
263.	Wick W, Hermisson M, Küker WM, Kortmann RD, Duffner F, Dichgans J, Bamberg M, Weller M . Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma. A phase II study. <i>J Neuro-Oncol</i> 2002;59:151-155	3.060	21
264.	Waltereit R, Küker W, Jürgens S, Weller M , Dichgans J, Wiendl H. Acute transverse myelitis associated with coxiella burnetii infection. <i>J Neurol</i> 2002;249:1459-1461	3.783	6

265. Wick W, Stock J, Seyfried J, Baumgart J, Wüllner U, **Weller M**. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by a glutathione depleting agent, BSO, in malignant glioma cells in vitro and in vivo. *Int J Oncol* 2002;21:213-200 3.333 4
266. Müller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, **Weller M**, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. *Am J Pathol* 2002;161:313-319 4.069 125
267. Schmidt F, Faul C, Dichgans J, **Weller M**. Low molecular weight heparin for deep vein thrombosis in glioma patients. *J Neurol* 2002;249:1409-1412 3.783 32
268. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, **Weller M**. Gliomatosis cerebri. Molecular pathology and clinical course. *Ann Neurol* 2002;52:390-399 10.250 55
269. Hipp MS, Urbich V, Mayer P, Wischhusen J, **Weller M**, Kracht M, Spyridopoulos I. Proteasome inhibition leads to NF- κ B independent interleukin-8 transactivation in human endothelial cells through induction of AP-1. *Eur J Immunol* 2002;32:2208-2217 4.248 55
270. Wick A, Wick W, Waltenberger J, **Weller M**, Dichgans J, Schulz JB. Hypoxic neuroprotection requires sequential activation of vascular endothelial growth factor receptor and Akt. *J Neurosci* 2002;22:6401-6407 5.971 225
271. Fulda S, Wick W, **Weller M**, Debatin KM. Smac agonists sensitize for TRAIL/Apo2L- or anticancer drug-induced apoptosis and induce regression of human glioma xenografts. *Nat Med* 2002;8:808-815 32.621 596
272. Küker W, Herrlinger U, Grönwäller E, Rohrbach JM, **Weller M**. Ocular manifestation of PCNSL: what can be expected from imaging? *J Neurol* 2002;249:1713-1716 3.783 13
273. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, **Weller M**, Jäättelä M. Eradication of glioblastoma and breast and colon carcinoma xenografts by Hsp70 depletion. *Cancer Res* 2002;62:7139-7142 9.130 115
274. Waltereit R, **Weller M**. The role of caspase 9 and 9-short (9S) in death ligand- and drug-induced apoptosis in human astrocytoma cells. *Mol Brain Res* 2002;106:42-49 3.125 10
- 2003**
275. Wiendl H, Mitsdörffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmüller H, Hohlfeld R, Melms A, **Weller M**. The nonclassical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. *Brain* 2003;126:176-185 10.848 66
276. Naumann U, Waltereit R, Schulz JB, **Weller M**. Adenoviral (full length) Apo2L/TRAIL gene therapy is an ineffective treatment strategy for malignant glioma. *J Neuro-Oncol* 2003;61:7-15 3.060 13
277. Wiendl H, Mitsdörffer M, Schneider D, Melms A, Lochmüller H, Hohlfeld R, **Weller M**. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible costimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. *Brain* 2003;126:1026-1035 10.848 78
278. Rieger J, Wick W, **Weller M**. Human malignant glioma cell lines express semaphorins and their receptors, neuropilins and plexins. *Glia* 2003;42:379-389 5.846 75

279.	Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M , Kolesnick R, Gulbins E. Host defense against <i>P. aeruginosa</i> requires ceramide-rich membrane rafts. <i>Nat Med</i> 2003;9:322-330	32.621	348
280.	Wiendl H, Feiden W, Scherieble H, Renz T, Dichgans J, Weller M . A 41 year old woman with a solitary lesion in the liver. <i>Brain Pathol</i> 2003;13:421-423	6.187	10
281.	Brötz D, Küker W, Maschke E, Wick W, Dichgans J, Weller M . A prospective trial of mechanical physiotherapy for lumbar disk prolapse. <i>J Neurol</i> 2003;250:746-749	3.783	12
282.	Hueber A, Weller M , Welsandt G, Kociok N, Kirchhof B, Esser P. Daunorubicin induces apoptosis in retinal pigment epithelial cells. Modulation by CD95L. <i>Invest Ophthalmol Vis Sci</i> 2003;44:2851-2857	3.388	6
283.	Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M . Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. <i>Cell Death Differ</i> 2003;10:823-832	8.000	64
284.	Wiendl H, Neuhaus O, Mehling M, Winterle S, Schreiner B, Mitsdörffer M, Wienhold W, Weissert R, Wessels J, Hartung HP, Weller M , Tolosa E, Melms A. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. <i>J Neuroimmunol</i> 2003;140:177-187	2.655	9
285.	Hermisson M, Weller M . NF- κ B-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signalling pathways in human malignant glioma cells. <i>Cell Death Differ</i> 2003;10:1078-1089	8.000	16
286.	Platten M, Kretz A, Naumann U, Aulwurm S, Isenmann S, Weller M . MCP-1 increases macrophage infiltration and aggressiveness of murine gliomas. <i>Ann Neurol</i> 2003;54:388-392	10.250	117
287.	Wiendl H, Mitsdörffer M, Schneider D, Chen L, Lochmüller H, Melms A, Weller M . Human muscle cells express the negative regulatory B7-related molecule B7-H1 (PD-L1): a mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies? <i>FASEB J</i> 2003;17:1892-1894	5.595	74
288.	Schreiner B, Wischhusen J, Mitsdörffer M, Schneider D, Bornemann A, Melms A, Tolosa E, Weller M , Wiendl H. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. <i>Glia</i> 2003;44:296-301	5.846	21
289.	Platten M, Eitel K, Wischhusen J, Dichgans J, Weller M . Involvement of protein kinase C α and extracellular signal-regulated kinase-1/2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). <i>Biochem Pharmacol</i> 2003;66:1263-1270	2.559	22
290.	Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P, Weller M . Adenoviral natural born killer (NBK) gene therapy of malignant glioma. <i>Hum Gene Therapy</i> 2003;14:1235-1246	4.241	26
291.	Neuro-Oncology Working Group (NOA) of the German Cancer Society. Neuro-Oncology Working Group (NOA)-01 trial of ACNU/VM26 <i>versus</i> ACNU/Ara-C chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. <i>J Clin Oncol</i> 2003;21:3276-3284 (Corresponding author)	26.360	105
292.	Bähr O, Rieger J, Duffner F, Meyermann R, Weller M , Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant	6.187	40

glioma cell lines, but not in primary glioma cells. *Brain Pathol* 2003;13:482-494

- | | | | |
|-------------|--|--------|-----|
| 293. | Baeza N, Weller M , Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. <i>Acta Neuropathol</i> 2003;106:479-485 | 15.876 | 83 |
| 294. | Herrlinger U, Schwärzler F, Beck R, Küker W, Hebart H, Kanz L, Dichgans J, Weller M . Progressive multifocal leukoencephalopathy. Cidofovir therapy in three patients with underlying haematological disease. <i>J Neurol</i> 2003;250:612-614 | 3.783 | 9 |
| 295. | Wintterle S, Schreiner B, Mitsdörffer M, Schneider D, Chen L, Meyermann R, Weller M , Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. <i>Cancer Res</i> 2003;63:7462-7467 | 9.130 | 245 |
| 296. | Meuth SG, Budde T, Duyar H, Landgraf P, Broicher T, Elbs M, Brock R, Weller M , Weissert R, Wiendl H. Modulation of neuronal activity by the endogenous pentapeptide QYNAD. <i>Eur J Neurosci</i> 2003;18:2697-2706 | 2.832 | 5 |
| 297. | Weissert R, Wiendl H, Pfrommer H, Storch MK, Schreiner B, Barth S, Seifert T, Melms A, Dichgans J, Weller M . Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. <i>J Neuroimmunol</i> 2003;144:28-37 | 2.655 | 21 |
| 298. | Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M . MICA/NKG2D-mediated immunogene therapy of experimental gliomas. <i>Cancer Res</i> 2003;63:8996-9006 | 9.130 | 131 |
| 299. | Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M . CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell death. <i>Oncogene</i> 2003;22:8233-8245 | 6.854 | 94 |
| 2004 | | | |
| 300. | Naumann U, Wick W, Beschorner R, Meyermann R, Weller M . Expression and functional activity of osteoprotegerin in human malignant gliomas. <i>Acta Neuropathol</i> 2004;107:17-22 | 15.876 | 13 |
| 301. | Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M . MIP-1alpha antagonizes the effect of a GM-CSF and IL-4-enhanced subcutaneous vaccine in a mouse glioma model. <i>J Neuro-Oncol</i> 2004;66:147-154 | 3.060 | 11 |
| 302. | Steinbach JP, Klumpp A, Wolburg H, Weller M . Inhibition of epidermal growth factor receptor 2 signalling protects human malignant glioma cells from hypoxia-induced cell death. <i>Cancer Res</i> 2004;64:1575-1578 | 9.130 | 53 |
| 303. | Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M . One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. <i>Neurology</i> 2004;62:2113-2115 | 8.055 | 105 |
| 304. | Küker W, Weller M , Klose U, Krapf H, Dichgans J, Nägele T. Diffusion-weighted MRI of spinal cord infarction: high resolution imaging and time course of diffusion abnormality. <i>J Neurol</i> 2004;251:818-824 | 3.783 | 65 |
| 305. | Wick W, Wick A, Küker W, Dichgans J, Weller M . Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. <i>J Neuro-Oncol</i> 2004;70:73-75 | 3.060 | 11 |
| 306. | Eberhardt O, Küker W, Dichgans J, Weller M . HSV-2 sacral radiculitis (Elsberg syndrome). <i>Neurology</i> 2004;63:758-759 | 8.055 | 37 |

307.	Wisshusen J, Melino G, Weller M. p53 and its family members – reporter genes may not see the difference. <i>Cell Death Differ</i> 2004;11:1150-1152	8.000	11
308.	Herrlinger U, Wiendl H, Renninger M, Förchler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. <i>Br J Cancer</i> 2004;91:219-224	5.922	40
309.	Herrlinger U, Förchler H, Küker W, Meyermann R, Bamberg M, Dichgans J, Weller M. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. <i>J Neurol Sci</i> 2004;223:167-178	2.448	72
310.	Steinbach J, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. <i>Biochem Biophys Res Commun</i> 2004;321:524-530	2.559	40
311.	Schreiner B, Mitsdörffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon- β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T cell activation: relevance for the immune modulatory effect in multiple sclerosis. <i>J Neuroimmunol</i> 2004;155:172-182	2.655	163
312.	Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J, Weller M, Schulz JB. Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. <i>J Neurochem</i> 2004;91:1067-1074	4.609	40
313.	Naumann U, Wischhusen J, Weit S, Wolburg H, Massing U, Weller M. Alkylphosphocholine-induced glioma cell death is BCL-X _L -sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. <i>Cell Death Differ</i> 2004;11:1326-1341	8.000	15
314.	Wick W, Wild-Bode C, Frank B, Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. <i>J Neurochem</i> 2004;91:1275-1283	4.609	27
315.	Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA interference targeting TGF- $\beta_{1,2}$ enhances NKG2D-mediated anti-glioma immune response, inhibits glioma cell migration and invasiveness and abrogates tumorigenicity <i>in vivo</i> . <i>Cancer Res</i> 2004;64:7596-7603	9.130	187
316.	Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel TGF- β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Res</i> 2004;64:7954-7961	9.130	277
317.	Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Löwenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. <i>Cancer Gene Ther</i> 2004;11:721-732	4.044	55
2005			
318.	Herrlinger U, Rieger J, Steinbach JP, Nägele T, Dichgans J, Weller M. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. <i>J Neuro-Oncol</i> 2005;71:295-299	3.060	26
319.	Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U, Weller M. Adult medulloblastoma: prognostic factors	3.783	55

and response to therapy at diagnosis and at relapse. *J Neurol* 2005;252:291-299

- | | | | |
|------|---|--------|------|
| 320. | Duffner F, Ritz R, Freudenstein D, Weller M , Dietz K, Wessels J. Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. <i>J Neuro-Oncol</i> 2005;71:107-111 | 3.060 | 24 |
| 321. | Küker W, Nägele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M , Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. <i>J Neuro-Oncol</i> 2005;72:169-177 | 3.060 | 167 |
| 322. | Mitsdörffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M , Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T-cell activation and is up-regulated by interferon- β in vitro and in vivo: rationale for the therapy of multiple sclerosis. <i>J Neuroimmunol</i> 2005;159:155-164 | 2.655 | 51 |
| 323. | Jahnke K, Korfel A, Martus M, Weller M , Herrlinger U, Schmittel A, Fischer L, Thiel E, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. <i>Ann Oncol</i> 2005;16:445-449 | 13.930 | 58 |
| 324. | Steinbach JP, Wolburg H, Klump A, Weller M . Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. <i>J Neurochem</i> 2005;92:1340-1349 | 4.609 | 7 |
| 325. | Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M , Coupland SE, Krümpelmann U, Stein H, Korfel A. Low-grade primary central nervous system lymphoma in immunocompetent patients. <i>Br J Hematol</i> 2005;128:616-624 | 4.248 | 24 |
| 326. | Stupp R, Mason WP, van den Bent MJ, Weller M , Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Cairncross JG, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Eisenhauer E, Mirimanoff RO, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. <i>N Engl J Med</i> 2005;352:987-996 | 79.260 | 8628 |
| 327. | Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M , Kros JM, Hainfellner JA, Mason WP, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross G, Janzer R, Stupp R. MGMT gene silencing and response to temozolomide in glioblastoma. <i>N Engl J Med</i> 2005;352:997-1003 | 79.260 | 3297 |
| 328. | Uhl M, Weiler M, Wick W, Jacobs AH, Weller M , Herrlinger U. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. <i>Biochem Biophys Res Commun</i> 2005;328:125-129 | 2.559 | 43 |
| 329. | Wischhusen J, Schneider D, Mittelbronn M, Meyermann R, Engelmann H, Jung G, Wiendl H, Weller M . Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. <i>J Neuroimmunol</i> 2005;162:28-42 | 2.655 | 23 |
| 330. | Eyüpoglu IY, Hahnen E, Buslei R, Siebzehrnühl FA, Savaskan NE, Lüders M, Tränkle C, Wick W, Weller M , Fahlbusch R, Blümcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. <i>J Neurochem</i> 2005;93:992-999 | 4.609 | 75 |
| 331. | Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M . Relapse of primary CNS lymphoma after more than 10 years in complete remission. <i>J Neurol</i> 2005;252:1409-1410 | 3.783 | 7 |
| 332. | Wick W, Weller M . How lymphotoxic is dose-intensified temozolomide? The glioblastoma | 26.360 | 38 |

experience. J Clin Oncol 2005;23:4235-4236

333. Wischhusen J, Friese M, Mittelbronn M, Meyermann R, **Weller M**. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 2005;64:523-528 3.490 79
334. Herrlinger U, Küker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, **Weller M**, for the Neuro-Oncology Working Group of the German Cancer Society. NOA-03 multicenter trial of high-dose methotrexate in primary CNS lymphoma: final report. Ann Neurol 2005;57:843-847 10.250 104
335. Amatya VJ, Naumann U, **Weller M**, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol 2005;110:178-184 15.876 57
336. Küker W, Nägele T, Thiel E, **Weller M**, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 2005;65:1129-1131 8.055 14
337. Beier CP, Wischhusen J, Gleichmann M, Gerhardt E, Pekanovic A, Krüger A, Taylor V, Suter U, Krammer PH, Endres M, **Weller M**, Schulz JB. FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 2005;25:6765-6774 5.971 39
338. Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Böhmler AM, Wischhusen J, Rieger J, Blümcke I, **Weller M**, Wick W. Lessons from the bone marrow: how malignant glioma cells attract adult hematopoietic progenitor cells. Brain 2005;128:2200-2211 10.848 58
339. Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brück W, Meyermann R, Bar-Or A, Kieseier BC, **Weller M**. Expression of the immune tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005;128:2689-2704 10.848 101
340. Grosse-Hovest L, Wick W, Minoia R, **Weller M**, Rammensee HG, Brem G, Jung G. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 2005;117:1060-1064 7.360 18
341. Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, **Weller M**. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005;28:391-396 44
342. Danielyan L, Mueller L, Proksch B, Kabisch D, **Weller M**, Wiesinger H, Bunitian GH, Gleiter CH. Similar protective effects of BQ-123 and erythropoietin on survival of neural cells and generation of neurons upon hypoxic injury. Eur J Cell Biol 2005;84:907-913 2.939 13
343. Ritz R, Müller M, **Weller M**, Dietz K, Kuci S, Roser F, Tatagiba M. Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitro. Int J Oncol 2005;27:1543-1549 3.333 9
- 2006**
344. Naumann U, Huang H, Wolburg H, Wischhusen J, Weit S, Ohgaki H, **Weller M**. PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells. Cancer Gene Ther 2006;13:469-478 4.044 7
345. Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, **Weller M**. Enhanced episodic-like 4.609 55

memory and kindling epilepsy in a rat model of tuberous sclerosis. *J Neurochem* 2006;96:407-413

346. Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, Tatagiba M, Bamberg M, Dichgans J, Karnath HO, **Weller M**. Surviving glioblastoma for more than 5 years: the patients' perspective. *Neurology* 2006;66:239-242 8.055 46
347. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, **Weller M**, Friese MA. TGF- β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. *Brain* 2006;129:2416-2425 10.848 128
348. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, **Weller M**. O⁶-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. *J Neurochem* 2006;96:766-776 4.609 196
349. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, **Weller M**. PCV chemotherapy for recurrent glioblastoma. *Neurology* 2006;66:587-589 8.055 39
350. Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, **Weller M**, Wick W. BCL-x(L): time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. *Cell Death Differ* 2006;13:1156-1169 8.000 31
351. Fischer L, Jahnke K, Martus P, **Weller M**, Thiel E, Korfel A. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. *Haematologica* 2006;91:429-430 9.090 16
352. Aulwurm S, Wischhusen J, Friese M, Borst B, **Weller M**. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting anti-glioma immunity in vivo. *Int J Cancer* 2006;118:1728-1735 7.360 25
353. Roth P, Aulwurm S, Gekel I, Beier D, Sperry RG, Mittelbronn M, Meyermann R, Beaman KD, **Weller M**, Wischhusen J. Regeneration and tolerance factor (RTF): a novel mediator of glioblastoma-associated immunosuppression. *Cancer Res* 2006;66:3852-3858 9.130 17
354. Ernemann U, Rieger J, Tatagiba M, **Weller M**. An MRI view of a ruptured dermoid cyst. *Neurology* 2006;66:270 8.055 1
355. Jahnke K, Thiel E, Martus P, Herrlinger U, **Weller M**, Fischer L, Korfel A, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. *J Neuro-Oncol* 2006;80:159-165 3.060 62
356. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger R, **Weller M**. UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. *J Clin Oncol* 2006;24:4412-4417 26.360 98
357. Tabatabai G, Frank B, Möhle R, **Weller M**, Wick W. Irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas by TGF- β -dependent HIF-1 α -mediated induction of CXCL12. *Brain* 2006;129:2426-2435 10.848 83
358. Grassme H, Jin J, Wilker B, von Kürthy G, Wick W, **Weller M**, Möröy T, Gulbins E. Regulation of pulmonary *Pseudomonas aeruginosa* infection by the transcriptional repressor Gfi1. *Cell Microbiol* 2006;8:1096-1105 4.410 11

359.	Eberhardt O, Nägele T, Raygrotzki S, Weller M , Ernemann U. Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: case series and review of the literature. <i>J Vasc Surg</i> 2006;43:1145-1154	3.294	72
360.	Scheel B, Aulwurm S, Probst J, Hoerr I, Rammensee HG, Weller M , Pascolo S. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. <i>Eur J Immunol</i> 2006;36:2807-2816	4.248	58
2007			
361.	Burghardt I, Tritschler F, Opitz CA, Frank F, Weller M , Wick W. Pirfenidone inhibits TGF- β expression in malignant glioma cells. <i>Biochem Biophys Res Commun</i> 2007;354:542-547	2.559	30
362.	Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M , Menck CFM, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O ⁶ -methylguanine. <i>Oncogene</i> 2007;26:186-197	6.854	285
363.	Mittelbronn M, Kröber SM, Wersebe A, Weller M , Hewer W, Meyermann R, Kaiserling E, Beschorner R. A 63-year-old man with dementia, ataxia and VI nerve palsy. <i>Brain Pathol</i> 2007;17:466-467	6.187	4
364.	Wiendl H, Kieseier BC, Weissert R, Mylius HA, Pichlmeier U, Hartung HP, Melms A, Küker W, Weller M . Treatment of active secondary progressive multiple sclerosis with treosulfan. <i>J Neurol</i> 2007;254:884-889	3.783	14
365.	Mittelbronn M, Capper D, Bunz B, Dietz K, Goepfert B, Ajaaj R, Tabatabai T, Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M , Meyermann R, Simon P. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. <i>Neuropathol Appl Neurobiol</i> 2007;33:299-307	6.059	18
366.	Tabatabai G, Frank B, Wick A, Lemke D, Von Kürthy G, Obermüller U, Heckl S, Christ G, Weller M , Wick W. Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Ann Neurol</i> 2007;61:153-156	10.250	67
367.	Warth A, Simon P, Capper D, Goepfert B, Tabatabai G, Herzog H, Dietz K, Stubenvoll F, Ajaaj R, Becker R, Weller M , Meyermann R, Wolburg H, Mittelbronn M. Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. <i>J Neurosci Res</i> 2007;85:1336-1346	2.662	72
368.	Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M , Wong DH. Inhibiting TGF- β signaling restores immune surveillance in the SMA-560 glioma model. <i>Neuro-Oncology</i> 2007;9:259-270	9.384	55
369.	Mittelbronn M, Schittenhelm J, Lemke D, Ritz R, Nägele T, Weller M , Meyermann R, Beschorner R. Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components. <i>Neuropathology</i> 2007;27:463-467	1.887	25
370.	Naumann U, Bähr O, Wolburg W, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M . Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. <i>Gene Therapy</i> 2007;14:147-161 (Corrigendum 2007;14:1434-1437)	3.203	22
371.	Rieger J, Frank B, Weller M , Wick W. Mechanisms of resistance of human glioma cells to	5.500	18

Apo2 ligand/TNF-related apoptosis-inducing ligand. *Cell Physiol Biochem* 2007;20:23-34

372. Brötz D, Eichner M, Gasser T, **Weller M**, Steinbach JP. Radicular and non-radicular back pain in Parkinson's disease: a controlled study. *Movement Disorders* 2007;22:853-856 8.324 67
373. Kita D, Yonekawa Y, **Weller M**, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. *Acta Neuropathol* 2007;113:295-302 15.876 64
374. Grammatikos G, Teichgräber V, Carpinteiro A, Trarbach T, **Weller M**, Hengge UR, Gulbins E. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. *Antioxid Redox Sign* 2007;9:1449-1456 6.530 24
375. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, **Weller M**, Wick W. Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma. *J Clin Oncol* 2007;25:3357-3361 26.360 196
376. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, **Weller M**, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? *Acta Neuropathol* 2007;114:111-119 15.876 39
377. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, **Weller M**. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. *Cancer Res* 2007;67:3540-3544 9.130 52
378. Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, Wong R, De Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, Van den Bent MJ, **Weller M**, Bottomley A. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an EORTC BTG, ROG, and NCIC international randomized phase III study. *Br J Cancer* 2007;97:302-307 5.922 60
379. Mittelbronn M, Simon P, Löffler C, Capper D, Bunz B, Harter P, Schlaszus H, Schleich A, Tabatabai G, Goeppert B, Meyermann R, **Weller M**, Wischhusen J. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8⁺ cells. *J Neuroimmunol* 2007;189:50-58 2.655 39
380. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, **Weller M**, Schackert G, for the German Glioma Network. Long-term survival with glioblastoma. *Brain* 2007;130:2596-2606 10.848 429
381. **Weller M**, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Löffler M, Pietsch P, von Deimling A, for the German Glioma Network. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? *Clin Cancer Res* 2007;13:6933-6937 10.199 102
- 2008**
382. Brötz D, Hahn U, Maschke E, Wick W, Küker W, **Weller M**. Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. *Neurorehabilitation* 2008;23:289-294 1.779 3
383. Gorlia T, Van den Bent MJ, Hegi ME, Mirimanoff RO, **Weller M**, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Denis Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *Lancet Oncol* 2008;9:29-38 36.421 273

384.	Roth P, Happold C, Eisele G, Nägele T, Weller M , Luft AR. A series of patients with subpial hemorrhage: clinical manifestation, neuroradiological presentation and therapeutic implications. <i>J Neurol</i> 2008;255:1018-1022	3.783	3
385.	Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, DasMahapatra B, Weller M . A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. <i>Cell Death Differ</i> 2008;15:718-729	8.000	47
386.	Schmidt F, Knobbe CB, Frank B, Wolburg H, Weller M . The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. <i>Oncol Rep</i> 2008;19:1061-1066	2.976	56
387.	Schittenhelm J, Reifenberger G, Ritz R, Nägele T, Weller M , Pantazis G, Capper D, Beschorner R, Meyermann R, Mittelbronn M. Primary anaplastic glioblastoma with a small-cell glioblastoma component. <i>Clin Neuropathol</i> 2008;27:91-95	1.015	11
388.	Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S, Voigt H, Becker JC, Leng L, Steinle A, Weller M , Bucala R, Dietl J, Wischhusen J. Macrophage migration inhibitory factor (MIF) contributes to the immune escape of ovarian cancer by down-regulating NKG2D. <i>J Immunol</i> 2008;180:7338-7348	4.539	86
389.	Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, Van Heeckeren AM, Barr ML, Von Kürthy G, Schmid KW, Weller M , Tümmler B, Lang F, Grassme H, Döring G, Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. <i>Nat Med</i> 2008;14:382-391	32.621	305
390.	Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason WP, van den Bent M, Weller M , Rorden C, Karnath HO, on behalf of the European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. A novel tool to analyse MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> 2008;10:1019-1024	9.384	56
391.	Naumann U, Maass P, Gleske Ak, Aulwurm S, Weller M , Eisele G. Glioma gene therapy with soluble transforming growth factor- β receptors II and III. <i>Int J Oncol</i> 2008;33:759-765	3.333	17
392.	Acioly MA, Carvalho CH, Pinheiro-Franco JL, Schittenhelm J, Ernemann U, Weller M , Honegger J. Unusual presentation of central nervous system metastases: mechanisms of spread and radiological findings. <i>Arq Neuropsiquiatr</i> 2008;66:755-757	1.015	2
393.	Glas M, Rasch K, Wiewrodt D, Weller M , Herrlinger U. Procarbazine and CCNU (PC) as initial treatment in gliomatosis cerebri. <i>Oncology</i> 2008;75:182-185		11
394.	Waerzeggers Y, Klein M, Miletic H, Himmelreich U, Li H, Herrlinger U, Hoehn M, Coenen HH, Weller M , Winkeler A, Jacobs AH. Multimodal imaging of neural progenitor cell fate in rodents. <i>Mol Imaging</i> 2008;7:77-91	2.976	41
395.	Strelau J, Schmeer C, Peterziel H, Paech T, Herold-Mende C, Steiner H, Weller M , Unsicker U. Expression and putative functions of GDF-15, a member of the TGF- β superfamily, in human glioma and glioblastoma cell lines. <i>Cancer Lett</i> 2008;270:30-39	6.491	18
396.	Fischer L, Martus P, Weller M , Klasen HK, Rhoden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. <i>Neurology</i> 2008;71:1102-1108	8.055	51
397.	Tabatabai G, Herrmann C, von Kürthy G, Mittelbronn M, Grau S, Frank B, Möhle R, Weller M , Wick W. VEGF-dependent induction of CD62E on endothelial cells mediates glioma	10.848	16

tropism of adult hematopoietic progenitor cells. *Brain* 2008;131:2579-2595

398. Kurzwelly D, Müller CA, Korfel A, Thiel E, Linnebank M, **Weller M**, Herrlinger U. Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. *J Neuro-Oncol* 2008;90:53-55 3.060 3
399. Rieger J, Lemke D, Maurer G, Weiler M, Frank B, Tabatabai G, **Weller M**, Wick W. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-X_L. *J Neurochem* 2008;106:2436-2448 4.609 23
400. Happold C, Ernemann U, Roth P, Wick W, **Weller M**, Schmidt F. Anticoagulation for radiation-induced neurotoxicity revisited. *J Neuro-Oncol* 2008;90:357-362 3.060 13
401. Tabatabai G, Schöber W, Ernemann U, **Weller M**, Krüger R. Vertebral artery dissection presenting with ipsilateral acute C5 and C6 sensorimotor radiculopathy: a case report. *Cases Journal* 2008;1:139 7
- 2009**
402. Maurer GD, Tritschler I, Adams A, Tabatabai G, Wick W, Stupp R, **Weller M**. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide *in vitro*. *Neuro-Oncology* 2009;11:747-756 9.384 60
403. Hofer S, Kollias S, **Weller M**. Evolution of glioblastoma. *Acta Oncol* 2009;48:630-631 3.473 1
404. Roth T, Sokolov AN, Messias A, Roth P, **Weller M**, Trauzettel-Klosinski S. Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. *Neurology* 2009;72:324-331 8.055 73
405. Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, Capper D, **Weller M**, Meyermann R, Mittelbronn M. Diagnostic value of WT1 in neuroepithelial tumours. *Neuropathol Appl Neurobiol* 2009;35:69-81 6.059 15
406. Mittelbronn M, Harter P, Warth A, Lupescu A, Schilbach K, Vollmann H, Capper D, Goepfert B, Frei K, Bertalanffy H, **Weller M**, Meyermann R, Lang F, Simon P. EGR-1 is regulated by N-methyl-D-aspartate receptor stimulation and associated with patient survival in human high grade astrocytomas. *Brain Pathol* 2009;19:195-204 6.187 13
407. Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, **Weller M**, Eisele G. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. *J Neuro-Oncol* 2009;92:45-48 3.060 29
408. Wick A, Pascher C, Wick W, Jauch T, **Weller M**, Bogdahn U, Hau P. Rechallenge with temozolomide in patients with recurrent gliomas. *J Neurol* 2009;256:734-741 3.783 67
409. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach PJ, Wick W, Kortmann RD, Reifenberger G, **Weller M**, Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. *J Clin Oncol* 2009;27:1257-1261 26.360 85
410. Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, **Weller M**. Modulation of TGF- β activity by latent TGF- β -binding protein 1 in human malignant glioma cells. *Int J Cancer* 2009;125:530-540 7.360 27
411. Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, **Weller M**, Steinbach JP. Antagonism of mTOR selectively mediates metabolic effects of EGFR inhibition and protects human malignant glioma cells from hypoxia-induced cell death. *Brain* 2009;132:1509-1522 10.848 23

412. Opitz CA, Litztenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, **Weller M**, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon- β and protein kinase R. *Stem Cells* 2009;27:909-919 5.587 170
413. Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, **Weller M**, Tritschler I. Aryl hydrocarbon receptor inhibition down-regulates the TGF- β /smad pathway in human glioblastoma cells. *Oncogene* 2009;28:2593-2605 6.854 53
414. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, **Weller M**, Lacombe D, Cairncross JG, Mirimanoff RO; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 2009;10:459-466 36.421 3099
415. Semmler A, Bao X, Cao G, Köhler W, **Weller M**, Aubourg P, Linnebank M. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. *J Neurol* 2009;256:1277-1280 3.783 10
416. Bähr O, Herrlinger U, **Weller M**, Steinbach JP. Very late relapses in glioblastoma long-term survivors. *J Neurol* 2009;256:1756-1758 3.783 11
417. **Weller M**, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler OD, Reifenberger G, von Deimling A, Loeffler M, for the German Glioma Network. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network. *J Clin Oncol* 2009;27:5743-5750 26.360 356
418. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, **Weller M**, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations in astrocytoma, oligodendroglioma and mixed oligoastrocytoma. *Acta Neuropathol* 2009;118:469-474 15.876 582
419. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, **Weller M**, for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *J Clin Oncol* 2009;27:5874-5880 26.360 468
420. Roth P, Kissel M, Herrmann C, Eisele G, Leban J, **Weller M**, Schmidt F. SC68896, a novel small molecule proteasome inhibitor, exerts anti-glioma activity in vitro and in vivo. *Clin Cancer Res* 2009;15:6609-6618 10.199 13
421. Dumitru CA, Sandalcioglu IE, Wagner M, **Weller M**, Gulbins E. Lysosomal ceramide mediates gemcitabine-induced death of glioma cells. *J Mol Med* 2009;87:1123-1132 4.938 30
422. Dumitru CA, **Weller M**, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy. *J Cell Physiol* 2009;221:688-695 4.155 17

423.	Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M , Rammensee HG, Oertel W. Neurological symptoms in patients with biopsy proven celiac disease. <i>Movement Disorders</i> 2009;24:2358-2362	8.324	43
424.	Semmler A, Moskau S, Stoffel-Wagner B, Weller M , Linnebank M. The effect of MTHFR c.677 C>T on plasma homocysteine levels depends on health, age and smoking. <i>Clin Invest Med</i> 2009;32:E310	4.938	4
2010			
425.	Zieker D, Königsrainer I, Tritschler I, Löffler M, Beckert S, Traub F, Nieselt K, Bühler S, Weller M , Gaedcke J, Taichman RS, Northoff H, Brücher BL, Königsrainer A. Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. <i>Int J Cancer</i> 2010;126:1513-1520	7.360	44
426.	Miller J, Eisele G, Tabatabai G, Aulwurm S, Noe-von Kürthy G, Stitz L, Roth P, Weller M . Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. <i>J Neurosurg</i> 2010;113:280-285	4.319	13
427.	Lanz T, Opitz Ch, Ho P, Agrawal A, Lutz Ch, Weller M , Mellor A, Steinmann L, Wick W, Platten M. Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). <i>Stem Cells Dev</i> 2010;19:657-668	7.144	29
428.	Dresemann G, Weller M , Rosenthal M, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver I, Steinbach J, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive preterated glioblastoma resistant to standard dose temozolomide. <i>J Neuro-Oncol</i> 2010;96:393-402	3.060	71
429.	Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M , Herrlinger U. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. <i>J Neuro-Oncol</i> 2010;97:389-392	3.060	37
430.	Maurer G, Schittenhelm J, Ernemann U, Kempf V, Ritz R, Weller M , Schmidt F. Intracranial hemangiomas in a patient with POEMS syndrome. <i>J Neurol</i> 2010;257:484-487	3.783	3
431.	Klotz L, Farkas M, Bain N, Keskitalo S, Semmler A, Ineichen B, Jelcic J, Klockengether T, Kölsch H, Weller M , Linnebank M. The variant methylenetetrahydrofolate reductase c.1298>C (p.E429A) is associated with multiple sclerosis in a German case-control study. <i>Neurosci Lett</i> 2010;468:183-185	2.159	10
432.	Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Oehsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krüger S, Picard M, Weller M . Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. <i>J Clin Oncol</i> 2010;28:2712-2718	26.360	266
433.	Brötz D, Maschke E, Burkard S, Engel C, Maenz C, Ernemann U, Wick W, Weller M . Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica? <i>Pain</i> 2010;149:470-475	5.559	16
434.	Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M , von Deimling A, Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i>	9.384	10

2010;12:894-907

435. Hofer S, Linnebank M, **Weller M**. Cancer risk among patients with multiple sclerosis and their parents. *Neurology* 2010;74:614-615 8.055 9
436. Wick W, Puduvalli VK, Chamberlain M, Van den Bent M, Carpentier AF, Cher LM, Mason W, **Weller M**, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. *J Clin Oncol* 2010;28:1168-1174 26.360 251
437. Brötz D, Burkard S, **Weller M**. A prospective study of mechanical physiotherapy for lumbar disk prolapse: five-year follow-up and final report. *Neurorehabilitation* 2010;26:155-158 1.779 5
438. Valko P, Waldvogel D, **Weller M**, Bassetti C, Held U, Baumann C. Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. *Eur J Neurol* 2010;17:1428-1436 4.621 49
439. Wegener S, Bremer J, Komminoth P, Jung HH, **Weller M**. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. *Case Rep Oncol* 2010;3:88-92
440. Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, Kulic L, Cvetanovska G, Blom H, Stoffel-Wagner B, Kölsch H, **Weller M**, Jessen F. S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. *Neurodegenerative Dis* 2010;7:373-378 2.785 43
441. Temme A, Geiger KD, Wiedermuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G, Tatsuka M, Hagel C, Westphal M, Berger H, Simon M, **Weller M**, Schackert G. Giant cell glioblastoma is associated with altered Aurora B expression and concomitant p53 mutation. *J Neuropathol Exp Neurol* 2010;69:632-642 3.490 15
442. Tabatabai G, Hasenbach K, Herrmann C, Maurer G, Möhle R, Marini P, Grez M, Wick W, **Weller M**. Glioma tropism of lentivirally transduced hematopoietic progenitor cells. *Int J Oncol* 2010;36:1409-1417 3.333 9
443. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, **Weller M**, Wick W. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. *Int J Rad Oncol Biol Phys* 2010;77:670-676 5.554 36
444. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, **Weller M**, Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. *Clin Cancer Res* 2010;26:3851-3859 10.199 52
445. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, **Weller M**, Löffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol* 2010;120:707-718 15.876 343
446. Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, Bähr O, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Löffler M, **Weller M**, Westphal M, for the German Glioma Network. Complementary therapy use in glioma patients. An observational study. *Neurology* 2010;75:2229-2235 8.055 17
447. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, Von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, 36.421 243

Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, **Weller M**. G-PCNSL-SG-1 randomised phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma. *Lancet Oncol* 2010;11:1036-1047

2011

448. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, **Weller M**. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. *Neuro-Oncology* 2011;13:155-164 9.384 25
449. Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, Platten M, **Weller M**, Bendszus M, Wick W. Bevacizumab does not increase the risk of remote relapse in malignant glioma. *Ann Neurol* 2011;69:586-592 10.250 59
450. Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, **Weller M**, Elger CE. Antiepileptic drugs interact with folate and vitamin B12 serum levels. *Ann Neurol* 2011;69:352-359 10.250 63
451. Kühnlein P, Jung H, Farkas M, Keskitalo S, Ineichen B, Jelcic I, Petersen J, Semmler A, **Weller M**, Ludolph AC, Linnebank M. The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2011;12:136-139 2.982 6
452. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loeffler M, **Weller M**, Reifenberger G, Tonn JC, for the German Glioma Network. Promoter methylation and expression of *MGMT* and the DNA mismatch repair genes *MLH1*, *MSH2*, *MSH6*, and *PMS2* in paired primary and recurrent glioblastomas. *Int J Cancer* 2011;129:659-670 7.360 125
453. Schittenhelm J, Simon P, Harter PN, Zachskorn C, Schlaszus H, Röttger F, Winkels M, **Weller M**, Meyermann R, Mittelbronn M. CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms. *Histopathology* 2011;58:739-749 3.267 5
454. **Weller M**, Gorlia T, Cairncross JG, van den Bent MJ, Mason WP, Belanger K, Brandes A, Bogdahn U, Macdonald D, Forsyth PA, Rossetti AO, Lacombe D, Miriamanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology* 2011;77:1156-1164 8.055 145
455. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Löffler M, **Weller M**, for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? *Clin Cancer Res* 2011;17:4588-4599 10.199 103
456. Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, **Weller M**, Herrlinger U, for the German Neuro-Oncology Group of the German Cancer Society. NOA-05 phase II trial of procarbazine and CCNU therapy in gliomatosis cerebri. *Ann Neurol* 2011;70:445-453 10.250 27
457. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, **Weller M**. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. *Acta Oncol* 2011;50:630-635 3.473 32
458. Guzek M, Zorina O, Semmler A, Gonzenbach R, Huber M, Kullak-Ublick GA, **Weller M**, Russmann S. Evaluation of drug interactions and dosing in 484 neurological inpatients using

clinical decision support software and an extended operational interaction classification system (ZHIAS). *Pharmacoepidemiol Drug Safety* 2011;20:930-938

459. Roth P, Wischhusen J, Happold C, Anoop Chandran P, Hofer S, Eisele G, **Weller M**, Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. *J Neurochem* 2011;118:449-457 4.609 105
460. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, **Weller M**, Wischhusen J. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. *Acta Neuropathol* 2011;122:353-365 15.876 35
461. Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, **Weller M**, Beier CP, Meister G. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. *EMBO J* 2011;30:4309-4322 10.557 86
462. Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, **Weller M**, Von Deimling A, Hartmann C, for the German Glioma Network. 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. *Int J Cancer* 2012;131:766-768 7.360 50
463. Opitz CA, Litznerberger UM, Sahn F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, **Weller M**, Jugold M, Guillemin GG, Miller CL, Lutz C, Radlwimmer B, Lehmann I, Von Deimling A, Wick W, Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature* 2011;478:197-203 41.577 620
464. Grauer O, Pascher C, Hartmann C, Zeman F, **Weller M**, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas - a prospective single-arm monocentric phase-II study (RNOP-05). *J Neuro-Oncol* 2011;104:801-809 3.060 11
- 2012**
465. Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, **Weller M**, Steinbach JP. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO trial. *Acta Neurochir* 2012;154:229-235 1.929 25
466. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, **Weller M**, Steinbach JP, Rieger J. Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. *Oncogene* 2012;31:3764-3776 6.854 22
467. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, **Weller M**. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. *Int J Cancer* 2012;131:1342-1350 7.360 125
468. Hasenbach K, Wiehr S, Herrmann C, Mannheim J, Cay F, Von Kürthy G, Bolmont T, Grathwohl SA, **Weller M**, Lengerke C, Pichler BJ, Tabatabai G. Monitoring the glioma tropism of bone marrow-derived progenitor cells by two-photon laser scanning microscopy and positron emission tomography. *Neuro-Oncology* 2012;14:471-481 9.384 3
469. Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MCM, Hartmann C, Von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, **Weller M**, Van den Bent M, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation

Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value. Central pathology review of the EORTC_26981 / NCIC_CE.3 trial. *Acta Neuropathol* 2012;123:841-852

470. Korfel A, **Weller M**, Martus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithauser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. *Ann Oncol* 2012;23:2374-2380 13.930 21
471. Christians A, Hartmann C, Benner A, Meyer M, von Deimling A, **Weller M**, Wick W, Weiler M. Prognostic value of three different methods of *MGMT* promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. *PLoS One* 2012;7:e33449 2.766 65
472. Burger MC, Brucker DP, Baumgarten P, Ronellenfisch MW, Nordhammer C, Hasselblatt M, Eccles MR, Klingebiel T, **Weller M**, Rieger J, Mittelbronn M, Steinbach JP. PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. *Int J Oncol* 2012;41:235-241 3.333 4
473. **Weller M**, Martus P, Roth P, Thiel E, Korfel A, for the German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. *Neuro-Oncology* 2012;14:1481-1484 9.384 77
474. Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, **Weller M**, Linnebank M. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. *Clin Neuropharmacol* 2012;35:77-80 1.370 14
475. Lemke D, Pfenning PN, Sahn F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, **Weller M**, Platten M, Wick W. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. *Clin Cancer Res* 2012;18:105-117 10.199 36
476. Zorina OI, Haueis P, Semmler A, Marti I, Gonzenbach RR, Guzek M, Kullak-Ublick GA, **Weller M**, Russmann S. Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. *Pharmacoepidemiol Drug Safety* 2012;21:872-80 3.643 4
477. Petersen JA, Jung HH, **Weller M**, Linnebank M. Autoimmune myasthenia gravis after sternal fracture. *Case Rep Neurol* 2012;4:20-22 1
478. Linnebank M, Moskau S, Semmler A, Widman G, **Weller M**, Kallweit U, Elger CE. Antiepileptic drugs and vitamin B6 plasma levels in adult patients. *Epilepsy Res* 2012;101:182-184 2.491 3
479. Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Roth A, Kaun S, Thiel E, Korfel A, **Weller M**. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. *Neurology* 2012;79:890-896 8.055 30
480. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, **Weller M**, for the Neurooncology Working Group (NOA) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol* 2012;13:707-715 36.421 467

481.	Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M . Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. <i>J Neurochem</i> 2012;122:444–455	4.609	57
482.	Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M , Eisele G. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. <i>J Neuroimmunol</i> 2012;250:27-34	2.655	22
483.	Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M . Antiangiogenic treatment for multiple CNS hemangioblastomas. <i>Onkologie</i> 2012;35:443-445		7
484.	Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M , Waldvogel D, Storch A, Baumann CR. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? <i>J Sleep Res</i> 2012;21:710-717	3.433	37
485.	Taegtmeyer AB, Curkovic I, Corti N, Rosen C, Egbring M, Russmann S, Gantenbein AR, Weller M , Kullak-Ublick GA. Drug-related problems and factors influencing acceptance of clinical pharmacologists' alerts in a large cohort of neurology inpatients. <i>Swiss Med Weekly</i> 2012;142:13615	1.928	7
486.	Bady P, Sciuscio D, Diserens AC, Bloch J, Van den Bent MJ, Marosi C, Dietrich PY, Weller M , Mariani M, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathol</i> 2012;124:547-560	15.876	111
2013			
487.	Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M , Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. <i>Eur Neurol</i> 2013;69:95-101	1.562	12
488.	Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D, Reithmeier T, Kowoll A, Weller M , Wick W. A comprehensive analysis of vascular complications in 3889 glioma patients from the German Glioma Network. <i>J Neurol</i> 2013;260:847-855	3.783	11
489.	Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM, Lauinger N, Tabatabai G, Paneni F, Cosentino F, Hock C, Weller M , Nitsch RM, Lüscher TF, Camici GG. Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. <i>Eur Heart J</i> 2013;34:96-103	23.425	32
490.	Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M . Integrin control of the transforming growth factor- β pathway in glioblastoma. <i>Brain</i> 2013;136:564-576	10.848	44
491.	Weiler M, Pfenning PN, Thielpold AL, Jestaedt L, Gronych J, Dittmann L, Berger B, Jugold M, Kosch M, Weller M , Combs SE, von Deimling A, Bendszus M, Platten M, Wick W. Suppression of invasion-driving RGS4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis. <i>Oncogene</i> 2013;32:1099-1109	6.854	16
492.	Schreglmann SR, Jelčić I, Taegtmeyer AB, Linnebank M, Weller M . Multifocal CNS demyelination after octreotide treatment for metastatic meningioma. <i>Clin Neurol Neurosurg</i> 2013;115:817-819	1.736	1
493.	Mittelbronn M, Warth A, Meyermann R, Goodman S, Weller M . Expression of integrins $\alpha\beta3$ and $\alpha\beta5$ and their ligands in primary and secondary central nervous system neoplasms. <i>Histol</i>	3.267	7

494. Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, Müller CP, Tischbirek CH, Groemer TW, Tabatabai G, Becker KA, Tripal P, Staedtler S, Ackermann TF, Van Brederode K, Alzheimer C, **Weller M**, Lang UE, Kleuser B, Grassmé H, Kornhuber J. Acid sphingomyelinase/ceramide system mediates effects of antidepressant drugs. *Nat Med* 2013;19:934-938 32.621 110
495. Gramatzki D, Herrmann C, Happold C, Becker KA, Gulbins E, **Weller M**, Tabatabai G. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. *PLoS One* 2013;e63527 2.766 4
496. Gonzenbach RR, Kong Y, Beck B, Buck A, **Weller M**, Semmler A. High-dose praziquantel therapy for cerebral sparganosis. *J Neurol* 2013;260:1423-1425 3.783 12
497. Vogetseder A, Thies S, Ingold B, Roth P, **Weller M**, Schraml P, Goodman S, Moch H. α -Integrin isoform expression in primary human tumors and brain metastases. *Int J Cancer* 2013;133:2362-2371 7.360 48
498. Wegener S, Artmann J, Luft AR, Buxton RB, **Weller M**, Wong EC. The time of maximum post-ischemic hyperperfusion indicates infarct growth following transient experimental ischemia. *PLoS One* 2013;8:e65322 2.766 7
499. Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Sabel M, Steiger HJ, Schlegel U, Löffler M, **Weller M**, Westphal M, for the German Glioma Network. End of life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. *Neuro-Oncology* 2013;15:1251-1256 9.384 14
500. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, **Weller M**, Wick W; for the Neuro-oncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. *Neuro-Oncology* 2013;15:1017-1026 9.384 48
501. Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, **Weller M**, Budka H, Martin R. JCV granule cell neuronopathy and GCN-IRIS in multiple sclerosis under natalizumab. *Ann Neurol* 2013;74:622-626 10.250 29
502. Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, **Weller M**, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. *Neuro-Oncology* 2013;15:1664-1672 9.384 55
503. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel M, Koeppen S, Ketter R, Weiler M, Tabatabai G, Von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, **Weller M**. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. *Neurology* 2013;81:1515-1522 8.055 86
504. Eisele G, Wolpert F, Decrey G, **Weller M**. APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. *Anticancer Res* 2013;33:3563-3571 1.865 7
505. Wiestler B, Capper D, Holland-Letz T, Korshunov A, Von Deimling A, Pfister SM, Platten M, **Weller M**, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of *IDH* mutant astrocytic tumors with better prognosis. *Acta Neuropathol* 2013;126:443-451 15.876 137

506. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger R, Pietsch T, von Deimling A, **Weller M**, for the German Glioma Network. Longterm survival in primary glioblastoma with *versus* without isocitrate dehydrogenase mutations. *Clin Cancer Res* 2013;19:5146-5157 10.199 57
507. Goepfert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, **Weller M**, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C, Mittelbronn M. Differential expression of the tumor suppressor A kinase anchor protein 12 (AKAP12) in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. *J Neuropathol Exp Neurol* 2013;72:933-941 3.490 5
508. Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, **Weller M**, Tonn JC. Gross total but not incomplete resection of GBM prolongs survival in the era of radiochemotherapy. *Ann Oncol* 2013;24:3117-3123 13.930 70
509. Vom Berg J, Vrohling M, Haller S, Haimovici A, Kulig P, Sledzinska A, **Weller M**, Becher B. T cells are crucial effectors of glioma rejection induced by local IL-12 application and can be further boosted by CTLA-4 blockade. *J Exp Med* 2013;210:2803-2811 10.790 79
510. Fan QW, Cheng C, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, **Weller M**, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. *Cancer Cell* 2013;24:438-449 22.844 101
511. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW, Kool M, Northcott PA, Wiestler B, Böhmer B, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, **Weller M**, Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of *TERT* promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol* 2013;126:907-915 15.876 124
- 2014**
512. **Weller M**, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, Von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G, for the German Glioma Network. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. *Int J Cancer* 2014;134:2437-2447 7.360 40
513. Wirsching HG, Krishnan S, Florea AF, Frei K, Krayenbühl N, Hasenbach K, Reifenberger R, **Weller M**, Tabatabai T. Thymosin-β4 gene silencing decreases stemness and invasiveness in glioblastoma. *Brain* 2014;137:433-448 10.848 18
514. Rossetti A, Jeckelmann S, Novy J, Roth P, **Weller M**, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. *Neuro-Oncology* 2014;16:584-588 9.384 27
515. Tonder M, Rushing EJ, Grotzer M, Sürücü O, Valavanis A, Buck A, **Weller M**, Roth P. A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades. *Neurology* 2014;82:e56-60 8.055 3
516. Wolpert F, Tritschler I, Steinle A, **Weller M**, Eisele G. A disintegrin and metalloproteinases (ADAM) 10 and 17 modulate the immunogenicity of glioblastoma stem cells. *Neuro-Oncology* 2014;16:382-391 9.384 20

517.	Silginer M, Weller M , Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. <i>Cell Death Dis</i> 2014;5:e1012	5.638	19
518.	Weiler W, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker SC, Osswald M, Meisner M, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitch M, Kempf T, Schölzer M, Abdollahi A, Lang F, Bendszus M, Von Deimling A, Winkler F, Weller M , Vajkoczy P, Platten M, Wick W. The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proc Natl Acad Sci USA</i> 2014;111:409-414	9.504	70
519.	Seystahl K, Weller M , Bozinov, Reimann R, Rushing E. Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma. <i>Onkologie</i> 2014;37:209-212		1
520.	Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M , Wick W. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. <i>J Neuro-Oncol</i> 2014;117:25-32	3.060	9
521.	Ineichen BV, Keskitalo S, Farkas M, Bain N, Kallweit U, Weller M , Klotz L, Linnebank M. Genetic variants of homocysteine metabolism and multiple sclerosis: A case-control study. <i>Neurosci Lett</i> 2014;562:75-78	2.159	5
522.	Eisele G, Wick A, Eisele AC, Clement PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M . Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>J Neuro-Oncol</i> 2014;117:141-145	3.060	25
523.	Valavanis A, Schwarz U, Baumann C, Weller M , Linnebank M. Amyotrophic lateral sclerosis after embolisation of cerebral arteriovenous malformations. <i>J Neurol</i> 2014;261:732-737	3.783	9
524.	Haertle M, Kallweit U, Weller M , Linnebank M. The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. <i>J Neurol</i> 2014;261:554-560	3.783	8
525.	Branscheidt M, Frontzek K, Bozinov O, Valavanis A, Rushing ER, Weller M , Wegener S. Etoposide/carboplatin chemotherapy for the treatment of metastatic myxomatous cerebral aneurysms. <i>J Neurol</i> 2014;261:828-830	3.783	3
526.	Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G, Weller M . Interferon- β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. <i>Mol Cancer Ther</i> 2014;13:948-961	5.365	23
527.	Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M , Loeffler M, for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>Int J Cancer</i> 2014;135:1822-1831	7.360	38
528.	Riehmer V, Gietzelt J, Beyer U, Hentschel B, Westphal M, Schackert G, Sabel MC, Radlwimmer B, Pietsch T, Reifenberger G, Weller M , Weber RG, Loeffler M, for the German Glioma Network. Genomic profiling reveals three molecular relapse patterns in IDH1/2 wild-type glioblastoma. <i>Genes, Chromosomes & Cancer</i> 2014;53:589-605	3.362	9
529.	Fischer S, Ronellenfitch MW, Thiebold AL, Harter PN, Reichert S, Kögel D, Paschke R,	2.766	6

- Mittelbronn M, **Weller M**, Steinbach JP, Fulda S, Bähr O. Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. *PLoS One* 2014;9:e94921
530. Hundsberger T, Tonder M, Hottinger A, Brügge D, Roelcke U, Putora PM, Stupp R, Weller M. Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. *J Neuro-Oncol* 2014;118:321-328 3.060 8
531. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, **Weller M**, Steinbach JP. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol* 2014;44:1843-1852 3.333 63
532. Tonder M, Eisele G, Weiss T, Hofer S, Seystahl K, Valavanis A, Stupp R, **Weller M**, Roth P. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. *Acta Oncol* 2014;26:1-4 3.473 5
533. Bracko O, Di Pietro V, Lazzarino G, Amorini AM, Tavazzi B, Artmann J, Wong EC, Buxton RB, **Weller M**, Luft AR, Wegener S. 3-nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. *J Cerebral Blood Flow Metab* 2014;34:1522-1530 6.045 10
534. Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Alexander Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch P, Reifenberger G, Lichter L, Radlwimmer B, Platten M, Pfister SM, von Deimling A, **Weller M**, Wick W. Integrated DNA methylation and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathol* 2014;128:561-571 15.876 81
535. Wiestler B, Capper D, Hovestadt V, Sill M, Jones DTW, Hartmann C, Felsberg J, Platten M, Feiden WE, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, **Weller M**, Wick W. Assessing CpG island methylator phenotype, 1p/19q codeletion and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology* 2014;16:1630-1638 9.384 36
536. Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein AC, Löw S, Eisele G, Radlwimmer B, Capper D, Schmieider K, Mittelbronn M, Combs SE, Bendszus M, **Weller M**, Platten M, Wick W. Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? *J Neurochem* 2014;131:251-254 4.609 12
537. Stupp R, Hegi ME, Gorlia T, Erridge S, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJB, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CK, Nabors LB, Reardon DA, Van den Bent MJ, Hicking C, Markivskyy A, Picard M, **Weller M**, on behalf of European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortium, and the CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter: final results of the multicentre, randomised, open-label, controlled, phase 3 CENTRIC (EORTC 26071-22072) study. *Lancet Oncol* 2014;15:1100-1108 36.421 312
538. Codo P, **Weller M**, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G, Roth P. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. *Oncotarget* 2014;5:7651-7662 45
539. Ahmad A, Frei K, Willscher E, Stefanski A, Kaulich K, Roth P, Stühler K, Reifenberger G, Binder H, **Weller M**. How stem-like are sphere cultures from long-term cancer cell lines: lessons from mouse glioma models. *J Neuropathol Exp Neurol* 2014;73:1062-1077 3.490 14

540.	Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M , Goodman SL, Birner P, Preusser M. $\alpha\text{v}\beta\text{3}$, $\alpha\text{v}\beta\text{5}$ and $\alpha\text{v}\beta\text{6}$ integrins in brain metastases of lung cancer. <i>Clin Exp Metastasis</i> 2014;31:841-851	3.455	16
541.	Wirsching HG, Tritschler I, Palla A, Renner C, Weller M , Tabatabai G. The management of lomustine overdose in malignant glioma patients. <i>Neuro-Oncol Pract</i> 2014;1:178-183		20
542.	Keskitalo S, Farkas M, Hanenberg M, Szodorai A, Kulic L, Semmler A, Weller M , Nitsch RM, Linnebank M. Reciprocal modulation of A β 42 aggregation by copper and homocysteine. <i>Frontiers in Aging Neuroscience</i> 2014;6:237		3
543.	Tonder M, Weller M , Eisele G, Roth P. Carboplatin and etoposide in heavily pre-treated patients with progressive high-grade glioma. <i>Chemotherapy</i> 2014;60:375-378	2.152	3
2015			
544.	Wegener S, Linnebank M, Martin R, Valavanis A, Weller M . Clinically isolated neurosarcoidosis: a recommended diagnostic path. <i>Eur Neurol</i> 2015;73:71-77	1.562	11
545.	Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M , Kretschmar H, Tonn JC, La Fougere C, Kreth FW. Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. <i>Int J Cancer</i> 2015;136:2132-2145	7.360	28
546.	Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M . Differential regulation of TGF- β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> 2015;17:254-265	9.384	22
547.	Kreher S, Strehlow F, Martus P, Roth P, Hertenstein B, Röth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M , Korfel A. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. <i>Ann Hematol</i> 2015;94:409-414	2.845	4
548.	Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M , Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> 2015;17:1064-1075	9.384	159
549.	Suchorska B, Jansen NL, Linn J, Kretschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, La Fougere C, Weller M , Tonn JC, for the German Glioma Network. Biological tumor volume in 18F-FET-PET prior to radio-chemotherapy correlates with survival in GBM. <i>Neurology</i> 2015;84:710-719	8.055	42
550.	Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M . Differentially regulated miRNAs as prognostic biomarkers in the blood of PCNSL patients. <i>Eur J Cancer</i> 2015;51:382-390	7.191	11
551.	Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M , for the German PCNSL Study Group. Randomized phase III study of radiotherapy for primary cerebral lymphoma. <i>Neurology</i> 2015;84:1242-1248	8.055	33
552.	Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Kölsche C, Schweizer L, Korshunov A,	15.876	180

- Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, **Weller M**, Wick W, Pfister SM, von Deimling A. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated“ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathol* 2015;129:133-146
553. Ulrich A, Weiler S, **Weller M**, Rordorf T, Tarnutzer AA. Cetuximab induced aseptic meningitis - case report and review of the literature. *J Clin Neurosci* 2015;22:1061-1063 1.640 3
554. Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Van Criekinge W, Daniel RT, Van den Bent MJ, Marosi C, **Weller M**, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. *Genome Biol* 2015;16:16 13.214 32
555. Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, **Weller M**. Phase I dose-escalation study of the anti-placental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. *Neuro-Oncology* 2015;17:1007-1015 9.384 16
556. Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ, **Weller M**. Transforming growth factor- β pathway activity in glioblastoma. *Oncotarget* 2015;6:5963-5977 27
557. **Weller M**, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger R, Wick W, for the DIRECTOR Study Group. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. *Clin Cancer Res* 2015;21:2057–2064 10.199 92
558. Kreher S, Jöhrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, **Weller M**, Korfel A. Prognostic impact of BCL-6 in primary CNS lymphoma. *Neuro-Oncology* 2015;17:1016-1021 9.384 4
559. **Weller M**, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach J, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G, for the German Glioma Network. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathol* 2015;129:679–693 15.876 75
560. Wörnle CM, Péus D, Hofer S, Rushing EJ, Held U, Bozinov O, Krayenbühl N, **Weller M**, Regli L. Efficacy of surgery and further treatment of progressive glioblastoma. *World Neurosurg* 2015;84:301-307 1.924 18
561. Traber GL, Pangalu A, Neumann M, Costa J, **Weller M**, Huna-Baron R, Landau K. Malignant optic glioma – the spectrum of disease in a case series. *Graefe's Arch Clin Exp Ophthalmol* 2015;253:1187-1189 2.249 9
562. Krishnan S, Szabo E, Tritschler I, Frei K, Tabatabai G, **Weller M**. Modulation of cerebral endothelial cell function by TGF- β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. *Oncotarget* 2015;6:22480-22495 19
563. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, 15.876 65

- Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister SM, Korshunov A, **Weller M**, Herold-Mende C, Wick W, Brandner S, von Deimling A. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathol* 2015;130:407-417
564. Wolpert F, Happend C, Reifenberger G, Florea AM, Deenen R, Roth P, Lamszus K, Westphal M, Neidert N, **Weller M**, Eisele G. Interferon- β modulates the innate immune response against glioblastoma initiating cells. *PLoS One* 2015;10:e0139603 2.766 5
565. Kumar KS, Pillong M, Kunze J, Burghardt I, **Weller M**, Grotzer MA, Schneider G, Baumgartner M. Computer-assisted quantification of motile and invasive capabilities of cancer cells. *Sci Rep* 2015;5:15338 4.122 7
- 2016**
566. Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske L, Rushing EJ, Hao N, Platten P, **Weller M**, Roth P. The aryl hydrocarbon receptor links integrin signaling to the TGF- β pathway. *Oncogene* 2016;35:3260-3271 6.854 13
567. Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, **Weller M**, Preusser M. Kinetics of tumor size and peritumoral brain edema before, during and after systemic therapy in recurrent WHO grade II or III meningioma. *Neuro-Oncology* 2016;18:401-407 9.384 11
568. Hundsberger T, Hottinger AF, Roelcke U, Roth P, Migliorini D, Dietrich PY, Conen K, Pesce G, Hermann E, Pica A, Gross MW, Brügge D, Plasswilm L, **Weller M**, Putora PM. Patterns of care in recurrent glioblastoma in Switzerland - a multicentre national approach based on diagnostic nodes. *J Neuro-Oncol* 2016;126:175-178 3.060 6
569. Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen G, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichten P, Pfister SM, **Weller M**, Reifenberger G. Gliomatosis cerebri: No evidence for a separate brain tumor entity. *Acta Neuropathol* 2016;131:309-319 15.876 25
570. Roelcke U, Wyss MT, Nowosielski M, Rudà R, Roth P, Hofer S, Galdiks N, Crippa F, **Weller M**, Soffietti R. Amino acid PET to monitor chemotherapy response, and to predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro-Oncology* 2016;18:744-751 9.384 14
571. Happend C, Gorlia T, Chinot O, Gilbert M, Nabors B, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon D, Perry JR, Mehta M, Stupp R, **Weller M**. Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma. *J Clin Oncol* 2016;34:731-739 26.360 33
572. Wirsching HG, Morel M, Gmür C, Neidert MC, Baumann CR, Valavanis A, Rushing ER, Krayenbühl N, **Weller M**. Predicting outcome of epilepsy after meningioma resection. *Neuro-Oncology* 2016;18:1002-1010 9.384 11
573. Codo P, **Weller M**, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P. Control of glioma cell migration and invasiveness by GDF-15. *Oncotarget* 2016;7:7732-7746 5
574. Suchorska B, **Weller M**, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HW. Complete resection of contrast enhancing tumor volume is associated with improved survival in recurrent glioblastoma— results from the DIRECTOR trial. *Neuro-Oncology* 2016;18:549-566 9.384 38

575.	Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, Weller M , Schaefer N, Kuhn FP. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? <i>Neuro-Oncology</i> 2016;18:1021-1027	9.384	10
576.	Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M , Holland EC, Hambardzumyan D. Corticosteroids compromise survival in glioblastoma. <i>Brain</i> 2016;139:1458-1471	10.848	46
577.	Stojcheva N, Schechtmann G, Sass S, Roth P, Florea AF, Stefanski A, Stühler K, Wolter M, Müller NS, Theis FJ, Weller M , Reifenberger G, Hoppold C. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. <i>Oncotarget</i> 2016;7:12937-12950		17
578.	Weller M , Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman S, Hegi M, Picard M, Moch H, Straub J, Stupp R. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> 2016;7:15018-1532		19
579.	Fierstra J, Van Niftrik B, Piccirelli M, Burkhardt JK, Pangalu A, Kocian R, Valavanis A, Weller M , Regli L, Bozinov O. Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. <i>Magnetic Resonance Imaging</i> 2016;34:803–808	2.564	3
580.	Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D, Rohrmann S, Pless M, Oberle J, Roth P, Ohgaki H, Weller M . Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009). <i>Cancer</i> 2016;122:2206-2215	6.537	18
581.	Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M . Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> 2016;18:1242-1252	9.384	12
582.	Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, Ilhan H, Pangalu A, Weller M , Tonn JC, Sommerauer M, Albert NL. Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma - benefit linked to ⁶⁸ Ga-DOTATATE/-TOC uptake. <i>Neuro-Oncology</i> 2016;18:1538-1154	9.384	11
583.	Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O, Wick W, Reifenberger G, Weller M . Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> 2016;16:287	3.288	6
584.	Mangani D, Weller M , Seyed Sadr E, Willscher E, Seystahl K, Reifenberger G, Tabatabai G, Binder H, Schneider H. Limited role for transforming growth factor- β pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> 2016;18:1610-1621	9.384	6
585.	Schneider H, Weller M . Boswellic acid activity against glioblastoma stem-like cells. <i>Oncol Lett</i> 2016;11:4187-4192	1.664	
586.	Burgett ME, Lathia JD, Roth P, Nowacki AS, Galileo DS, Pugacheva E, Huang P, Vasanji A, Li M, Byzova T, Mikkelsen T, Bao S, Rich JN, Weller M , Gladson CL. Direct contact with perivascular tumor cells enhances integrin $\alpha\beta3$ signaling and migration of endothelial cells. <i>Oncotarget</i> 2016;7:43852-43867		8
587.	Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M , Stupp R, Roth P, Golfopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte	10.199	19

B, Pesce GA, Hegi ME. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). *Clin Cancer Res* 2016;22:4797-4806

588. Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Hoppold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, **Weller M**, for the Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *Neuro-Oncol* 2016;18:1529-1537 9.384 35
589. Gramatzki D, Frei K, Cathomas G, Moch H, **Weller M**, Mertz KD. Interleukin-33 in human gliomas: Expression and prognostic significance. *Oncol Lett* 2016;12:445-452 1.664
590. Strehlow F, Bauer S, Martus P, **Weller M**, Roth P, Schlegel U, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. *J Neurooncol* 2016;129:165-171 3.060 9
591. Linnebank M, McDougall C, Krueger S, Biskup S, Neumann M, Weller M, Valavanis A, Prudlo J. Novel cases of ALS after treatment of cerebral arteriovenous malformations. *Swiss Medical Weekly* 2016;146:w14361 1.928
592. Zörner B, Filli L, Reuter K, Kapitza S, Lörinicz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, **Weller M**, Linnebank M. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. *Mult Scler* 2016;22:1463-1475 5.280 12
- 2017**
593. **Weller M**, Roth P, Sahm F, Burghardt I, Schuknecht B, Rushing ER, Regli L, Lindemann JP, von Deimling A. Durable control of metastatic AKT1-mutant WHO-grade I meningothelial meningioma by the AKT inhibitor, AZD5363. *J Natl Cancer Inst* 2017;109:1-4 11.238 5
594. Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen M, Chinot O, Balana C, Macdonald DR, Westphal M, Hopkins K, **Weller M**, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS. A randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and HGF and MGMT biomarker analyses. *J Clin Oncol* 2017;35:343-351 26.360 6
595. Schneider H, Szabo E, Machado R, Broggin-Tenzer A, Walter A, Lobell M, Heldmann D, Suessmeier F, Gruenewald S, **Weller M**. Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models. *J Neurochem* 2017;140:170-182 4.609 3
596. Filli L, Zörner B, Kapitza S, Reuter R, Lörinicz L, Weller D, Sutter T, Killeen T, Gruber P, Petersen JA, **Weller M**, Linnebank M. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. *Neurology* 2017;88:832-841 8.055 11
597. Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, **Weller M**, Preusser M. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases – development and validation of the LabBM-Score. *Neuro-Oncology* 2017;19:1255-1262 9.384 2
598. Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, **Weller M**. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. *Neurology* 2017;88:1422-1430 8.055 6

599. Roth P, Valavanis A, **Weller M**. Long-term control and partial remission after initial pseudoprogession of glioblastoma by anti-PD-1 treatment with nivolumab. *Neuro-Oncology* 2017;19:454-456 9.384 6
600. Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten P, **Weller M**, Plass C, Wick W. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. *Oncotarget* 2016;7:82028-82045 8
601. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss D, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing ER, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, **Weller M**, von Deimling A. Molecular analysis of meningioma increases prognostic power: A methylation-based classification and grading system. *Lancet Oncol* 2017;18:682-694 36.421 54
602. Feddermann-Demont N, Junge A, **Weller M**, Dvorak J, Tarnutzer AA. Prevalence of potential sports-associated risk factors in Swiss ALS patients. *Brain Behav* 2017;7:e0063 2.219 3
603. Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, **Weller M**, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. *Oncotarget* 2016;7:81995-82012 2
604. Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Nabors LB, Mason WP, Hegi ME, Zhang P, Golfopoulos V, Perry JR, Nam DH, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, Van den Bent MJ, Reardon DA, **Weller M**, Stupp R. Is more better? The impact of extended adjuvant temozolomide in newly-diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. *Neuro-Oncology* 2017;19:1119-1126 9.384 12
605. Van Niftrik CHB, Piccirelli M, Bozinov O, Pangalu A, Fisher JA, Valavanis A, Luft AR, **Weller M**, Regli L, Fierstra J. Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition. *Brain Behav* 2017;7:e00705 2.219 3
606. Silginer M, Nagy S, Happold C, Schneider H, **Weller M**, Roth P. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. *Neuro-Oncology* 2017;19:1338-1349 9.384 3
607. Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, **Weller M**. Biological role and therapeutic targeting of TGF- β_3 in glioblastoma. *Mol Cancer Ther* 2017;16:1177-1186 5.365 5
608. Silginer M, **Weller M**, Stupp R, Roth P. Biological activity of tumor-treating fields (TTFields) in preclinical glioma models. *Cell Death Dis* 2017;8:e2753 5.638 5
609. Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, **Weller M**. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. *J Cancer Res Clin Oncol* 2017;143:1815-1821 3.332 5

610. Ventura E, **Weller M**, Burghardt I. Extracellular signal-regulated kinase 1 (ERK1) mediates the autocrine positive feedback loop of TGF- β and furin in glioma-initiating cells. *J Immunol* 2017;198:4569-4574 4.539
611. Le Rhun E, Rudà R, Devos P, Hoang-Xuan K, Brandsma D, Pérez Segura P, Soffietti R, **Weller M**. Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. *J Neuro-Oncol* 2017;133:419-427 3.060 2
612. Cimino P, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, Von Deimling A, Jones D, Reifenberger G, **Weller M**, Holland E. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. *Acta Neuropathol Comm* 2017;5:39 8
613. **Weller M**, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH, for the ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. *Lancet Oncol* 2017;18:1373-1385 36.421 60
614. Schneider H, Lohmann B, Wirsching HG, Hasenbach K, Rushing EJ, Frei K, Pruschy M, Tabatabai G, **Weller M**. Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. *Oncotarget* 2017;8:87124-87135 1
615. Suchorska B, Giese A, Biczok A, Unterrainer M, **Weller M**, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL. Identification of time-to-peak on dynamic ^{18}F -FET-PET as a prognostic marker specifically in *IDH1/2* mutant diffuse astrocytoma. *Neuro-Oncology* 2018;20:279-288 9.384 9
616. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, **Weller M**, von Deimling A, Golfopoulos V, Bromberg JC, Platten M, Klein M, Van den Bent MJ. Lomustine and bevacizumab in progressive glioblastoma. *N Engl J Med* 2017;377:1954-1963 79.260 39
617. Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, Schackert G, Tonn JC, Pietsch T, von Deimling A, Loeffler M, Reifenberger G, **Weller M**, for the German Glioma Network. Epidermal growth factor receptor variant III (EGFRvIII) positivity in *EGFR*-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors. *Clin Cancer Res* 2017;23:6846-6855 10.199 8
618. van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, **Weller M**, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. *Lancet* 2017;390:1645-1653 53.254 32
619. Venturini E, Leanza L, Azzolini M, Kadow S, Mattarei A, **Weller M**, Tabatabai G, Edwards MJ, Zoratti M, Paradisi C, Szabó I, Gulbins E, Becker KA. Targeting the potassium channel Kv1.3 kills glioblastoma cells. *Neurosignals* 2017;25:26-38 2
620. Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, 9.384 8

Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge Hudler M, Jones D, Pfister SM, **Weller M**, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. *Neuro-Oncology* 2018;20:367-379

621. Fierstra J, Van Niftrik CH, Piccirelli M, Bozinov O, Pangalu A, Krayenbühl N, Valavanis A, **Weller M**, Regli L. Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. *Magnetic Resonance Imaging* 2018;45:78-83 2.564 1
622. Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, **Weller M**, Wick W, Kortmann RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro-Oncology* 2018;20:400-410 9.384 1
623. Beyer U, Brand F, Martens H, Weder J, Christians A, Elyan N, Hentschel B, Westphal M, Schackert G, Pietsch T, Hong B, Krauss JK, Samii A, Raab P, Das A, Dumitru CA, Sandalcioğlu IE, Hakenberg OW, Erbersdobler A, Lehmann U, Reifenberger G, **Weller M**, Reijns MAM, Preller M, Wiese B, Hartmann C, Weber RG. Rare *ADAR* and *RNASEH2B* variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. *Acta Neuropathol* 2017;134:905-922 15.876 1
624. Papa E, **Weller M**, Weiss T, Ventura E, Burghardt I, Szabó E. Negative control of the HGF/c-MET pathway by TGF- β : a new look at the regulation of stemness in glioblastoma. *Cell Death Dis* 2017;8:3210 5.638 3
625. Weiss T, Schneider H, Silginer M, Steinle A, Pruschy MN, Polic B, **Weller M**, Roth P. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. *Clin Cancer Res* 2018;24:882-895 10.199
626. Weiss T, **Weller M**, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR-T cells and radiotherapy exert synergistic efficacy in glioblastoma. *Cancer Res* 2018;78:1031-1043 9.130 7
627. Ventura E, **Weller M**, Macnair W, Eschbach K, Beisel C, Cordazzo C, Claassen M, Zardi L, Burghardt I. TGF- β induces oncofetal fibronectin, which in turn modulates TGF- β superfamily signaling in endothelial cells. *J Cell Sci* 2018;131:209619 4.401
628. Signorell RD, Papachristodoulou A, Xiao J, Arpagaus B, Casalini T, Grandjean J, Thamm J, Steiniger F, Luciani P, Brambilla D, Werner B, Martin E, **Weller M**, Roth P, Leroux JC. Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. *Int J Pharm* 2018;536:388-396 3.862 1
629. Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, **Weller M**, Revillion F, Bonnetterre J. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. *Eur J Cancer* 2017;87:189-198 7.191 5
630. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, **Weller M**, Palti Y, Hegi ME, Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. A randomized clinical trial. *J Am Med Assoc* 2017;318:2306-2316 47.661 48

631. Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, **Weller M**, Martin R, Lutterotti A, Schippling S. Unfavourable structural and functional outcomes in MOG antibody-associated optic neuritis. *J Neuroophthalmol* 2019;39:3-7 2.152
632. Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hicking C, Picard M, Stupp R, **Weller M**, for the EORTC Brain Tumor Group and on behalf of the CENTRIC and CORE Clinical Trial Groups. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? *J Neuro-Oncol* 2018;138:163-171 3.060
633. Happold C, Stojcheva N, Silginer M, Weiss T, Roth P, Reifenberger G, **Weller M**. Transcriptional control of O⁶-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *J Neurochem* 2018;144:780-790 4.609 1
634. Szabó E, Phillips DJ, Droste M, Marti A, Kretzschmar T, Shamshiev A, **Weller M**. Anti-tumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models. *J Pharmacol Exp Ther* 2018;365:422-429 3.706 1
635. Filli L, Sutter T, Easthope CS, Killeen T, Meyer C, Reuter K, Lörincz L, Bolliger M, **Weller M**, Curt A, Straumann D, Linnebank M, Zörner B. Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. *Sci Rep* 2018;8:4984 4.122 1
636. Wolpert F, **Weller M**, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, Roth P, Reyns N, Kaufmann PA, Preusser M, Le Rhun E. Diagnostic value of ¹⁸F-fluorodesoxyglucose positron emission tomography (FDG)-PET/CT for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018;96:64-72 7.191
637. Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, Korol D, Regli L, Pangalu A, Pless M, Oberle J, Bernays R, Moch H, Rohrmann S, **Weller M**. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. *Ann Oncol* 2018;29:1431-1436 13.930 2
638. Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SSY, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, **Weller M**, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018;135:923-938 15.876 2
639. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschoner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, **Weller M**, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt 41.577 44

M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM. DNA methylation-based classification of central nervous system tumours. *Nature* 2018;555:469-474

640. Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, Thomale UW, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AF, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez FJ, Giannini C, NageswaraRao AA, Tabori U, Nunes NM, **Weller M**, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, von Deimling A, Capper D. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. *Acta Neuropathol* 2018;136:273-291 15.876 5
641. Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundesberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenein A, **Weller M**. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. *Ann Oncol* 2018;29:1423-1430 13.930
642. Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, **Weller M**, von Deimling A, Snuderl M, Sen C, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. *Acta Neuropathol* 2018;135:955-963 15.876 2
643. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, **Weller M**, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol* 2018;136:153-166 15.876 6
644. Von Achenbach C, **Weller M**, Szabo E. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. *J Neurochem* 2018;147:99-109 4.609
645. Schuster H, Shao W, Weiss T, Pedrioli P, Roth P, **Weller M**, Campbell D, Deutsch E, Moritz R, Planz O, Rammensee HG, Aebersold R, Caron E. A tissue-based draft map of the murine MHC class I immunopeptidome. *Sci Data* 2018;5:180157 5.311
646. Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, **Weller M**. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. *Eur J Cancer* 2018;101:95-104 7.191
647. Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, **Weller M**, Holland EC. Copy number profiling across glioblastoma populations has implications for clinical trial design. *Neuro-Oncology* 2018;20:1368-1373 9.384 1
648. Valko PO, Roschitzki B, Faigle W, Grossmann J, Panse C, Biro P, Dambach M, Spahn DR, **Weller M**, Martin R, Baumann CR. In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. *J Sleep Res* 2018;e12721 3.433
649. Witt H, Gramatzki D, Hentschel B, Pajtler KW, Felsberg J, Schackert G, Löffler M, Capper D, Sahm F, Sill M, von Deimling A, Kool M, Herrlinger U, Westphal M, Pietsch P, Reifenberger

G, Pfister SM, Tonn JC, **Weller M**, for the German Glioma Network. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. *Neuro-Oncology* 2018;20:1616-1624

650. Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, **Weller M**, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM. Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development. *Cancer Cell* 2018;34:163-177 22.844
651. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, **Weller M**, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nat Med* 2018;24:1192-1203 32.621 2
652. Huang RY, Unadkat P, Linda Bi W, George E, Preusser M, McCracken DJ, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, **Weller M**, Raizer JJ, Schiff D, Wen PY. Response assessment of meningioma: 1D, 2D and volumetric criteria for treatment response and tumor progression. *Neuro-Oncology* 2019;21:234-241 9.384
653. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, **Weller M**, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, for the Neurooncology Working Group (NOA) of the German Cancer Society. Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed *MGMT*-methylated glioblastoma patients: the randomized, open-label CeTeG/NOA-09 trial. *Lancet* 2019;393:678-688 53.254
654. van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, **Weller M**, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfopoulos V, Gorlia T, Idbaih A. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. *Lancet Oncol* 2018;19:1170-1179 36.421 1
655. Filli L, Werner J, Beyer G, Reuter K, Petersen J, **Weller M**, Zörner B, Linnebank M. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis. *Eur J Neurol* 2019;26:281-289 4.621
656. Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, Reifenberger G, **Weller M**, Hänggi D, Wick W, Herold-Mende C, Westphal M, Brandner S, Pfister SM, Capper D, Sahm F, von Deimling A. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathol* 2018;136:793-803 15.876 1
657. Wirsching HG, Richter JK, Sahm F, Morel C, Krayenbühl N, Rushing ER, von Deimling A, Valavanis A, **Weller M**. Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective 3.060

cohort study of 741 patients. *J Neuro-Oncol* 2018;140:659-667

658. Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, **Weller M**. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. *Int J Cancer* 2019;145:242-253 7.360
659. Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, van Criekinge W, Straub S, **Weller M**. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide. A pooled analysis of four clinical trials. *Clin Cancer Res* 2019;25:1809-1816 10.199
660. Thurner L, Preuss KD, Kemele M, Fadle N, Regitz E, Altmeyer S, Bewarder M, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, **Weller M**, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Mackensen A, Hartmann S, Hansmann ML, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M. Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL. *Blood* 2018;132:2744-2753 15.132
661. Eisele G, Roelcke U, Conen K, Huber F, Weiss T, Hofer S, Heese O, Westphal M, Hertler C, Roth P, **Weller M**. Complementary and alternative medicine use by glioma patients in Switzerland. *Neuro-Oncology Practice* 2019;6:237-244
662. Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winter-Kristensen B, Thomas C, Brokinkel B, Ketter R, Idoate Gastearna MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter P, Felsberg J, Herold-Mende C, Berghoff AS, **Weller M**, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A, Sahm F. Chordoid meningiomas can be sub-stratified into clinically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. *Acta Neuropathol* 2018;136:975-977 15.876
663. El Amki M, Binder N, Steffen R, Schneider H, Luft AR, **Weller M**, Imthurn B, Merki-Feld GS, Wegener S. Contraceptive drugs mitigate experimental stroke-induced brain injury. *Cardiovasc Res* 2019;115:637-646 6.290
664. Krell A, Wolter M, Stojcheva N, Hertler C, Liesenberg F, Zapatka M, **Weller M**, Malzkorn B, Reifenberger G. *MiR-16-5p* is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis, and response to cytotoxic therapy. *Neuropathol Appl Neurobiol* 2019;45:441-445 6.059
665. Papachristodoulou A, Signorell RD, Werner B, Brambilla D, Luciani P, Cavusoglu M, Grandjean J, Silginer M, Rudin M, Martin M, **Weller M**, Roth P, Leroux JC. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. *J Contr Release* 2018;295:130-139 7.877
666. Cavusoglu M, Zhang J, Ielacqua GD, Pellegrini G, Signorell RD, Papachristodoulou A, Brambilla D, Roth P, **Weller M**, Rudin M, Martin E, Leroux JC, Werner B. Closed-loop cavitation control for focused ultrasound-mediated blood-brain-barrier opening by long-circulating microbubbles. *Phys Med Biol* 2019;64:045012 2.761
667. Machado RAC, Schneider H, DeOcesano-Pereira C, Lichtenstein F, Andrade F, Fujita A, Trombetta-Lima M, **Weller M**, Bowman-Colin C, Sogayar MC. CHD7 promotes glioblastoma cell motility and invasiveness through transcriptional modulation of an invasion signature. *Sci Rep* 2019;9:3952 4.122
668. Körber V, Yang Y, Barah P, Wu Y, Stichel D, Gu Z, Fletcher MNC, Jones D, Hentschel B, Lamszus K, Tonn JC, Schackert G, Sabel M, Felsberg J, Zacher A, Kaulich K, Hübschmann D, 22.844

Herold-Mende C, von Deimling A, **Weller M**, Radlwimmer B, Schlesner M, Reifenberger G, Höfer T, Lichter P. Evolutionary trajectories of IDH-wildtype glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. *Cancer Cell* 2019;35:692-704

669. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winkelhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, van den Bent M, Wen PY, Bendzus M, **Weller M**, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee. The RANO Leptomeningeal Metastasis Group proposal to assess disease burden and response to treatment: lack of feasibility and clinical utility, and a revised proposal. *Neuro-Oncology* 2019;21:648-658 9.384
670. Nowosielski M, Gorlia T, Bromberg JEC, Sahm F, Harting I, Kickingereder P, Brandes AA, Taphoorn MJB, Taal W, Domont J, Idhah A, Campone M, Clement PM, **Weller M**, Fabbro M, Le Rhun E, Platten M, Golfopoulos V, van den Bent M, Bendzus M, Wick W. Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. *Neurology* 2019;92:e2754-e2763 8.055
671. Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westphal M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, **Weller M**, Loeffler M. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. *Acta Neuropathol Commun* 2019;7:59
672. Seliger C, Genbrugge E, Gorlia T, Chinot O, Stupp R, Nabors B, **Weller M**, Hau P. Use of metformin and outcome of patients with newly diagnosed glioblastoma – a pooled analysis. *Int J Cancer* 2020;146:803-809 7.360
673. Le Joncour V, Filppu P, Hyvönen M, Holopainen M, Turunen P, Sihto H, Burghardt I, Joensuu H, Tynninen O, Jääskeläinen J, **Weller M**, Lehti K, Käkälä R, Laakkonen P. Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. *EMBO Mol Med* 2019;11:e9034 10.293
674. Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, **Weller M**, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, Zadeh G, Aldape KD, and the International Consortium on Meningiomas. Predicting brain tumor recurrence: development and validation of a DNA methylation based nomogram in meningioma. *Neuro-Oncology* 2019;21:901-910 9.384
675. Coomans M, Dirven L, Aaronson A, Baumert BG, Van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, **Weller M**, Wick W, Reijneveld JC, Taphoorn MJB, on behalf of the EORTC Quality of Life Group and the EORTC Brain Tumor Group. The added value of Health-Related Quality of Life (HRQoL) as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomized controlled trials. *Eur J Cancer* 2019;116:190-198 7.191
676. Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, **Weller M**, Finer M, Quéva C, Glorioso JC, McGarry Houghton A, Holland EC. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. *J Clin Invest* 2019;4:128217

677. French PJ, Eoli M, Sepulveda JM, De Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, **Weller M**, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Van den Bent M. Defining EGFR amplification status for clinical trial inclusion. *Neuro-Oncology* 2019;21:1263-1272 9.384
678. Le Rhun E, Devos P, Houillier C, Cartalat S, Chinot O, Di Stefano AL, Lepage C, Reyns N, Dubois F, **Weller M**. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial. *Neurology* 2019;93:e1799-e1806 8.055
679. Paramasivam N, Hübschmann D, Toprak UH, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers AK, Jones DTW, Gu Z, Werner J, Uhrig S, Wirsching HG, Schick M, Bewerunge-Hudler M, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister SM, Wick W, **Weller M**, Grossmann R, von Deimling A, Schlesner M, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathol* 2019;138:295-308 15.876
680. Coomans M, Dirven L, Aaronson NK, Baumert BG, Van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, **Weller M**, Wick W, Reijneveld JC, Taphoorn MJB, on behalf of the EORTC Quality of Life Group and the EORTC Brain Tumor Group. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? *Neuro-Oncol* 2019;21:1447-1457 9.384
681. Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfopoulos V, **Weller M**, van den Bent MJ, Wick W, Preusser M. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. *Neuro-Oncology* 2019;21:1587-1594 9.384
682. Wirsching HG, Arora S, Zhang H, Szulzewsky F, Cimino PJ, Quéva C, McGarry Houghton A, Glorioso JC, **Weller M**, Holland EC. Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. *Neuro-Oncology* 2019;21:1607-1609 9.384
683. Brand F, Förster A, Christians A, Bucher M, Thomé CM, Raab MS, Westphal M, Pietsch T, von Deimling A, Reifenberger G, Claus P, Hentschel B, **Weller M**, Weber RG. *FOCAD* loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. *Acta Neuropathol* 2019;139:175-192 15.876
684. Papachristodoulou A, Silginer M, **Weller M**, Schneider H, Hasenbach K, Janicot M, Roth R. Therapeutic targeting of TGF- β ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. *Clin Cancer Res* 2019;25:7189-7201 10.199
685. Imbach LL, Baumann CR, Poryazova R, Geissler O, Brugger P, Sarnthein J, Mothersill I, **Weller M**, Oertel MF, Stieglitz LH. Anticonvulsive effect of anterior thalamic deep brain stimulation in super-refractory status epilepticus crucially depends on active stimulation zone – a single case observation. *Seizure* 2019;71:286-288 2.839
686. Wolpert F, Lareida A, Terziev R, Grossenbacher B, Neidert MC, Roth P, Poryazova R, Imbach L, Le Rhun E, **Weller M**. Risk factors for the development of epilepsy in patients with brain metastasis. *Neuro-Oncology* 2020;22:718-728 9.384
687. Reinhardt A, Stichel D, Schrimpf D, Korshunov A, Sahm F, Reuss DE, Koelsche C, Huang K, Wefers AK, **Weller M**, Gramatzki D, Felsberg F, Reifenberger G, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Buslei R, Deckert M, Mawrin C, Hewer E, Pohl U, Jaunmuktane Z, Brandner S,

- Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, Capper D, von Deimling A. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathol Commun* 2019;7:163
688. Zipser CM, Deuel J, Ernst J, Schubert M, **Weller M**, von Känel R, Boettger S. Predisposing and precipitating factors for delirium in neurology: a prospective cohort study of 1,487 neurological patients. *J Neurol* 2019;266:3065-3075 3.783
689. Le Rhun E, **Weller M**, Niclou SP, Short S, Piil K, Boele F, Rudà R, Theodorou M, Brandsma D, van den Bent M, Dirven L, on behalf of the EANO Women in Neuro-Oncology committee. Gender issues from the perspective of healthcare professionals in Neuro-oncology: an EANO & EORTC Brain Tumor Group survey. *Neuro-Oncol Pract* 2020;7:249-259
690. Lohmann B, Le Rhun E, Silginer M, Epskamp M, **Weller M**. Interferon- β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. *Oncol Lett* 2020;19:2649-2656 1.664
691. Lareida A, Terziev R, Grossenbacher B, Andratschke N, Roth P, Rohrmann S, Stahel R, Guckenberger M, Le Rhun E, **Weller M**, Wolpert F. Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. *J Neuro-Oncol* 2019;145:339-347 3.060
692. Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser CD, Schmid MB, Rutishauser D, Ljubicic J, Christiansen A, Fritz C, Rupp NJ, Poyet C, Rushing E, **Weller M**, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild PJ, Aebersold R, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol* 2019;13:2305-2328 5.962
693. Ma Q, Schlegel F, Bachmann SB, Schneider H, Decker Y, Rudin M, **Weller M**, Proulx ST, Detmar M. Lymphatic outflow of cerebrospinal fluid is reduced in glioma. *Sci Rep* 2019;9:14815 4.122
694. Le Rhun E, Devos P, Bourg V, Darlix A, Lorgis V, Ahle G, Boone M, Taillandier L, Curtit E, Gras L, Lebrun Frenay C, Gramatzki D, Ramirez C, Simon N, **Weller M**. Complementary and alternative medicine use in glioma patients in France. *J Neuro-Oncol* 2019;145:487-499 3.060
695. von Achenbach C, **Weller M**, Kaulich K, Gramatzki D, Zacher A, Fabbro D, Reifenberger G, Szabó E. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. *J Neurochem* 2020;153:510-524 4.609
696. Le Rhun E, Wallet J, Mailliez A, Le Deley MC, Rodrigues I, Boulanger T, Lorgis V, Barrière J, Robin YM, **Weller M**, Bonnetterre J. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. *Neuro-Oncology* 2020;22:524-538 9.384
697. Mayinger M, Kraft J, Lohaus N, **Weller M**, Schanne D, Heitmann J, Willmann J, Wilke L, Krayenbuehl J, Tanadini-Lang S, Guckenberger M, Andratschke N. Leukoencephalopathy after prophylactic whole brain irradiation with or without hippocampal sparing: a longitudinal MRI analysis. *Eur J Cancer* 2019;124:194-203 7.191
698. Sievers P, Chiang J, Schrimpf D, Stichel D, Paramasivam N, Sill M, Gayden T, Casalini B, Reuss DE, Dalton J, Pajtler KW, Hänggi D, Herold-Mende C, Rushing E, Korshunov A, Mawrin C, **Weller M**, Schlesner M, Wick W, Jabado N, Jones DTW, Pfister SM, von Deimling A, Ellison DW, Sahm F. YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathol* 2020;139:215-218 15.876

699. Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N, Tatagiba M, Pietsch T, Reifenberger G, Löffler M, Wick W, **Weller M**, on behalf of the German Glioma Network. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. *J Cancer Res Clin Oncol* 2020;146:659-670 3.332
700. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhyay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, **Weller M**, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW; GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. *Nature* 2019;576:112-120 41.577
701. van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, de Vos F, Whenham N, Sanghera P, **Weller M**, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brillhante J, Coens C, Gorlia T, Golfopoulos V. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro-Oncology* 2020;22:684-693 9.384
702. Hoogstrate Y, Vallentgoed W, J.M. Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda J, Walenkamp A, Frenel JS, Franceschi E, Clement PM, **Weller M**, van Royen M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfopoulos V, van den Bent M, French PJ. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. *Neuro-Oncology Advances* 2019;2:vdz051
703. Yust-Katz S, O'Brien B, Vera E, Acquaye A, **Weller M**, Armstrong T. Burnout and career satisfaction in Neuro-Oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology membership. *Neuro-Oncology* 2020;22:838-850 9.384
704. Seiler A, Schubert M, Hertler C, Schettle M, Blum D, Guckenberger M, **Weller M**, Ernst J, von Känel R, Boettger S. Predisposing and precipitating risk factors for delirium in palliative care patients. *Palliat Support Care* 2019;14:1-10
705. Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, **Weller M**, Wick W, for the NOA-08 Study Group of the Neurooncology Working Group (NOA) of the German Cancer Society. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, *MGMT* promoter-methylated malignant astrocytoma. *Neuro-Oncology* 2020;22:1162-1172 9.384
706. Wirsching HG, Morel C, Roth P, **Weller M**. Socioeconomic burden and quality of life in meningioma patients. *Qual Life Res* 2020;29:1801-1808 2.488
707. von Achenbach C, Silginer M, Blot V, Weiss WA, **Weller M**. Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not EGFR Y1068 phosphorylation. *Mol Cancer Ther* 2020;19:1328-1339 5.365

708. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt T, Zwirter R, Sampson J, **Weller M**. Nivolumab versus bevacizumab in patients with recurrent glioblastoma: a randomized, open-label, multicenter, phase 3 study (CheckMate 143). *JAMA Oncol* 2020;6:1003-1010 22.416
709. Hertler C, Eisele G, Gramatzki D, Seystahl K, Wolpert F, Roth P, **Weller M**. End-of-life care for glioma patients; the caregivers' perspective. *J Neuro-Oncol* 2020;147:663-669 3.060
710. Lohmann B, Silginer M, Picard D, Schneider H, Remke M, Roth P, Reifenberger G, **Weller M**. Interferon- β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. *Neuro-Oncology Advances* 2020;2:vdaa043
711. Muscas G, Van Niftrik C, Sebök M, Seystahl K, Piccirelli M, Stippich C, **Weller M**, Regli L, Fierstra J. Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. *Magnetic Resonance Imaging* 2020;70:50-56 2.122
712. Dirven L, Luerding R, Beier D, Bumès E, Reinert C, Seidel C, Bonsanto MM, Bremer M, Rieken S, Combs SE, Herrlinger U, Seliger C, Kuntze H, Mayer-Steinacker R, Dieing A, Bartels C, Schnell O, Weyerbrock A, Seidel S, Grauer O, Nadji-Ohl M, Paulsen F, **Weller M**, Wick W, Hau P. Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. *J Neuro-Oncol* 2020;148:117-130 3.060
713. Friebel E, Kapolou K, Unger S, Gonzalo Núñez N, Utz S, Rushing EJ, Regli L, **Weller M**, Greter M, Tugues S, Neidert MC, Becher B. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue invading leukocytes. *Cell* 2020;181:1626-1642 36.216
714. Le Rhun R, Wolpert F, Fialek M, Devos P, Andratschke N, Reyns N, Regli L, Dummer R, Mortier L, **Weller M**. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. *ESMO Open* 2020;5:e000763
715. Gramatzki D, Rogers JL, Neidert MC, Hertler C, Le Rhun E, Roth P, **Weller M**. Antidepressant drug use in glioblastoma patients: an epidemiological view. *Neuro-Oncol Pract* 2020;7:514-521
716. Wolpert F, Berghoff AS, Grossenbacher B, Lareida A, Löb R, Roth P, Neidert MC, Andratschke N, Le Rhun E, Preusser M, **Weller M**. Venous thromboembolic events in patients with brain metastases: the PICOS score. *Eur J Cancer* 2020;134:75-85 7.191
717. Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, **Weller M**, Platten M, Maier-Hein KH, von Deimling A, van den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. *Neuro-Oncology* 2020;22:1667-1676 9.384
718. Berghoff AS, Wippel C, Starzer AM, Ballarini N, Wolpert F, Bergen E, Wolf P, Steindl A, Widhalm G, Gatterbauer B, Marosi C, Dieckmann K, Bartsch R, Scherer T, Koenig F, Krebs M, **Weller M**, Preusser M. Hypothyroidism correlates with favorable survival prognosis in patients with brain-metastatic cancer. *Eur J Cancer* 2020;135:150-158 7.191
719. Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, **Weller M**, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M. Non-invasive characterization of tumor angiogenesis and oxygenation in bevacizumab-treated

- recurrent glioblastoma using dynamic susceptibility MRI: post-hoc analysis of the EORTC-26101 trial. *Radiology* 2020;297:164-175
720. Wolpert F, Kulcszar Z, Hänsel M, Rushing E, Seystahl K, Schweizer J, Roth P, Luft AR, Wegener S, **Weller M**. Embolization of tumor cells is rare in patients with systemic cancer and cerebral large vessel occlusion. *Eur J Neurol* 2020;27:2041-2046 4.621
721. Weller D, Filli L, Meyer C, Linnebank M, **Weller M**, Curt A, Zörner B. Impaired speed-dependent modulation of the gait pattern in multiple sclerosis. *J Neurol* 2020;267:2998-3007 3.783
722. Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin C, Ketter R, Paulus W, Reifenberger G, Lamszus K, Westphal M, Etminan N, Ratliff M, Herold-Mende C, Pfister SM, Jones DTW, **Weller M**, Harter PN, Wick W, Preusser M, von Deimling A, Sahm F. *CDKN2A/B* homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathol* 2020;140:409-413 15.876
723. Weller D, Lörinicz L, Sutter T, Reuter K, Linnebank M, **Weller M**, Zörner B, Filli L. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis. *J Neurol Sci* 2020;416:116978 2.448
724. Johnson RM, Phillips HS, Bais C, Brennan CW, Cloughesy TF, Daemen A, Herrlinger U, Jenkins RB, Lai A, Mancao C, **Weller M**, Wick W, Bourgon R, Garcia J. Development of a gene expression-based prognostic signature for *IDH* wild-type glioblastoma. *Neuro-Oncology* 2020;22:1742-1756 9.384
725. El Amki M, Glück C, Binder N, Middleham W, Wyss MT, Weiss T, Meister H, Luft A, **Weller M**, Weber B, Wegener S. Neutrophils obstructing brain capillaries are a major cause of no-reflow in ischemic stroke. *Cell Rep* 2020;33:108260 2.448
726. von Achenbach C, Le Rhun E, Sahm F, Wang SS, Sievers P, Neidert MC, Rushing EJ, Lawhon T, Schneider H, von Deimling A, **Weller M**. Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. *Transl Oncol* 2020;13:100852 3.318
727. Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, Bink A, **Weller M**, Neri D, Roth P. Immunocytokines are a novel immunotherapeutic approach against glioblastoma. *Sci Transl Med* 2020;12:eabb2311 17.161
728. Sebök M, van Niftrik CHB, Halter M, Hiller A, Seystahl K, Pangalu A, **Weller M**, Stippich C, Regli L, Fierstra J. Crossed cerebellar diaschisis in patients with diffuse glioma is associated with impaired supratentorial cerebrovascular reactivity and worse clinical outcome. *Cerebellum* 2020;19:824-832 3.413
729. Frappaz D, Bonneville-Levard A, Ricard D, Carrie S, Schiffler C, Hoang Xuan K, **Weller M**. Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias. *Supportive Care Cancer in press* 2.754
730. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, **Weller M**, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. *Neuro-Oncology in press* 9.384
731. Burghardt I, Ventura E, Weiss T, Schroeder JJ, Seystahl K, Zielasek C, Gramatzki D, **Weller M**. Endoglin and TGF- β signaling in glioblastoma. *Cell Tissue Res in press* 3.043

732. Gramatzki D, Felsberg J, Roth P, Kaulich K, von Deimling A, Rushing EJ, Reifenberger G, **Weller M**. The molecular evolution of glioblastoma treated by gross total resection alone. *Neuro-Oncology* 2021;23:334-336 9.384
733. Nadal L, Corbellari R, Villa A, Weiss T, **Weller M**, Neri D, De Luca R. Novel human monoclonal antibodies specific to the alternatively spliced domain D of tenascin C efficiently target tumors in vivo. *MAbs*. 2020;12:1836713 4.634
734. Kessler T, Berberich A, Sadik A, Sahm F, Gorlia T, Meisner C, Hoffmann DC, Wick A, Kickingereder P, Rübmann P, Bendszus M, Opitz C, **Weller M**, van den Bent M, Stupp R, Winkler F, Brandes A, von Deimling A, Platten M, Wick W. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. *Cancer Med* 2020;9:8373-8385 3.491
735. Wu Y, Fletcher M, Gu Z, Wang Q, Costa B, Bertoni A, Man KA, Schlotter M, Felsberg J, Mangei J, Barbus M, Gaupel AC, Wang W, Weiss T, Eils R, **Weller M**, Liu H, Reifenberger G, Korshunov A, Angel P, Lichter P, Herrmann C, Radlwimmer B. Glioblastoma epigenome profiling identifies SOX10 as a master 2 regulator of molecular tumour subtype. *Nat Commun* 2020;11:6434 12.121
736. Mock J, Stringhini M, Villa A, **Weller M**, Weiss T, Neri D. An engineered 4-1BBL fusion protein with "activity on demand". *Proc Natl Acad Sci USA* 2020;117:31780-31788 9.504
737. Le Rhun R, Devos P, Weller J, Seystahl K, Mo F, Compter A, Berghoff AS, Jongen JLM, Wolpert F, Rudà R, Brandsma D, Van den Bent M, Preusser M, Herrlinger U, **Weller M**. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. *Neuro-Oncology* in press 9.384
738. Wirsching HG, Silginer M, Ventura E, Macnair W, Burghardt I, Claassen M, Gatti S, Wichmann J, Riemer C, Schneider H, **Weller M**. Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. *Mol Ther Oncolytics* 2020; 20:166-174 5.650
739. Coomans MB, Taphoorn MJB, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, **Weller M**, Wick W, Reijneveld JC, Dirven L. Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. *Neurooncology Practice* 2020;7:668-675
740. Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, **Weller M**, Chinot O, De Vos FYFL, Whenham N, Sanghera P, Looman J, Kundu MG, de Geus JP, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfopoulos V, Reijneveld JC, van den Bent MJ. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. *Eur J Cancer* 2021;147:1-12 7.191
741. Galldiks N, Abdulla DS, Scheffler M, Wolpert F, Werner JM, Huellner MW, Stoffels G, Schweinsberg V, Schlaak M, Kreuzberg N, Landsberg J, Lohmann P, Cecon G, Baues C, Trommer M, Celik E, Ruge MI, Kocher M, Marnitz S, Fink GR, Tonn JC, **Weller M**, Langen KJ, Wolf J, Mauch C. Treatment monitoring of immunotherapy and targeted therapy using ¹⁸F-FET PET in patients with melanoma and lung cancer brain metastases: initial experiences. *J Nucl Med* 2020 in press 7.887
742. Schneider F, Wolpert F, Stolzmann P, Albatly AA, Kenkel D, Weller J, **Weller M**, Kollias SS, Rushing EJ, Veit-Haibach P, Huellner MW. Prognostic value of O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. *Acta Oncol* 2020;59:1357-1364 3.473

743. Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing ER, Pietsch T, von Deimling A, Sabel M, Loeffler M, **Weller M**, Reifenberger G. TERT promoter mutation and MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: is there a link? *Eur J Cancer* 2021;22;147:84-94 7.191
744. Gramatzki D, Felsberg J, Hentschel B, Bähr O, Westphal M, Schackert G, Tonn JC, Herrlinger U, Loeffler M, Pietsch T, Steinbach JP, Reifenberger G, Roth P, **Weller M**. Chemotherapy for adult patients with spinal cord gliomas. *Neuro-Oncology Practice* in press
745. Werner J, Reichen I, Huber M, Abela IA, **Weller M**, Jelcic I. Subacute cerebellar ataxia following respiratory symptoms of COVID-19: A Case Report. *BMC Infect Dis* 2021;21:98
746. Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H, Gill S, Griffin M, Rogers L, Rudà R, **Weller M**, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, de Vos F, Mulholland PJ, Taphoorn MJB, de Heer I, Hoogstrate Y, de Wit M, Boggiani L, Venneker S, Oosting J, Bovée JVMG, Erridge S, Vogelbaum MA, Nowak AK, Mason WP, Kros JM, Wesseling P, Aldape K, Jenkins RB, Dubbink HJ, Baumert B, Golfinopoulos V, Gorlia T, van den Bent M, French PJ. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. *Acta Neuropathol* in press 15.876
747. Vils A, Bogowicz M, Tanadini-Lang S, Vuong D, Saltybaeva N, Kraft J, Wirsching HG, Gramatzki D, Wick W, Rushing E, Reifenberger G, Guckenberger M, **Weller M**, Andratschke N. Radiomic analysis to predict outcome in recurrent glioblastoma based on multi-center MR imaging from the prospective DIRECTOR trial. *Frontiers in Oncology* in press 5.425
748. Conde J, Pumroy R, Baker C, Rodrigues T, Guerreiro A, Sousa B, Marques M, De Almeida B, Lee S, Leites E, Picard D, Samanta A, H. Vaz S, Sieglitz F, Langini M, Remke M, Roque R, Weiss T, **Weller M**, Liu Y, Han S, Corzana F, Morais V, Faria C, Carvalho T, Filippakopoulos P, Snijder B, Barbosa-Morais N, Moiseenkova-Bell V, Bernardes G. Allosteric antagonist modulation of TRPV2 by piperlongumine impairs glioblastoma progression. *ACS Central Science* in press 12.837
749. Burghardt I, Schroeder JJ, Weiss T, Gramatzki D, **Weller M**. A tumor-promoting role for soluble TβRIII in glioblastoma. *Mol Cell Biochem* in press 2.850
750. Seystahl K, Hug A, Weber SJ, Kapitza S, Gramatzki D, Wanner M, Katan M, Luft AR, Rohrmann S, Wegener S, **Weller M**. Cancer is associated with inferior outcome in patients with ischemic stroke. *J Neurol* in press 3.781
751. Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, Muhlenbruch L, Szolek A, Lubke M, Wagner P, Engler T, Matovina S, Wang J, Hauri-Hohl M, Martin R, Kapolou K, Walz JS, Velz J, Moch H, Regli L, Silginer M, **Weller M**, Löffler MW, Erhard F, Schlosser A, Kohlbacher O, Stevanović S, Rammensee HG, Neidert MC. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunotherapy Cancer* in press 10.252
752. Sebök M, van Niftrik CHB, Muscas G, Pangalu A, Seystahl K, **Weller M**, Regli L, Fierstra J. Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI identified tumor border indicate diffuse glioma extended tissue infiltration. *Neuro-Oncology Advances* in press
753. Khasraw M, **Weller M**, Lorente D, Kolibaba K, Lee CK, Gedye C, De La Fuente MI, Vicente

D, Reardon DA, Gan HK, Scott AM, Dussault I, Helwig C, Ojalvo LS, Gourmelon C, Groves M. Bintrafusp alfa (M7824) a bifunctional fusion protein targeting TGF- β and PD-L1: results from a phase 1 expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances in press

754. Tesileanu CMS, Van den Bent MJ, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, **Weller M**, McBain C, Van Linde MD ME, Sabedot TS, Hoogstrate Y, Von Deimling A, De Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Cheung KJ, Golfopoulos V, Baumert BG, Gorlia T, Noushmehr H, French PJ. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology in press 9.384
755. Zipser CM, Deuel JW, Philipp J, Held O, Ernst J, Schubert M, **Weller M**, Luft AR, Von Känel R, Boettger S. Economic impact of post-stroke delirium and associated risk factors: findings from 1 a prospective cohort study. Stroke in press
756. Muscas G, Van Niftrik CHB, Sebök M, Della Puppa A, Seystahl K, Andratschke N, Brown M, **Weller M**, Regli L, Piccirelli M, Fierstra J. Distinct cerebrovascular reactivity patterns for brain radiation necrosis. Cancers in press

B. Reviews and Correspondence

	IF 2017	CI 2017
1988		
1. Wiedemann P, Weller M . The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol 1988;66(Suppl. 189):7-15	3.324	41
1989		
2. Weller M , Heimann K, Wiedemann P. Immunochemical analysis of periretinal membranes. Review and outlook. Dev Ophthalmol 1989;16:54-74		16
3. Weller M , Wiedemann P. Visual hallucinations. An outline of etiological and pathogenetic concepts. Int Ophthalmol 1989;13:193-199		5
4. Weller M , Wiedemann P. Hysterical symptoms in ophthalmology. Doc Ophthalmol 1989;73:1-33	2.362	22
1990		
5. Weller M , Heimann K, Wiedemann P. Mononukleäre Phagozyten und ihre Wachstumsfaktoren: Schrittmacher der proliferativen Vitreoretinopathie? Klein Monatsbl Augenheilkd 1990;196:121-127	0.882	7
6. Weller M , Wiedemann P, Heimann K. Proliferative vitreoretinopathy. Is it anything more than wound healing at the wrong place? Int Ophthalmol 1990;14:105-117		101
7. Weller M , Heimann K, Wiedemann P. The pathogenesis of vitreoretinal proliferation and traction. Med Hypotheses 1990;31:157-159	1.120	19
8. Wiedemann P, Weller M , Heimann K. Proliferative Vitreoretinopathie: Neue Erkenntnisse in Pathophysiologie und Therapie. Klein Monatsbl Augenheilkd 1990;197:355-361	0.882	14
1991		
9. Weller M , Wiedemann P, Heimann K. Humorale Faktoren in der Genese der proliferativen Vitreoretinopathie: zur Bedeutung der Integrität der Blut-Retina-Schranke. Spektrum Augenheilkd 1991;5/6:245-247		
10. Weller M , Esser P, Heimann K, Wiedemann P. Mononuclear phagocytes in proliferative vitreoretinopathy (PVR). A specific role of microglial cells in non-traumatic disease? Eur J Ophthalmol 1991;1:161-166	1.897	3
1992		
11. Weller M . Diagnostic value of fibronectin determination in the CSF. J Clin Pathol 1992;45:548-549	2.894	
12. Weller M . Elevated levels of fibronectin in the CSF: what do they signify? J Neurol Sci 1992;110:232-233	2.448	3
13. Weller M . How to define the opercular syndrome? J Neurol 1992;239:294-295	3.783	8
14. Weller M . Anti-Phospholipid-Antikörper und zerebrale Ischämie. Fortschr Neurol Psychiatr 1992;60:246-247	0.395	

15. **Weller M.** The age of Karl Ludwig Kahlbaum. *Biol Psychiatry* 1992;32:213-214 11.984 1
16. **Weller M,** Kornhuber J. Elektrokonvulsionstherapie: Fehlerquellen und Hilfsmaßnahmen bei insuffizienter Konvulsionsdauer. *Fortschr Neurol Psychiatr* 1992;60:223-226 0.395 9
17. **Weller M.** NMS and lethal catatonia. *J Clin Psychiatry* 1992;53:294 4.247 7
18. **Weller M,** Kornhuber J. N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome. *Arch Neurol* 1992;49:900-901 11.460 6
19. **Weller M,** Kornhuber J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. *Med Hypotheses* 1992;38:329-333 1.120 25
20. **Weller M,** Kornhuber J. Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. *Nervenarzt* 1992;63:645-655 0.738 22
- 1993**
21. **Weller M,** Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? *J Clin Psychiatry* 1993;54:70-71 4.247 27
22. Kornhuber J, **Weller M,** Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. *J Neural Transmission [P-D Sect]* 1993;6:63-72 2.779 39
23. **Weller M,** Kornhuber J. Amantadine withdrawal and neuroleptic malignant syndrome. *Neurology* 1993;43:2155 8.055 8
24. **Weller M.** Anterior opercular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia. Foix-Chavany-Marie syndrome and "automatic voluntary dissociation" revisited. *J Neurol* 1993;240:199-208 3.783 100
25. Sommer N, Melms A, **Weller M,** Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. *Doc Ophthalmol* 1993;84:309-333 2.362 52
- 1994**
26. Kornhuber J, **Weller M.** Neuroleptic malignant syndrome. *Curr Opin Neurol* 1994;7:353-357 4.010 30
27. Kornhuber J, **Weller M.** Clozapin (Leponex®). *Intern Prax* 1994;34:656-660
28. Kornhuber J, **Weller M.** Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. *Nervenarzt* 1994;65:741-754 0.738 22
29. Kornhuber J, **Weller M,** Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. *J Neural Transmission* 1994;Suppl. 43:91-104 2.779 211
- 1995**
30. **Weller M,** Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF- β , T cell apoptosis, and the immune privilege of the brain. *Brain Res Rev* 1995;21:128-151 19.97 216
- 1996**

31.	Kornhuber J, Weller M . Neue therapeutische Möglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten. <i>Nervenarzt</i> 1996;67:77-82	0.738	7
32.	Weller M , Kornhuber J. Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. <i>Austr N Z J Med</i> 1996;26:232-233		3
33.	Weller M . Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. <i>Cell Physiol Biochem</i> 1996;6:376-380	5.500	5
1997			
34.	Weller M , Kornhuber J. Clozapine and NMS: a never-ending story. <i>J Clin Psychopharmacol</i> 1997;17:233	2.939	2
35.	Kornhuber J, Weller M . Psychogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. <i>Biol Psychiatry</i> 1997;41:135-144	11.984	180
36.	Schabet M, Herrlinger U, Weller M , Bamberg M, Clemens R, Dichgans J. Neue Entwicklungen in Diagnostik und Therapie primärer Non-Hodgkin-Lymphome des zentralen Nervensystems. <i>Nervenarzt</i> 1997;68:298-308	0.738	7
37.	Kornhuber J, Weller M . Das maligne neuroleptische Syndrom. <i>Aktuel Neurol</i> 1997;24:129-133		
38.	Weller M , Schulz JB, Wüllner U, Löschnann P, Klockgether T, Dichgans J. Developmental and genetic regulation of programmed neuronal death. <i>J Neural Transmission</i> 1997;Suppl. 50:115-123	2.779	15
1998			
39.	Weller M . Assessing response to chemotherapy in malignant glioma: the role of steroids. <i>Neurology</i> 1998;50:1196	8.055	2
40.	Weller M . Predicting response to cancer chemotherapy: the role of p53. <i>Cell Tissue Res</i> 1998;292:435-445	3.043	188
41.	Weller M , Kleihues P, Dichgans J, Ohgaki H. CD95 ligand: lethal weapon for malignant glioma? <i>Brain Pathol</i> 1998;8:285-293	6.187	72
42.	Weller M , Dichgans J. Erstbeschreibung des Ross-Syndroms durch Hans Huetlin. <i>Nervenarzt</i> 1998;69:540	0.738	1
43.	Herrlinger, Weller M , Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. <i>J Neuro-Oncol</i> 1998;38(Suppl.):233-239	3.060	28
44.	Zipp F, Martin R, Dichgans J, Weller M . CD95 (Fas/APO-1) and Parkinson's disease: reply. <i>Ann Neurol</i> 1998;44:426	10.250	
1999			
45.	Ständer M, Naumann U, Wick W, Weller M . TGF- β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. <i>Cell Tissue Res</i> 1999;296:221-227	3.043	101
46.	Schulz JB, Weller M , Moskowitz M. Caspases as treatment targets in stroke and neurodegenerative diseases. <i>Ann Neurol</i> 1999;45:421-429	10.250	262

47.	Zipp F, Krammer PH, Weller M . Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system? <i>Immunol Today</i> 1999;20:550-554	7.33	68
48.	Rieger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M . Glioblastoma multiforme: mechanisms of resistance to chemotherapy. <i>Neurol Psychiatr Brain Res</i> 1999;7:37-46		6
49.	Roth W, Weller M . Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. <i>Cell Mol Life Sci</i> 1999;56:481-506	6.721	51
50.	Weller M . Glucocorticoid treatment of primary CNS lymphoma. <i>J Neuro-Oncol</i> 1999;43:237-239	3.060	57
2000			
51.	Weller M . Chemotherapie maligner Gliome. <i>Nervenheilkunde</i> 2000;19:116-120		
52.	Weller M , Reed JC. Apoptosis 2000. Preface. <i>Cell Tissue Res</i> 2000;301:3	3.043	1
2001			
53.	Weller M , Wick W, Platten M. Role of TGF- β in oncogenesis (Editorial). <i>Microscop Res Techn</i> 2001;52:353	1.087	6
54.	Platten M, Wick W, Weller M . Malignant glioma biology: role for TGF- β in growth, motility, angiogenesis and immune escape. <i>Microscop Res Techn</i> 2001;52:401-410	1.087	158
55.	Weller M , Thömke F. Meningeosis neoplastica. <i>Aktuel Neurol</i> 2001;28:265-272		1
2002			
56.	Steinbach JP, Weller M . Mechanisms of apoptosis in central nervous system tumors: application to theory. <i>Curr Neurol Neurosci Rep</i> 2002;2:246-253	2.832	12
57.	Bögler O, Weller M . Apoptosis in glioma, and its role in their current and future treatment. <i>Front Biosci</i> 2002;7:E339-353	3.95	29
58.	Plasswilm L, Herrlinger U, Korfel A, Weller M , Küker W, Kanz L, Thiel E, Bamberg M. Primary central nervous system (CNS) lymphoma in immunocompetent patients. <i>Ann Hematol</i> 2002;81:415-423	2.845	18
2003			
59.	Waltreit R, Weller M . Signaling from Camp/PKA to MAPK and synaptic plasticity. <i>Mol Neurobiol</i> 2003;27:99-106	9.384	153
60.	Bögler O, Weller M . Meeting Report: International Hermelin Brain Tumor Center Symposium on Apoptosis. <i>Cell Death Differ</i> 2003;10:1112-1115	8.000	3
61.	Wiendl H, Mitsdörffer M, Weller M . Hide-and-seeK in the brain: a role for HLA-G mediating immune privilege for glioma cells. <i>Semin Cancer Biol</i> 2003;13:343-351	10.198	29
62.	Kortmann RD, Jeremic B, Weller M , Plasswilm L, Bamberg M. Radiochemotherapy of malignant glioma in adults. Clinical experiences. <i>Strahlenther Onkol</i> 2003;179:219-232	2.459	51
63.	Weller M . Differentialdiagnose und medikamentöse Therapie neurogener Blasenstörungen.		

Aktuel Neurol 2003;30:382-389

64. **Weller M.** Modulation der Apoptosevulnerabilität und Motilität von Glioblastomzellen durch Gammastrahlung. *Mol Radiat Biol Oncol* 2003;4:57-59
65. Wiendl H, Mitsdörffer M, **Weller M.** Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. *Human Immunol* 2003;64:1050-1056 1.994 23
66. **Weller M.** Neuroonkologie. *Nervenarzt* 2003;74:1139-1149 0.738 3
- 2004**
67. Steinbach JP, **Weller M.** Apoptosis in gliomas: Molecular mechanisms and therapeutic implications. *J Neuro-Oncol* 2004;70:245-254 3.060 55
68. **Weller M.** Therapeutische Antagonisierung von transforming growth factor- β (TGF- β) beim Glioblastom: Rationale und aktuelle Behandlungskonzepte. *Aktuel Neurol* 2004;31:14-18 1
69. Naumann U, Wick W, Beschorner R, Meyermann R, **Weller M.** Osteoprotegerin in the central nervous system. *Acta Neuropathol* 2004;107:578 15.876
70. Friese MA, Steinle A, **Weller M.** The innate immune response in the central nervous system and its role in glioma immune surveillance. *Onkologie* 2004;27:487-491 21
71. Kortmann RD, Jeremic B, **Weller M,** Lutterbach J, Paulsen F, Bamberg M. Immediate postoperative radiotherapy or “watch and wait” in the management of adult low-grade glioma? *Strahlenther Onkol* 2004;180:408-418 2.459 14
- 2005**
72. Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, **Weller M,** Kanz L. Primary central nervous system lymphoma: standards of care and future perspectives. Meeting report. *Onkologie* 2005;28:109-111 5
73. Brötz D, **Weller M.** A prospective trial of mechanical physiotherapy for lumbar disk prolapse (Response). *J Neurol* 2005;253:118 3.783
74. **Weller M.** Standards und neue Entwicklungen bei der Chemotherapie des Glioblastoms. *Dtsch Med Wschr* 2005;130:2270-2274 0.523
75. **Weller M,** Steinbach JP, Wick W. Temozolomide: a milestone in the pharmacotherapy of brain tumors. *Future Oncol* 2005;1:747-754 2.369 23
- 2006**
76. Wick W, Naumann U, **Weller M.** Transforming growth factor- β : a molecular target for the future therapy of glioblastoma. *Curr Pharm Design* 2006;12:341-349 2.757 106
77. Stupp R, Hegi ME, Van den Bent MJ, Mason WP, **Weller M,** Mirimanoff RO, Cairncross JG, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada (NCIC) Clinical Trials Group. Changing paradigms. An update on the multidisciplinary management of malignant glioma. *Oncologist* 2006;11:165-180 5.306 267

2007

78. Diener HC, Elger CE, Hartung HP, Maschke M, **Weller M**, Deuschl G, Kastrup O, Schuchardt V. Off label use in der Neurologie. *Aktuel Neurol* 2007;34:75-79
79. **Weller M**. Radiochemotherapy for brain metastasis: how to define a role for temozolomide. *Onkologie* 2007;30:350-351 5
80. **Weller M**. Diagnostische und therapeutische Strategien bei rezidivierten Gliomen. *Aktuel Neurol* 2007;34:564-569 1
- 2008**
81. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, **Weller M**, Mehta MP, Gilbert MR. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *J Clin Oncol* 2008;26:4189-4199 26.360 449
82. **Weller M**. Chemotherapie von Hirntumoren des Erwachsenenalters. *Nervenarzt* 2008;79:231-241 0.738 4
83. Semmler A, Köhler W, Jung HH, **Weller M**, Linnebank M. Therapy of X-linked adrenoleukodystrophy. *Expert Rev Neurother* 2008;8:1367-1379 27
84. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, **Weller M**, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. *Clin Cancer Res* 2008;14:2900-2908 10.199 183
85. **Weller M**, Yung WKA. Bevacizumab – News from the fast lane? *Neuro-Oncology* 2008;10:647 9.384 4
- 2009**
86. Wick W, Platten M, **Weller M**. New (alternative) temozolomide regimens for the treatment of glioma. *Neuro-Oncology* 2009;11:69-79 9.384 93
87. Diener HC, Hartung HP, Bien CG, Hacke W, Ringelstein EB, Ludolph A, Deuschl G, Wiltfang J, **Weller M**, Steinhausen K, Stemper B, Klatt J, Drepper J, Griewing B, Meier U, Herschel M, Hummel K, Paar WD, Dintsios CM, Schade-Brittinger C, Weber R, Weimar C. Klinische Studien in der Neurologie in Deutschland 2008. *Aktuel Neurol* 2009;36:8-18
88. **Weller M**, Aguzzi A. Movement disorders reveal Creutzfeldt-Jakob disease. *Nature Rev Neurol* 2009;5:185-186 19.819 1
89. **Weller M**, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic. *Nature Med* 2009;15:726-727 32.621 21
90. **Weller M**, Stupp R. Approval of new drugs for glioblastoma. *Curr Opin Neurol* 2009;22:617-618 4.010 5
91. Wick W, **Weller M**. Classification and management of anaplastic gliomas. *Curr Opin Neurol* 2009;22:650-656 4.010 11
- 2010**
92. **Weller M**, Stupp R, Reifenberger G, Brandes AA, Van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nature Rev Neurol* 2010;6:39-51 19.819 365

93.	Wick W, Weller M , van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. <i>J Clin Oncol</i> 2010;28:e188-189	26.360	72
94.	Weller M . Temozolomide and MGMT forever? <i>Neuro-Oncology</i> 2010;12:219-220	9.384	4
95.	Weller M . Immunotherapy for glioblastoma: a long and winding road. <i>Neuro-Oncology</i> 2010;12:319	9.384	3
96.	Weller M . Angiogenesis in glioblastoma: just another moving target? <i>Brain</i> 2010;133:955-956	10.848	4
97.	Wick W, Weller M . Strukturen neuroonkologischer Forschung und Versorgung. <i>Nervenarzt</i> 2010;81:911-912	0.738	
98.	Wick W, Weller M . Anaplastische Gliome: Neuropathologie, molekulare Diagnostik und aktuelle Studienkonzepte. <i>Nervenarzt</i> 2010;81:928-935	0.738	1
99.	Weller M . Chemotherapy for low-grade gliomas: When? How? How long? <i>Neuro-Oncology</i> 2010;12:1013	9.384	8
100.	Tabatabai G, Weller M , Nabors B, Picard M, Reardon M, Mikkelsen T, Ruegg C, Stupp R. Targeting integrins in malignant glioma. <i>Targ Oncol</i> 2010;5:175-181	3.907	56
101.	Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M . Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathol</i> 2010;120:585-592	15.876	66
102.	Weller M , Wick W, Hegi ME, Stupp R, Tabatabai G. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? <i>Future Oncol</i> 2010;6:1407-1414	2.369	16
103.	Weller M , Wick W. Nanotechnologie in der Neuro-Onkologie: eine Herausforderung für die evidenzbasierte Medizin. <i>Akt Neurol</i> 2010;37:382-383		
104.	Stupp R, Hegi M, Weller M . Neuro-oncology, a decade of temozolomide and beyond. <i>Expert Rev Anticancer Ther</i> 2010;10:1675-1677	2.347	18
105.	Wick W, Roth P, Wick A, Weller M . What is new in Neurooncology? <i>Akt Neurol</i> 2010;37:454-460		
106.	Stupp R, Weller M . 2010: neuro-oncology is moving! <i>Curr Opin Neurol</i> 2010;23:553-555	4.010	3
107.	Roth P, Wick W, Weller M . Steroids in neurooncology: actions, indications, side-effects. <i>Curr Opin Neurol</i> 2010;23:597-602	4.010	35
108.	Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Ochsenein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krüger S, Picard M, Weller M . Reply to M.C. Chamberlain. <i>J Clin Oncol</i> 2010;28:e696-e697	26.360	
2011			
109.	Weller M , Wick W. "Nanomania" ante portas of neurooncology? <i>J Neuro-Oncol</i> 2011;104:613-614	3.060	1
110.	Tabatabai G, Weller M . Glioblastoma stem cells. <i>Cell Tissue Res</i> 2011;343:459-465	3.043	48
111.	Tabatabai G, Tonn JC, Stupp R, Weller M . The role of integrins in glioma biology and anti-	2.757	26

glioma therapies. *Curr Pharm Design* 2011;17:2402-2410

112.	Korfel A, Thiel E, Martus P, Weller M . Whole-brain radiotherapy in primary CNS lymphoma. <i>Lancet Oncol</i> 2011;12:119-120	36.421	1
113.	Preusser M, De Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M , Stupp R. Current concepts and management of glioblastoma. <i>Ann Neurol</i> 2011;70:9-21	10.250	235
114.	Wick W, Wick A, Weiler M, Weller M . Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. <i>Curr Neurol Neurosci Rep</i> 2011;11:305-312	2.832	42
115.	Weller M , Wick W. Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? <i>Neuro-Oncol</i> 2011;13:365-366	9.384	5
116.	Wick W, Weller M . Trabedersen to target transforming growth factor- β : when the journey is not the reward. <i>Neuro-Oncol</i> 2011;13:559-560	9.384	10
117.	Wick W, Weller M , Weiler M, Batchelor T, Yung AWK, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncol</i> 2011;13:566-579	9.384	92
118.	Weller M . Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. <i>Neuro-Oncol</i> 2011;13:565	9.384	4
119.	Weller M . Novel diagnostic and therapeutic approaches to malignant glioma. <i>Swiss Med Weekly</i> 2011;141:w13210	1.928	29
120.	Tabatabai G, Wick W, Weller M . Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach. <i>Discovery Medicine</i> 2011;11:529-536	2.398	19
121.	Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M , Elger CE. Vitamin B12, folate and hyperhomocysteinemia in patients with epilepsy. Reply. <i>Ann Neurol</i> 2011;69:1068	10.250	63
122.	Weller M , Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> 2011;59:1200-1204	5.846	33
123.	Reardon DA, Neyns B, Weller M , Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide $\alpha v\beta 3$ and $\alpha v\beta 5$ integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncol</i> 2011;7:339-354	2.369	62
124.	Weller M , Stupp R. Clinical trials in Neuro-Oncology: one step forward, two steps back? <i>Curr Opin Neurol</i> 2011;24:597-598	4.010	1
125.	Weller M , Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to biology. <i>Curr Opin Neurol</i> 2011; 24:599-604	4.010	15
2012			
126.	Weller M . Angiogenesis inhibition: quo vadis? <i>Neuro-Oncology</i> 2012;14:1315	9.384	
127.	Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, Rovira A, Weller M , Law M. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. <i>Am J Neuroradiol</i> 2012;33:803-817	3.653	41
128.	Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M , Stupp R; On behalf of European Organisation for Research and Treatment of Cancer	7.191	16

	Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. <i>Eur J Cancer</i> 2012;48:896-903		
129.	Weller M , Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? <i>Cancer J</i> 2012;18:40-44	3.519	45
130.	Seystahl K, Weller M . Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? <i>Exp Opin Invest Drugs</i> 2012;21:605-617	3.88	15
131.	Roth P, Korfel A, Martus P, Weller M . Pathogenesis and management of primary central nervous system lymphoma. <i>Exp Rev Anticancer Ther</i> 2012;12:623-633	2.347	11
132.	Tabatabai G, Hegi M, Stupp R, Weller M . Clinical implications of molecular neuropathology and biomarkers for malignant glioma. <i>Curr Neurol Neurosci Rep</i> 2012;12:302-307	2.832	20
133.	Weller M . More on the immune privilege of glioblastoma. <i>Neuro-Oncology</i> 2012;14:527-528	9.384	3
134.	Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M , Vogelbaum M, Colman H, Sargent DJ, Van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncol</i> 2012;13:e196-204	36.421	31
135.	Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gerloff C, Gold R, Hacke W, Hufschmidt A, Mattle HP, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M , Kopp IB, Olma M, Heuschmann P. Wie entstehen die Leitlinien der Deutschen Gesellschaft für Neurologie? <i>Aktuel Neurol</i> 2012;39:525-529		1
136.	Weller M , Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? <i>Lancet Oncol</i> 2012;13:e375-e382	36.421	53
137.	Weller M . Microglia: a novel treatment target in gliomas. <i>Neuro-Oncology</i> 2012;14:957	9.384	
138.	Weller M , Stupp R, Hegi ME, Van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing in malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> 2012;14:iv100-iv108	9.384	81
139.	Weller M , Stupp R. Prime time for molecular marker diagnostics in Neuro-Oncology. <i>Curr Opin Neurol</i> 2012;25:743-744	4.010	
140.	Hegi ME, Rajakannu P, Weller M . Epidermal growth factor receptor: a re-emerging target in glioblastoma. <i>Curr Opin Neurol</i> 2012;25:774-779	4.010	58
2013			
141.	Laperriere N, Weller M , Stupp R, Perry JR, Brandes AA, Wick W, Van den Bent MJ. Optimal management of elderly patients with glioblastoma. <i>Cancer Treat Rev</i> 2013;39:350-357	8.122	66
142.	Weller M , Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? <i>Neuro-Oncology</i> 2013;15:4-27	9.384	234
143.	Weller M , Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncol</i> 2013;14:e370-e379	36.421	100
144.	Eisele G, Weller M . Targeting apoptosis pathways in glioblastoma. <i>Cancer Lett</i> 2013;332:335-345	6.491	33

145.	Maercker A, Perkonigg A, Preisig M, Schaller K, Weller M . The costs of disorders of the brain in Switzerland. An update from the European Brain Council study for 2010. <i>Swiss Med Weekly</i> 2013;143:w13751	1.928	6
146.	Weller M . Assessing the MGMT status in glioblastoma: one step forward, two steps back? <i>Neuro-Oncology</i> 2013;15:253-254	9.384	6
147.	Riemenschneider MJ, Louis DN, Weller M , Hau P. Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <i>Acta Neuropathol</i> 2013;126:21-37	15.876	7
148.	Weller M . Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? <i>Neuro-Oncology</i> 2013;15:809-810	9.384	8
149.	Weller M , Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. <i>Neuro-Oncology</i> 2013;15:971	9.384	23
150.	Roth P, Wick W, Weller M . Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. <i>Curr Treat Options Oncol</i> 2013;14:505-513	1.994	9
151.	Roth P, Regli L, Tonder M, Weller M . Tumor-associated edema in brain cancer patients: pathogenesis and management. <i>Expert Review Anticancer Ther</i> 2013;13:1319-1325	2.347	15
152.	Tabatabai G, Stupp R, Wick W, Weller M . Malignant astrocytoma in elderly patients: where do we stand? <i>Curr Opin Neurol</i> 2013;26:693-700	4.010	3
2014			
153.	Mohme M, Neidert MC, Regli L, Weller M , Martin M. Immunological challenges for peptide-based immunotherapy in glioblastoma. <i>Cancer Treat Rev</i> 2014;40:248-258	8.122	23
154.	Weller M , Soffietti R, Brada M. The legend of CMV and glioblastoma lives on. <i>Neuro-Oncology</i> 2014;16:266	9.384	7
155.	Weller M , Wick W. Improving outcome in newly diagnosed malignant glioma. <i>Nat Rev Neurol</i> 2014;10:68-70	19.819	
156.	Roth P, Stupp R, Eisele G, Weller M . Treatment of primary CNS lymphoma. <i>Curr Treat Options Neurol</i> 2014;16:277	1.994	10
157.	Weller M , Van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and Treatment of Malignant Glioma. <i>Lancet Oncol</i> 2014;15:e395-403	36.421	237
158.	Wick W, Weller M , Van den Bent M, Sanson M, Weiler M, Von Deimling A, Plass C, Hegi M, Platten M, Reifenberger R. MGMT testing - the challenges for biomarker-based glioma treatment. <i>Nature Rev Neurol</i> 2014;10:372-385	19.819	137
159.	Stupp R, Weller M . Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. <i>Neuro-Oncology</i> 2014;16:765-767	9.384	8
160.	Weller M . The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. <i>Neuro-Oncology</i> 2014;16:1035-1036	9.384	4

161.	Batchelor TT, Reardon DA, De Groot J, Wick W, Weller M . Anti-angiogenic therapy for glioblastoma: current status and future prospects. <i>Clin Cancer Res</i> 2014;20:5612-5619	10.199	46
162.	Weller M . Primary central nervous system lymphoma in the elderly. <i>Oncol Res Treat</i> 2014;37:376-377		
163.	Roth P, Weller M . Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. <i>Neuro-Oncology</i> 2014;16:viii14–viii19	9.384	19
164.	Langen KJ, Tonn JC, Weller M , Galldiks N. Letter to the Editor: The role of imaging in the management of progressive glioblastoma. <i>J Neurooncol</i> 2014;120:665-666	3.060	3
165.	Stupp R, Picard M, Weller M . Does cilengitide deserve another chance?-Authors' reply. <i>Lancet Oncol</i> 2014;15:e585-586	36.421	3
2015			
166.	Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CMF, Ferreri AJM, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffiotti R, Weller M , for the European Association for Neuro-Oncology (EANO) Task Force on Primary CNS Lymphoma. EANO Guideline for the diagnosis and treatment of primary CNS lymphoma in immunocompetent patients. <i>Lancet Oncol</i> 2015;16:e322-332	36.421	81
167.	Roth P, Weller M . Chemotherapie von Hirntumoren bei Erwachsenen. <i>Nervenarzt</i> 2015;86:495-508	0.738	
168.	Roth P, Happold C, Weller M . Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncol Pract</i> 2015;2:6-12		
169.	Preusser M, Weller M . Brain metastasis research: a late awakening. <i>Chin Clin Oncol</i> 2015;4:17		2
170.	Roth P, Weller M . Management of neoplastic meningitis. <i>Chin Clin Oncol</i> 2015;4:26		11
171.	Weller M , Wick W, Aldape K, Brada M, Berger M, Pfister S, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. <i>Nat Rev Dis Primers</i> 2015;1:5017	16.155	32
172.	Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M , Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, Van den Bent MJ, Chang S, Yung WKA, Cloughesy TF, Wen PY, Gilbert MR, and the Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Clinical Trials. <i>Neuro-Oncology</i> 2015;17:1188-1198	9.384	23
173.	Okada H, Weller M , Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A Report of the RANO Working Group. <i>Lancet Oncol</i> 2015;16:e534-542	36.421	115
174.	Wick W, Weller M . Neuroonkologie. <i>Nervenarzt</i> 2015;86:671	0.738	
175.	Reardon DA, Weller M . Cancer immunology and immunotherapy for CNS tumors. Introduction. <i>Neuro-Oncology</i> 2015;17 Suppl 7:viii1	9.384	1

175.	Reardon DA, Weller M . Dedication: Andrew T. Parsa. <i>Neuro-Oncology</i> 2015;17 Suppl 7:vii2	9.384	
176.	Nduom EK, Weller M , Heimberger A. Immunosuppressive mechanisms in glioblastoma. <i>Neuro-Oncology</i> 2015;17 Suppl 7:vii9-vii14	9.384	47
177.	Wirsching HG, Happold C, Roth P, Weller M . Management of diffusely infiltrating glioma in the elderly. <i>Curr Opin Oncol</i> 2015;27:502-509	3.653	5
178.	Baron R, Ferriero D, Frisoni GB, Bettegowda C, Gokaslan ZL, Kessler JA, Vezzani A, Waxman S, Jarius S, Wildemann B, Weller M . Neurology - the next 10 years. <i>Nat Rev Neurol</i> 2015;11:658-664	19.819	3
179.	Happold C, Weller M . New insights into acquired temozolomide resistance in glioblastoma? <i>Brain</i> 2015;138:3468-3470	10.848	
180.	Weiss T, Weller M , Roth P. Immunotherapy for glioblastoma: concepts and challenges. <i>Curr Opin Neurol</i> 2015;28:639-646	4.010	13
181.	Preusser M, Berghoff AS, Wick W, Weller M . PD-L1: emerging biomarker in glioblastoma? <i>Clin Neuropathol</i> 2015;34:313-321	1.015	13
182.	Seystahl K, Wick W, Weller M . Therapeutic options in recurrent glioblastoma - an update. <i>Crit Rev Oncol Hematol</i> 2016;99:389-408	4.495	41
183.	Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M , Glantz M. Therapy for secondary CNS involvement in malignant lymphomas: no standard yet! <i>J Clin Oncol</i> 2016;34:1829-1830	26.360	3
184.	Albert NL, Weller M , Suchorska B, Galldiks N, Soffietti R, Kim MM, La Fougère C, Pope W, Law I, Arbizu J, Chamberlain M, Vogelbaum MA, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology (RANO) Working Group and European Association for Neuro-Oncology (EANO) Recommendations for the Clinical Use of PET Imaging in Gliomas. <i>Neuro-Oncology</i> 2016;18:1199-1208	9.384	87
185.	Seystahl K, Gramatzki D, Roth P, Weller M . Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. <i>Exp Opin Pharmacother</i> 2016;21:1-12	2.766	7
186.	Roth P, Preusser M, Weller M . Immunotherapy of brain cancer. <i>Oncol Res Treatment</i> 2016;39:326-334		4
187.	Gulden-Sala W, Roth P, Brown M, Andratschke N, Weller M , Stupp R. Gliome - was ich wissen muss in 10 Fragen. <i>Praxis</i> 2016;105:330-337		
188.	Esposito G, Burgunder JM, Dunlop J, Gorwood P, Inamdar A, Pfister SM, Pochet R, Van den Bent MJ, Van Hoylandt N, Weller M , Westphal M, Wick W, Nutt D. Gene-tailored treatments for brain disorders: challenges and opportunities. <i>Public Health Genomics</i> 2016;19:170-177		1
189.	Mason M, Laperriere N, Wick W, Reardon DA, Malmstrom A, Hovey E, Weller M , Perry JR. Glioblastoma in the elderly: making sense of the evidence. <i>Neurooncol Pract</i> 2016;3:77-86		
190.	Goldbrunner R, Minniti G, Preusser P, Jenkinson MD, Sallabanda K, Houdart E, Von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Cohen-Jonathan Moyal E, Brandsma D, Henriksson R, Soffietti R, Weller M . EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncol</i> 2016;17:e383-e391	36.421	44

191. Hoppold C, Gorlia T, Chinot O, Gilbert M, Nabors B, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon D, Perry JR, Mehta M, Stupp R, **Weller M**. Reply to F. Felix et al and M.F. Fay et al. *J Clin Oncol* 2016;34:3107-3108 26.360 33
192. Wirsching HG, **Weller M**. The role of molecular diagnostics in the management of patients with gliomas. *Curr Treat Options Oncol* 2016;17:51 1.994 13
193. Gramatzki D, **Weller M**. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. *Cancer* 2016;122:3740-3741 6.537 18
194. Weiss T, **Weller M**, Roth P. Immunological effects of chemotherapy and radiotherapy against brain tumors. *Exp Rev Anticancer Ther* 2016;16:1087-1094 2.347 10
- 2017**
195. Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, **Weller M**, Koekkoek JAF, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, Van den Bent MJ, DeAngelis LM. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. *Neuro-Oncology* 2017;19:12-21 9.384 17
196. Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, **Weller M**. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). *Neuro-Oncology* 2017;19:162-174 9.384 22
197. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, **Weller M**. Advances in the molecular genetics of gliomas - implications for classification and therapy. *Nat Rev Clin Oncol* 2017;14:434-445 24.653 44
198. Hundsberger T, **Weller M**. Bevacizumab: Zankapfel der Glioblastomtherapie. *Praxis* 2017;106:415-420
199. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, **Weller M**, Wick W, von Deimling A. Announcing cIMPACT-NOW: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. *Acta Neuropathol* 2017;133:1-3 15.876 18
200. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, **Weller M**, Wick W, von Deimling A. cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathol* 2017;27:851-852 6.187 7
201. Van den Bent M, **Weller M**, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. *Neuro-Oncology* 2017;19:614-624 9.384 15
202. Mangani D, **Weller M**, Roth P. The network of immunosuppressive pathways in glioblastoma. *Biochem Pharmacol* 2017; 130:1-9 2.559 14
203. **Weller M**, Holland EC, Hambardzumyan D. Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. *Brain* 2017;140:e17 10.848

204. **Weller M**, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi M, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger R, Soffietti S, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Gliomas. EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncol* 2017;18:e315-e329 36.421 67
205. Roth P, **Weller M**. Immuntherapie von Hirntumoren. *Akt Neurol* 2017;44:400-408
206. Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasmán HRW, Oberndorfer S, **Weller M**, Taphoorn MJB, on behalf of the European Association of Neuro-Oncology palliative care task force. EANO guidelines for palliative care in adult glioma patients. *Lancet Oncol* 2017;18:e330–e340 36.421 15
207. Roth P, Gramatzki D, **Weller M**. Management of elderly patients with glioblastoma. *Curr Neurol Neurosci Rep* 2017;17:35 2.832 2
208. **Weller M**, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson J. Vaccine-based immunotherapeutic approaches to gliomas and beyond. *Nat Rev Neurol* 2017;13:363-374 19.819 25
209. Le Rhun E, **Weller M**, Brandsma D, Van den Bent M, De Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà E, Preusser M, on behalf of the EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. *Ann Oncol* 2017;28(Supplement 4):iv84–iv99 13.930 16
210. Galldiks N, Albert ML, Sommerauer M, Grosu AL, Ganswindt U, Law L, Preusser M, Le Rhun E, Vogelbaum MA, Zadeh G, Dhermain F, **Weller M**, Langen KJ, Tonn JC. PET imaging in patients with meningioma - report of the RANO/PET group. *Neuro-Oncology* 2017;19:1576-1587 9.384 6
211. **Weller M**. Surgery for patients with “lower grade” glioma: putting assumptions, beliefs and convictions into perspective. *Ann Oncol* 2017;28:1696-1697 13.930
212. **Weller M**, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi M, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger R, Soffietti S, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Gliomas. Evidence-based management of adult patients with diffuse glioma. Authors’ reply. *Lancet Oncol* 2017;18:e430-e431 36.421
213. Rudà R, Reifenberger G, Frappaz D, Pfister SM, Laprie L, Santarius T, Roth P, Tonn JC, Soffietti R, **Weller M**, Cohen-Jonathan Moyal E. EANO guidelines for the diagnosis and treatment of ependymal tumors. *Neuro-Oncology* 2018;20:445-456 9.384 4
214. **Weller M**, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O’Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH, for the ACT IV trial investigators.Go, No-Go decision making for phase 3 clinical trials: Act IV rindopepimut revisited - Authors' reply. *Lancet Oncol* 2017;18:e709-e710 36.421 2
215. Renfrow JJ, **Weller M**, Strowd RE. Meeting update – World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017. *Neuro-Oncology* 2017;19:1457-1459 9.384 1
216. **Weller M**. Where does MGMT promoter methylation assessment place temozolomide in the 6.537

future standards of care for glioblastoma? *Cancer* 2018;124:1316-1318

217. Lim M, Xia Y, Bettgowda C, **Weller M**. Current state of immunotherapy for glioblastoma. *Nat Rev Clin Oncol* 2018;15:422-442 24.653 8
218. Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, **Weller M**, Wen PY, Taphoorn MJB. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. *Lancet Oncol* 2018;19:e173-e180 36.421
219. **Weller M**. Next Generation Neuro-Oncology. *Eur J Cancer* 2018;96:1-5 7.191
220. Wirsching HG, Weiss T, Roth P, **Weller M**. Grundlagen zur Diagnose und Therapie von Gliomen. *Nervenarzt* 2018;89:692-698 0.738
221. Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DM, Reardon DA, Vogelbaum MA, Yuan Y, **Weller M**, Van Den Bent M, Wen PY. Corticosteroid Use Endpoints in Neuro-Oncology: Response Assessment in Neuro-Oncology (RANO) Working Group. *Neuro-Oncology* 2018;20:897-906 9.384
222. **Weller M**. Tumor-treating fields: time for demystification. *Ann Oncol* 2018;29:1628-1630 13.930
223. Lefranc F, Le Rhun E, Kiss R, **Weller M**. Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets? *Cancer Treat Rev* 2018;68:145-154 8.122
224. Huang RY, Bi WL, **Weller M**, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY. Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology (RANO) Working Group. *Neuro-Oncology* 2019;21:26-36 9.384
225. Jenkinson MD, Weber DC, Haylock BJ, Sherratt FC, Young B, **Weller M**, Bulbeck H, Culeddu G, Hughes DA, Brain A, Das K, Preusser M, Francis P, Gamble C. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. *J Neurosurg* 2018;129:1104-1105 4.319
226. Reardon DA, **Weller M**. Pseudoprogression, fact or wishful thinking in Neuro-Oncology? *Lancet Oncol* 2018;19:1561-1563 36.421
227. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters B, Perry A, Reifenberger G, Stupp R, von Deimling A, **Weller M**. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. *Acta Neuropathol* 2018;136:805-810 15.876
228. Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, **Weller M**. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. *Ann Oncol* 2019;30:211-218 13.930
229. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, La Fougère C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, **Weller M**. A joint EANM/EANO/RANO practice guideline/SNMMI procedure standard for imaging of gliomas using PET with radiolabeled amino acids and [18F]FDG: Version 1.0. *Eur J Nucl Med Mol Imag* 2019;46:540-557 7.704
230. Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, **Weller M**, Tonn JC. PET

- imaging in patients with brain metastasis. Report of the RANO/PET Group. *Neuro-Oncology* 2019;21:584-595
231. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, **Weller M**, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffiatti R. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. *Neuro-Oncology* 2019;21:571-583 9.384
 232. **Weller M**, Le Rhun E. Immunotherapy for glioblastoma: quo vadis? *Nat Rev Clin Oncol* 2019;16:405-406 24.653
 233. Le Rhun E, Preusser M, Van den Bent M, Andratschke N, **Weller M**. How we treat patients with leptomeningeal metastases. *ESMO Open* 2019;4:e000507
 234. **Weller M**, Le Rhun E, Preusser M, Tonn JC, Roth P. How we treat patients with glioblastoma. *ESMO Open* 2019;4:e000520
 235. Tabatabai G, **Weller M**. Herausforderungen und Zukunftsperspektiven in der Neuroonkologie. *Nervenarzt* 2019;90:594-600 0.738
 236. Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, **Weller M**, Reardon DA, Wen PY. Barriers to accrual and enrollment in brain tumor trials. *Neuro-Oncology* 2019;21:1100-1117 9.384
 237. Louis DN, Wesseling P, Brandner S, Brat DJ, Ellison DW, Giangaspero F, Hattab EM, Hawkins C, Judge MJ, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, Perry A, Reifenberger G, **Weller M**, Rous B. Data sets for the reporting of tumors of the central nervous system. *Arch Pathol Lab Med* 2020;144:196-206 3.658
 238. Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, **Weller M**, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. *Neurooncol Pract* 2019;6:249-258
 239. Galldiks N, Kocher M, Ceccon G, Werner JM, Brunn A, Deckert M, Pope WB, Soffiatti R, Le Rhun E, **Weller M**, Tonn JC, Fink GR, Langen KJ. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. *Neuro-Oncology* 2020;22:17-30 9.384
 240. Goldbrunner R, **Weller M**, Regis J, Lund-Johansen M, Stavrinou P, Reuss D, Evans DG, Lefranc F, Sallabanda K, Falini A, Axon P, Sterkers O, Fariselli L, Wick W, Tonn JC. EANO guideline on the diagnosis and treatment of vestibular schwannoma. *Neuro-Oncology* 2020;22:31-45 9.384
 241. **Weller M**. Challenges in the diagnoses and treatment of CNS tumors. *Neurooncol Pract* 2019;6:329
 242. Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Guerreiro Stucklin AS, Idhahbi A, Preusser M, van den Bent M, **Weller M**, Hau P. EANO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up of post-pubertal and adult patients with medulloblastoma. *Lancet Oncol* 2019;20:e715-e728 36.421

243. Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, **Weller M**. Molecular targeted therapy of glioblastoma. *Cancer Treat Rev* 2019;80:101896 8.122
244. Armstrong TS, Dirven L, Arons D, Bates A, Chang SM, Coens C, Espinasse C, Gilbert MR, Jenkinson D, Kluetz P, Mendoza T, Rubinstein L, Sul J, **Weller M**, Wen PY, van den Bent MJ, Taphoorn M. Glioma Patient Reported Outcome Assessment in Clinical Care and Research: A RANO Collaborative Report. *Lancet Oncol* 2020;21:e97-e103 36.421
245. Wirsching HG, **Weller M**. Does neuronal activity promote glioma progression? *Trends in Cancer* 2020;6:1-3 8.884
246. Brat DJ, Aldape K, Colman H, Figarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent M, von Deimling A, **Weller M**. Recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathol* 2020;139:603-608 15.876
247. Lee EQ, **Weller M**, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Optimizing eligibility criteria and clinical trial conduct for primary brain tumor patients. *Neuro-Oncology* 2020;22:601–612 9.384
248. Kaufmann TJ, Smits M, Boxerman J, Huang R, Barboriak DP, **Weller M**, Chung C, Tsien C, Brown PD, Shankar L, Galanis E, Gerstner E, van den Bent MJ, Burns TC, Parney IF, Dunn G, Brastianos PK, Lin NU, Wen PY, Ellingson BM. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM). *Neuro-Oncology* 2020;22:757-772 9.384
249. Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, **Weller M**, White VA, Ellison DW. cIMPACT update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol* 2020;30:844-856 6.187
250. Le Rhun E, Seoane J, Salzet M, Soffiatti R, **Weller M**. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. *Cancer Lett* 2020;480:24-28 6.491
251. **Weller M**, Preusser M. How we treat brain tumor patients during the COVID-19 pandemic. *ESMO Open* 2020;4(Suppl 2):e000789
252. Wen PY, **Weller M**, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinger IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro-Oncology* 2020;22:1073-1113 9.384
253. **Weller M**, Le Rhun E. How did CCNU become standard of care in recurrent glioblastoma? *Cancer Treat Rev* 2020;87:102029 8.122

254. **Weller M**, Reifenberger G. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? *Curr Opin Neurol* 2020;33:701-706 4.010
255. Khasraw M, Reardon D, **Weller M**, Sampson J. PD-1 inhibitors: Do they have a future in the treatment of glioblastoma? *Clin Cancer Res* 2020;26:5287-5296 10.199
256. Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, **Weller M**, Wick W, Soffiatti R, Reardon DA, Aghi MK, Galanis E, Wen PY, van den Bent M, Chang S. Phase 0 and window of opportunity clinical trial design in Neuro-Oncology: a RANO review. *Neuro-Oncology* 2020;22:1568-1579 9.384
257. Roth P, Hottinger AF, Hundsberger T, Läubli H, Schucht P, Reinert M, Mamot C, Roelcke U, Pesce G, Hofer S, **Weller M**. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. *Swiss Med Wkly* 2020;150:w20256
258. Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, **Weller M**, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Chung C, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Rosen BR, Ellingson BM, Schmainda KM; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. *Neuro-Oncology* 2020;22:1262-1275 9.384
259. Roth P, Mason WP, Richardson PG, **Weller M**. Proteasome inhibition for the treatment of glioblastoma. *Expert Opin Investig Drugs* 2020;29:1133-1141 5.081
260. Pace A, Koekkoek JAF, van den Bent MJ, Bulbeck HJ, Fleming J, Grant R, Golla H, Henriksson R, Kerrigan S, Marosi C, Oberg I, Oberndorfer S, Oliver K, Pasmán HRW, Le Rhun E, Rooney AG, Rudà R, Veronese S, Walbert T, **Weller M**, Wick W, Taphoorn MJB, Dirven L, on behalf of the European Association of Neuro-Oncology palliative care task force. Determining medical decision-making capacity in brain tumor patients: why and how? *Neuro-Oncology Practice* 2020;7:599-612
261. **Weller M**. Important themes in Neuro-Oncology Practice: rare brain tumors, radiotherapy and its side effects, and supportive and palliative care. *Neuro-Oncology Practice* 2020;7:357-358
262. Le Rhun E, **Weller M**. Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumors. *ESMO open* 2020;5:e001034
263. **Weller M**, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffiatti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol* 2021;18:170-186 24.653
264. Roth P, Pace A, Le Rhun E, **Weller M**, Ay C, Cohen-Jonathan Moyal E, Coomans M, Giusti R, Jordan K, Nishikawa R, Winkler F, Hong YK, Ruda R, Villà S, Taphoorn MJB, Wick W, Preusser M, on behalf of the EANO Executive Board and ESMO Guidelines Committee. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice For Peer Review Guidelines for prophylaxis, diagnosis, treatment and follow-up. *Ann Oncol* 2021;32:171-182 13.930
265. **Weller M**, Tatsuoka K, Reardon DA. Appropriate analysis of duration of response data in cancer trials - reply. *JAMA Oncol* 2020 in press 22.416

266. Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, Minniti G, Kim MM, Tsien C, Dhermain F, Soffietti R, Mehta MP, **Weller M**, Tonn JC. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. *Neuro-Oncology* in press 9.384
267. Wirsching HG, Roth P, **Weller M**. A vasculature-centric approach to developing novel treatment options for glioblastoma. *Exp Opin Therap Targets* in press
268. Wen PY, **Weller M**, Chiocca EA, Lim M, Tonn JC, Zadeh G, Aldape K, van den Bent M. Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. *Neuro-Oncology* 2021 in press 9.384
269. Weiss T, **Weller M**. Pathway-based stratification of glioblastoma. *Nat Rev Neurol* 2021 in press 19.819
270. Karschnia P, Vogelbaum MA, Van den Bent M, Cahill DP, Bello L, Narita Y, Berger MS, **Weller M**, Tonn JC. Evidence-based recommendations on categories for extent of resection in diffuse glioma. *Eur J Cancer* in press 7.191
271. Roth P, Winklhofer S, Müller AMS, Dummer R, Mair MJ, Gramatzki D, Le Rhun E, Manz MG, **Weller M**, Preusser M. Neurological complications of cancer immunotherapy. *Cancer Treat Rev* in press 8.122

C. Chapters in Books and Conference Proceedings

1989

1. **Weller M**, Wiedemann P, Zilles K, Heimann K. Macrophages, fibronectin, transferrin – major pathogenetic factors in proliferative vitreoretinopathy. In Heimann K, Wiedemann P (Hrsg.). Proliferative Vitreoretinopathy (PVR). Kaden, Köln, 1989, 104-108
2. Moter H, Wiedemann P, **Weller M**, Heimann K, Zilles K. Characterization of vitreous proteins by isoelectric focusing. In Heimann K, Wiedemann P (Hrsg.). Proliferative Vitreoretinopathy (PVR). Kaden, Köln, 1989, 113-117

1990

3. Hartmann C, Wiedemann P, Gothe K, **Weller M**, Heimann K. Nachstarprävention durch endokapsuläre Daunomycinapplikation. In Freyler H, Skorpik CH, Grasl M (Hrsg.). 3. Kongress der Deutschen Gesellschaft für Intraokularlinsenimplantation. Springer, Wien New York, 1990, 414-422

1991

4. Schabet M, Melms A, **Weller M**, Wiethölter H. Autochthone IgG-Bildung bei Meningeosis neoplastica. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:329-330
5. Sommer N, **Weller M**, Petersen D, Wiethölter H, Dichgans J. Neurosarkoidose. Neuere diagnostische Möglichkeiten und Falldarstellung. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:608-609
6. **Weller M**, Sommer N, Stevens A, Wiethölter H, Dichgans J. Liquor und Serumfibronektin bei entzündlichen und neoplastischen Erkrankungen des Zentralnervensystems. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:606-607
7. **Weller M**, Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H. Monitoring of disease activity in multiple sclerosis by cerebrospinal fluid interleukin determination. Proceedings of the ECTRIMS Symposium, Tübingen 1990. Elsevier, Amsterdam, 1991, 117-122

1992

8. **Weller M**, Wilhelm H, Sommer N, Dichgans J, Wiethölter H. Das Ross-Syndrom. Pupillotonie, Hyporeflexie und segmentale Anhidrose. In Huffmann G, Braune HJ (Hrsg.). Läsionen des peripheren Nervensystems. Einhorn, Reinbeck, 1992, 253-256

1994

9. **Weller M**, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Induktion von programmiertem Zelltod und Apoptose humaner maligner Gliomzellen durch Anti-Fas/APO-1/CD95-Antikörper. Verhandlungen der Deutschen Gesellschaft für Neurologie 1994;8:664-666
10. Sommer N, Löschmann PA, Northoff GH, **Weller M**, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmüller A, Dichgans J, Martin R. Der Phosphodiesterase IV Inhibitor Rolipram supprimiert die klinischen Symptome der experimentell autoimmunen Enzephalomyelitis. Verhandlungen der Deutschen Gesellschaft für Neurologie 1994;8:713-715

1995

11. Kornhuber J, **Weller M**. Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (Hrsg.).

Schizophrenia. An integrated view. Alfred Benzon Symposium 38. Munksgaard, Kopenhagen, 1995, 314-325

12. Fontana A, Constam DB, Frei K, Koedel U, Pfister W, **Weller M**. Cytokines and defense against CNS infection. In Benveniste E, Ransohoff RM (Hrsg.). Cytokines and the CNS: Development, Defense and Disease. CRC Press, Boca Raton, FL, 1995, 187-219
13. Remé CE, **Weller M**, Szczesny P, Munz K, Hafezi F, Reinboth JJ, Clausen M. Light-induced apoptosis in the rat retina in vivo: morphological features, threshold and time course. In Anderson RA, La Vail MM, Hollyfield JG (Hrsg.). Degenerative diseases of the retina. Plenum Press, New York, NY, 1995, 19-25

1996

14. **Weller M**, Fontana A. Multiple Sklerose. In Peter HH, Pichler WJ (Hrsg.). Klinische Immunologie. 2. Aufl. Urban & Schwarzenberg, München, 1996, 626-633
15. Zimmermann I, Widmer U, **Weller M**, Spillmann T, Fontana A. Cogan-Syndrom. In Peter HH, Pichler WJ (Hrsg.). Klinische Immunologie. 2. Aufl. Urban & Schwarzenberg, München, 1996, 872-875
16. Kornhuber J, **Weller M**. Die Rolle des glutamatergen Systems beim malignen neuroleptischen Syndrom. Kongressband des DGPPN-Jubiläumskongresses 1992: Peters UH, Schifferdecker M, Krahl A (Hrsg.) 150 Jahre Psychiatrie. Eine vielgestaltige Psychiatrie für die Welt von morgen. Martini, Köln, 1996
17. Kornhuber J, **Weller M**. Ursachen und Therapie des malignen neuroleptischen Syndroms. In Feiereis H, Saller R (Hrsg.). 170 neue, noch unveröffentlichte Fragen und Antworten aus der Praxis. Hans Marseille, München, 1996, 173-175

1997

18. Kornhuber J, **Weller M**, Riederer P. Which phencyclidine-like N-methyl-D-aspartate receptor antagonists are currently available for clinical use? Bibliotheca Psychiatrica (Proceedings of the CINP Regional Conference Wien 1995) Karger, Basel, 1997, 175-180
19. Kornhuber J, **Weller M**. Das maligne neuroleptische Syndrom. Fortbildungsband III der Deutschen Gesellschaft für Neurologie, 1997, W102-106

1998

20. Schulz JB, **Weller M**. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 536-540
21. **Weller M**. Hyperthermie. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 587-594
22. Schabet M, **Weller M**. Primäre intrakranielle und spinale Tumoren im Erwachsenenalter. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 645-693
23. **Weller M**, Schabet M. Leptomeningeale Metastasen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 722-734
24. **Weller M**. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 1245-1261

25. Schulz JB, Simons M, von Coelln R, Dichgans J, **Weller M**. The role of caspases in neuronal cell death. In Kriegelstein J (Hrsg.). *Pharmacology of Cerebral Ischemia*. Medpharm Scientific Publ., Stuttgart, 1998, 141-150

1999

26. Klockgether T, **Weller M**. Trinukleotid-Erkrankungen. In Ganten D, Ruckpaul K (Hrsg.). *Handbuch der molekularen Medizin*. Springer, Berlin, 1999, Band 5, 67-102

2000

27. Cavenee WK, Furnari FB, Nagane M, Huang HJS, Newcomb EW, Bigner DD, **Weller M**, Berens M, Plate KH, Israel MA, Noble MD, Kleihues P. Diffusely infiltrating astrocytomas. In Kleihues P, Cavenee WK (Hrsg.) *Pathology and Genetics of Tumors of the Nervous System*. IARC Press, Lyon, 2000, 10-21

2001

28. Roth W, **Weller M**. Death ligand/death receptor-mediated apoptosis in malignant glioma. In Liao LM, Becker DP, Cloughsey TF, Bigner DD (Hrsg.). *Brain Tumor Immunotherapy*. Humana Press, Totowa, NJ, 2001, 327-344
29. Schabet M, **Weller M**. Hirn- und Rückenmarkstumoren. In Huhn D, Herrmann R (Hrsg.) *Medikamentöse Therapie maligner Erkrankungen*. Urban & Fischer, München, 2001, 437-471
30. **Weller M**. Sein oder Nichtsein: über sinnvolle und unerwünschte Selbstmorde von Gehirnzellen. In Kettenmann H, Gibson M (Hrsg.) *Kosmos Gehirn*. Neurowissenschaftliche Gesellschaft, Berlin, 2001, 30-31
31. **Weller M**. Chemotherapie von Gliomen. Intensivkurs Neurologie. Ärzte-Seminare Karlsruhe. KKA, Holler, Karlsruhe, 2001, 42-46
32. **Weller M**. Indikation zur Chemotherapie bei Gliomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 74. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2001, 209-211

2002

33. **Weller M**. Primäre Hirntumoren. In Riess O, Schöls L (Hrsg.) *Neurogenetik. Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen*. Kohlhammer, Stuttgart, 2002, 247-252
34. **Weller M**, Wick W, Steinbach JP, Wagenknecht B, Naumann U, Roth W. The role of apoptosis in cancerogenesis and resistance to therapy: lessons from malignant glioma. In Zierhut M, Jager M, Ksander B (Hrsg.) *Immunology of ocular tumors*. Swets & Zeitlinger Publishers, Sassenheim, 2002, 131-139
35. **Weller M**. Therapiekonzepte bei niedergradigen Gliomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 75. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2002, 78-80

2003

36. **Weller M**, Lehmann-Horn F. Malignant hyperthermia and neuroleptic malignant syndrome. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) *Course and Treatment of Neurological Disorders*. Academic Press, San Diego, CA, 2003, 783-789

37. **Weller M**, Thomas DGT. Primary tumors of the central and peripheral nervous system. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 827-863
38. **Weller M**. Brain metastases from systemic solid tumors. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 881-895
39. **Weller M**. Leptomeningeal metastasis. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 897-909
40. Schulz JB, **Weller M**. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 664-670
41. **Weller M**, Lehmann-Horn F. Maligne Hyperthermie und neuroleptisches malignes Syndrom. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 722-727
42. **Weller M**, Wick W. Primäre intrakranielle und spinale Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 776-811
43. **Weller M**. Hirnmetastasen solider extrazerebraler Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 829-847
44. Wick W, **Weller M**. Leptomeningeale Metastasierung. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 849-859
45. **Weller M**. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 1408-1424
46. **Weller M**, Schlegel U. Diagnostik. Andere diagnostische Maßnahmen. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 82-83
47. **Weller M**, Westphal M. Grundlagen der speziellen Therapie. Therapiestudien. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 114-115
48. **Weller M**, Schlegel U. Grundlagen der speziellen Therapie. Chemotherapie. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 156-164
49. **Weller M**, Westphal M. Primäre Tumoren des Gehirns und seiner Häute. Anaplastische Astrozytome. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 192-196
50. **Weller M**, Westphal M. Primäre Tumoren des Gehirns und seiner Häute. Glioblastome. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 196-204
51. Schlegel U, **Weller M**. Primäre Tumoren des Gehirns und seiner Häute. Astrozytäre Varianten. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 204-206
52. Schlegel U, **Weller M**. Primäre Tumoren des Gehirns und seiner Häute. Oligodendrogliale Tumoren. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 207-211
53. Schlegel U, **Weller M**. Primäre Tumoren des Gehirns und seiner Häute. Primäre ZNS-Lymphome. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 285-292

54. **Weller M.** Medikamentöse Therapie. Chemotherapie. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 424-425
55. **Weller M.** Medikamentöse Therapie. Hemmung der Signaltransduktion. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 426-427
56. **Weller M.** Medikamentöse Therapie. Apoptoseinduktion. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 427-428
57. Schlegel U, **Weller M**, Westphal M. Medikamentöse Therapie. Ausblick. In Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 442
58. **Weller M**, Schlegel U, Schackert G. Hirnmetastasen und Meningeosis neoplastica. In Domschke W, Hohenberger W, Meinertz T, Possinger K, Reinhardt D, Tölle R (Hrsg.) Therapie-Handbuch Urban & Fischer, München, 2003, P3-P10

2004

59. **Weller M.** Hirnmetastasen und Meningeosis neoplastica. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 77. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2004, 116-119
60. **Weller M.** Maligne Gliome. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 77. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2004, 588-590

2005

61. **Weller M.** Therapiestrategien bei Meningeosis neoplastica. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 78. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2005, 341-342
62. **Weller M.** Neue Studien und Stand der Therapieoptionen beim Glioblastom. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 78. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2005, 624-626
63. **Weller M.** Gliomas. In Kettenmann H, Ransom BR (Hrsg.) Neuroglia. Oxford University Press, New York, NY, 2005, 521-531

2006

64. **Weller M**, Krauseneck P, Kath R, Kortmann RD, Schmoll HJ. Primäre Hirntumoren bei Erwachsenen. In Schmoll HJ, Höffken K, Possinger K (Hrsg.). Kompendium Internistische Onkologie. Springer, Berlin, 2006, 3219-3260
65. **Weller M**, Kortmann RD, Schmoll HJ. Pinealstumoren bei Jugendlichen und Erwachsenen. In Schmoll HJ, Höffken K, Possinger K (Hrsg.). Kompendium Internistische Onkologie. Springer, Berlin, 2006, 3261-3272
66. **Weller M**, Schlegel U. Onkologie. In Deuschl G, Reichmann H (Hrsg.) Gerontoneurologie. Thieme, Stuttgart, 2006, S. 193-201
67. **Weller M.** Oligodendroglioma. In Tonn JC, Westphal M, Rutka J, Grossman S (Hrsg.) Neuro-Oncology of CNS tumors. Springer, Heidelberg, 2006, 139-144
68. Steinbach JP, **Weller M.** Apoptosis pathways and chemotherapy. In Newton HB (Hrsg.) Handbook of

Brain Tumor Chemotherapy. Elsevier, San Diego, CA, 2006, 141-154

69. Rieger J, **Weller M**. Exploiting apoptosis pathways for glioblastoma therapy. In Debatin KM, Fulda S (Hrsg.) Apoptosis and cancer therapy. Wiley, Weinheim, 2006, 1033-1048
70. Rössler K, Knosp E, **Weller M**. Zerebrale raumfordernde Prozesse. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2006, VI-1, 1-45
71. **Weller M**. Kontroversen bei der Therapie „niedrigmaligner“ Gliome. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 79. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2006, 94-97
72. **Weller M**. Maligne Gliome: Aktuelle Therapiestudien in Deutschland. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 79. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2006, 419-421

2007

73. Diener HC, **Weller M**. Neurologie. In Gerok W, Huber C, Meinertz T, Zeidler H. (Hrsg.) Die Innere Medizin. Schattauer, Stuttgart, 2007, 1395-1442
74. **Weller M**, Müller B, Kortmann RD. Tumoren des Nervensystems. In Seeber S, Schütte J (Hrsg.) Therapiekonzepte Onkologie. Springer, Heidelberg, 2007, 458-487
75. **Weller M**, Wick W. New approaches to brain tumor therapy. In Baehring JM, Piepmeier JM (Hrsg.) Brain tumors. Practical guide to diagnosis and treatment. Informa Healthcare New York, NY, 2007, 69-91
76. Schulz JB, **Weller M**. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 716-722
77. **Weller M**, Lehmann-Horn F. Maligne Hyperthermie und neuroleptisches malignes Syndrom. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 780-785
78. Wick W, Tonn JC, **Weller M**. Primäre intrakranielle und spinale Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 832-867
79. Wick W, **Weller M**. Hirnmetastasen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 885-901
80. Wick W, **Weller M**. Meningeosis neoplastica. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 902-910
81. Gratzke C, **Weller M**, Stief CG. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 1465-1483
82. **Weller M**. Wieviele Therapeuten braucht ein Hirntumorpatient? Sonderband Aktuelle Neurologie. Fortbildungsakademie der 80. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2007, 477-478
83. **Weller M**. Gehirntumore: mehr Lebensqualität für die Patienten. In Kömpf D (Hrsg.) 100 Jahre Deutsche Gesellschaft für Neurologie. Berlin, 2007, 253-256

84. **Weller M**, Novak K. Spinale raumfordernde Prozesse. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2007, VI-2.1, 1-14; zusätzlich publiziert in Zeller WJ, Zur Hausen H (Hrsg.) Onkologie. Grundlagen, Diagnostik, Therapie, Entwicklungen 2007, V-2.491, 1-11
85. Novak K, **Weller M**. Intraoperatives neurophysiologisches Monitoring bei spinalen neurochirurgischen Eingriffen. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2007, VI-2.1, 1-8

2008

86. **Weller M**. Einführung in die Erkrankungen des zentralen, peripheren und autonomen Nervensystems. In Letzel S, Nowak D (Hrsg.) Handbuch der Arbeitsmedizin Ecomed Medizin, Landsberg/Lech, 2008, DI-2.1, 1-20
87. **Weller M**. Hirntumoren. In Bäumer R, Maiwald A (Hrsg.) Onkologische Pflege. Thieme, Stuttgart, 2008, 301-305
88. **Weller M**, Kornhuber J. Neuroleptic malignant syndrome. In Lang F (Hrsg.) Encyclopedia of Molecular Mechanisms of Disease. Springer, Heidelberg, 2008
89. **Weller M**. Gliomas. In Lang F (Hrsg.) Encyclopedia of Molecular Mechanisms of Disease. Springer, Heidelberg, 2008
90. **Weller M**, Schlegel U. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. Springer, Heidelberg, 2008, 577-588
91. **Weller M**. Die Wertigkeit molekularer Marker in der Gliomtherapie. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 81. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2008, 345-346

Naumann U, **Weller M**. Modulating TGF- β receptor signaling: a novel approach of cancer therapy. In Jakowlew SB (Hrsg.) Transforming growth factor- β in cancer therapy. Vol II. Cancer treatment and therapy. Humana Press, Totowa, NJ, 2008 (ISBN 978-1-58829-715-0)

2009

92. Wick W, **Weller M**. Adjuvant therapy. In von Deimling A (Hrsg.) Recent results in cancer research. Gliomas. Springer, Heidelberg, 2009, 141-153
93. **Weller M**. Neue Studien bei primären ZNS-Lymphomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 82. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2009, 447-448
94. **Weller M**. Highlights aus dem Deutschen Gliomnetzwerk. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 82. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2009, 549-550
95. **Weller M**, Schlegel U, Schackert G. Hirnmetastasen und Meningeosis neoplastica. In Domschke W, Berger M, Hohenberger W, Meinertz T, Possinger K (Hrsg.) Therapie-Handbuch Urban & Fischer, München, 2009, P3-1-12

2010

96. Hofer S, Happold C, **Weller M**. Oligodendroglioma. In Tonn JC, Westphal M, Rutka JT (Hrsg.) Oncology of CNS Tumors, Springer, Heidelberg 2010, 163-169

97. Jung H, Bremer J, **Weller M**. Myositis. In Chernajvovsky Y, Robbins PD (Hrsg.) Gene Therapy in Inflammatory and Autoimmune Diseases. Birkhäuser, Springer Basel AG, 2010, 79-90
98. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 10 – Update Hämatologie/Onkologie 2010. Lukon, München, 2010, 555-568
99. **Weller M**. Bevacizumab (Avastin®) and malignant glioma: is there a role? In Chen T, Chamberlain MC (Hrsg.) Controversies in Neuro-Oncology - Volume 1: Avastin & Malignant Gliomas. Bentham e-books / Bentham Science Publishers 2010, Chapter 23

2011

100. Perry JR, Wick W, **Weller M**. Optimizing the use of alkylators in Neuro-Oncology. American Society of Clinical Oncology (ASCO), Chicago, Educational, 2011
101. Schackert G, Pinzer T, Kortmann RD, **Weller M**. Hirntumoren. In Schlag PM, Bamberg M, Jäger D (Hrsg.) Interdisziplinäre Entscheidungswege in der Onkologie. Deutscher Ärzteverlag, Köln, 2011, 41-47
102. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 12 – Update Hämatologie/Onkologie 2011. Lukon, München, 2011, 509-520
103. **Weller M**, Schlegel U. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. 2. Auflage Springer, Heidelberg, 2008, 573-584

2012

104. Roth P, Eisele G, **Weller M**. Immunology of brain tumors. Handbook of Clinical Neurology. Elsevier, Amsterdam, NL, 2012;104:45-51 (ISBN 978-0-444-52138-5)
105. Wick W, Tonn JC, **Weller M**. Primäre intrakranielle und spinale Tumoren. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 813-847 (ISBN 978-3-17-021674-7)
106. Wick W, Winkler F, Westphal M, **Weller M**. Hirnmetastasen. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 862-877
107. Wick W, **Weller M**. Meningeosis neoplastica. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 878-86
108. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 14 – Update Hämatologie/Onkologie 2011. Lukon, München, 2012, 485-495 (ISBN 978-3-933012-23-4)
109. Sandor P, **Weller M**. Kopf- und Gesichtsschmerzen sowie Neuralgien. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 220-233
110. Sandor P, **Weller M**. Arm- und Beinschmerzen neurogener Art. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 318-331
111. Schwarz U, **Weller M**, Lüscher TF. Schwindel und synkopale Zustände. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 941-980

112. Schwarz U, **Weller M**, Spinas GA, Kupferschmidt H. Bewusstseinsstörungen und komatöse Zustände. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 981-1001
113. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 16 – Update Hämatologie/Onkologie 2013. Lukon, München, 2013, 497-510 (ISBN 978-3-933012-27-2)
114. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 18 – Update Hämatologie/Onkologie 2014. Lukon, München, 2014, 509-520 (ISBN 978-3-933012-32-6)
115. **Weller M**, Schlegel U, Schmieder K. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. 3. Auflage. Springer, Heidelberg, 2015, 609-619
116. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 20 – Update Hämatologie/Onkologie 2015. Lukon, München, 2015, 542-552 (ISBN 978-3-933012-34-0)
117. Tallen G, Mynarek M, Tischler T, **Weller M**, Rutkowski S. Diagnostics and diagnosis of late effects in childhood brain tumour survivors. In Langer T, Beck JD, Bokemeyer C (Hrsg.) Cancer aftercare and late treatment effects in the young. From childhood to early adulthood. Springer, Heidelberg, 2020, 239-251 (ISBN 978-3-030-49138-3)
118. Berger MS, **Weller M**. Preface. Handb Clin Neurol 2016;134:ix
119. Wirsching HG, Galanis E, **Weller M**. Glioblastoma. Handb Clin Neurol 2016;134:381-97
120. Lim M, **Weller M**, Chiocca EA. Current state of immune-based therapies for glioblastoma. Am Soc Clin Oncol Educ Book 2016;35:e132-e139
121. Happend C, **Weller M**. Intracranial tumors. In Fillit HM, Rockwood K, Young J (Hrsg.) Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Elsevier, Philadelphia, PA, 2017, 532-537
122. Von Deimling A, Huse JT, Yan H, Brat DJ, Reifenberger G, Ohgaki O, Kleihues P, Berger MS, **Weller M**, Nakazato Y, Burger PC, Ellison DW, Louis DN. Diffuse astrocytoma, IDH-mutant. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A. WHO Classification of Tumors of the Central Nervous System. WHO Press. Geneva, Switzerland, 2016, 18-23 ISBN 978-92-832-4492-9
123. Von Deimling A, Huse JT, Yan H, Brat DJ, Ohgaki O, Kleihues P, Berger MS, **Weller M**, Burger PC, Ellison DW, Rosenblum MK, Reifenberger G, Paulus W, Wesseling P, Aldape KD, Louis DN. Anaplastic astrocytoma, IDH-mutant. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A. WHO Classification of Tumors of the Central Nervous System. WHO Press. Geneva, Switzerland, 2016, 24-27
124. Ohgaki O, Kleihues P, Von Deimling A, Louis DN, Reifenberger G, Yan H, **Weller M**. Glioblastoma, IDH-mutant. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A. WHO Classification of Tumors of the Central Nervous System. WHO Press. Geneva, Switzerland, 2016, 52-56.
125. **Weller M**. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 22 – Update Hämatologie/Onkologie 2016. Lukon, München, 2016, 239-249 (ISBN 978-3-933012-36-4)
126. Roth P, **Weller M**. Peptide-specific vaccines. In Sampson JH (ed.) Translational Immunotherapy of Brain Tumors. Academic Press, San Diego, CA, USA, 2017, 213-227 (ISBN 9780128024201)
127. Schwarz U, **Weller M**. Schwindel. In Battegay E (Hrsg.) Differenzialdiagnose innerer Krankheiten. Thieme, Stuttgart, 2017, 586-610

128. Schwarz U, **Weller M**, Spinas GA, Kupferschmidt H. Bewusstseinstörungen. In Battegay E (Hrsg.) Differenzialdiagnose innerer Krankheiten. Thieme, Stuttgart, 2017, 628-649
129. Sandor P, **Weller M**. Kopf- und Gesichtsschmerzen sowie Neuralgien. In Battegay E (Hrsg.) Differenzialdiagnose innerer Krankheiten. Thieme, Stuttgart, 2017, 962-977
130. Battegay E, Sandor P, **Weller M**, Hoffmann U, Tato F, Kraenzlin ME, Jakob F. Schmerzen der Extremitäten. In Battegay E (Hrsg.) Differenzialdiagnose innerer Krankheiten. Thieme, Stuttgart, 2017, 1072-1147
131. **Weller M**, Brada M, Wong TT, Vogelbaum. Astrocytic tumors: diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, and gliomatosis cerebri. In Batchelor TT, Nishikawa R, Tarbell NJ, Weller M (eds.). Oxford Textbook of Neuro-Oncology. Oxford University Press, Oxford, UK, 2017, 27-36
132. **Weller M**. Tumoren des Nervensystems. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 24 – Update Hämatologie/Onkologie 2017. Lukon, München, 2017, 219-230 (ISBN 978-3-933012-38-8)
133. Wick W, Vajkoczy P, **Weller M**. Primäre intrakranielle und spinale Tumoren. In Diener HC, Gerloff C, Dieterich M (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2018, 899-936 (ISBN 978-3-17-031612-6)
134. Wick W, Winkler F, Westphal M, **Weller M**. Hirnmetastasen. In Diener HC, Gerloff C, Dieterich M (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2018, 953-968
135. Wick W, **Weller M**. Meningeosis neoplastica. In Diener HC, Gerloff C, Dieterich M (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2018, 969-978
136. Le Rhun E, **Weller M**. CNS Tumors in Older Adults. In Extermann M (ed.) Geriatric Oncology. Springer Nature Switzerland, 2020, 1-9 (978-3-319-57414-1 print oder 415-8)
137. Louis DN, Brandner S, Brat D, Ellison D, Giangaspero F, Hattab E, Hawkins C, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, Perry A, Reifenberger G, **Weller M**, Wesseling P, Rous B. Tumours of the Central Nervous System (CNS) Reporting Guide, 1st Edition. International Collaboration on Cancer Reporting; Sydney, Australia, 2018 (ISBN: 978-1-925687-26-2)
138. **Weller M**. Tumoren des Nervensystems. In Ehninger G, Overkamp (Hrsg.) Colloquium Onkologie 26 – Update Hämatologie/Onkologie 2018. Lukon, München, 2018, 237-246 (ISBN 978-3-933012-46-3)
139. Wirsching HG, **Weller M**. Basics of brain tumor biology for clinicians. In Bartolo M, Soffietti R, Klein M (eds.) Neurorehabilitation in Neuro-Oncology. Springer, Cham, Switzerland, 2019, 7-19 (ISBN 978-3-319-95683-1)
140. **Weller M**, Westphal M, Reardon DR. Concepts of personalized medicine in Neuro-oncology. In Tonn JC, Reardon DR, Rutka JT, Westphal M (eds.) Oncology of CNS Tumors. Springer Nature Switzerland, Cham, 2019, 153-158 (ISBN 978-3-030-04151-9)
141. **Weller M**, Watts C, Reardon DR, Mehta MP. Glioblastoma. In Tonn JC, Reardon DR, Rutka JT, Westphal M (eds.) Oncology of CNS Tumors. Springer Nature Switzerland, Cham, 2019, 237-247 (ISBN 978-3-030-04151-9)
142. Le Rhun E, Tonn JC, **Weller M**. Hydrocephalus Related to CNS Malignancies in Adults. In Tonn JC, Reardon DR, Rutka JT, Westphal M (eds.) Oncology of CNS Tumors. Springer Nature Switzerland, Cham, 2019, 729-736 (ISBN 978-3-030-04151-9)
143. **Weller M**, Wirsching HG. Gliome. In Diener HC, Steinmetz H, Kastrup O (Hrsg.) Referenz

Neurologie. Thieme, Stuttgart, 2019, 942-949 (ISBN 978-3-13-241387-0)

144. Le Rhun E, **Weller M**. Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors. In Ahluwalia M, Metellus P, Soffiatti R (eds.) Central Nervous System Metastases. Springer Nature Switzerland, Cham, 2020, 173-179
145. Le Rhun E, **Weller M**. Treatment of Leptomeningeal Metastases. In Ahluwalia M, Metellus P, Soffiatti R (eds.) Central Nervous System Metastases. Springer Nature Switzerland, Cham, 2020, 301-311 (ISBN 978-3-030-23416-4)
146. **Weller M**. Tumoren des Nervensystems. In Ehninger G, Overkamp (Hrsg.) Colloquium Onkologie 28 – Update Hämatologie/Onkologie 2020. Lukon, München, 2020, 125-135 (ISBN 978-3-933012-67-8)

D. Books

Weller M, Wiedemann P. Seele und Sehen. Interdisziplinäre Aspekte von Augenheilkunde und Psychiatrie. Deutscher Ärzteverlag, Köln, 1990

Schlegel U, **Weller M**, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003

Brötz D, **Weller M**. Diagnostik und Therapie bei Bandscheibenschäden. Neurologie, Physiotherapie und das McKenzie-Konzept. Thieme, Stuttgart, 2004

Brötz D, **Weller M**. Bandscheibenleiden. Ihr Aktivprogramm. Trias, Stuttgart, 2006

Schlegel U, **Weller M**, Westphal M. Neuroonkologische Therapie. Kohlhammer, Stuttgart, 2009

Brötz D, Weller M. Physical therapy for intervertebral disk disease. A practical guide to diagnosis and treatment. Thieme, Stuttgart, 2016

Berger MS, **Weller M** (Hrsg.). Glioma. Handbook of Clinical Neurology. Elsevier, Amsterdam, 2016

Brötz D, **Weller M**. Diagnostik und Therapie bei Bandscheibenschäden. Neurologie und Physiotherapie. Thieme, Stuttgart, 2017

Batchelor TT, Nishikawa R, Tarbell NJ, **Weller M** (eds.). Oxford Textbook of Neuro-Oncology. Oxford University Press, Oxford, UK, 2017

E. Guidelines

Lead author

Interdisziplinäres Tumorzentrum Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 3. Auflage, 2000

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Meningeosis neoplastica. www.neuroonkologie.de, 2001

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Interdisziplinäre Leitlinien für die Diagnostik und Therapie supratentorieller Gliome des Erwachsenenalters. www.neuroonkologie.de, 2001

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2002, 133-136

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2002, 137-140

Interdisziplinäres Tumorzentrum Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 4. Auflage, 2003

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Maligne Gliome. Thieme, Stuttgart, 2003, 434-443

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2003, 444-447

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2003, 448-451

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Diagnostik und Therapie der Gliome des Erwachsenenalters. www.neuroonkologie.de, Zuckschwerdt, München, 2004

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Maligne Gliome. Thieme, Stuttgart, 2005, 662-677

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2005, 678-683

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2005, 684-688

Südwestdeutsches Tumorzentrum / Comprehensive Cancer Center Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 5. Auflage, 2006

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, **Weller M**, Wiegel T, Hrsg.). Gliome des Erwachsenenalters. Zuckschwerdt, München, 2006, 340-359

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, **Weller M**, Wiegel T, Hrsg.). Meningeosis neoplastica. Zuckschwerdt, München, 2006, 360-372

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Gliome. Thieme, Stuttgart, 2008, 774-788

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Solide Hirnmetastasen. Thieme, Stuttgart, 2008, 789-796

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Spinale Metastasen und Meningeosis neoplastica. Thieme, Stuttgart, 2008, 797-802

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (**Weller M**, Hofer S, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2009

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (**Weller M**, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2011

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Gliome. Thieme, Stuttgart, 2012, 922-940

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimer C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Metastasen und Meningeosis neoplastica. Thieme, Stuttgart, 2012, 941-958

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (**Weller M**, Roth P, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2013

Coauthor

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2002, 128-130

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2002, 227-232

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Hirnmetastasen. www.neuroonkologie.de, 2003

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Primäre ZNS-Lymphome. www.neuroonkologie.de, 2003

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Neurosyphilis. Thieme, Stuttgart, 2003, 253-257

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2003, 452-454

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2003, 455-460

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Neurosyphilis. Thieme, Stuttgart, 2005, 376-381

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC,

Putzki N, Berlit P, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2005, 689-694

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2005, 695-702

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, **Weller M**, Wiegel T, Hrsg.). Diagnostische Bildgebung bei Hirntumoren. Zuckschwerdt, München, 2006, 333-339

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, **Weller M**, Wiegel T, Hrsg.). Primäre ZNS-Lymphome. Zuckschwerdt, München, 2006, 373-378

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, **Weller M**, Wiegel T, Hrsg.). Zerebrale Metastasen. Zuckschwerdt, München, 2006, 379-393

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Bildgebung bei Hirntumoren. Thieme, Stuttgart, 2008, 766-773

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Primäre ZNS-Lymphome. Thieme, Stuttgart, 2008, 803-808

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2008, 809-816

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Primäre ZNS-Lymphome (PZNSL). Thieme, Stuttgart, 2012, 959-964

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, **Weller M**, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2012, 966-976